
<html lang="en"     class="pb-page"  data-request-id="30cc7da4-1ebd-4759-9861-bb5a55606a70"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-2;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.8b01365"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development" /></meta><meta name="dc.Creator" content="Kelly&#xA;A.  Bachovchin" /></meta><meta name="dc.Creator" content="Amrita  Sharma" /></meta><meta name="dc.Creator" content="Seema  Bag" /></meta><meta name="dc.Creator" content="Dana M.  Klug" /></meta><meta name="dc.Creator" content="Katherine M.  Schneider" /></meta><meta name="dc.Creator" content="Baljinder  Singh" /></meta><meta name="dc.Creator" content="Hitesh B.  Jalani" /></meta><meta name="dc.Creator" content="Melissa J.  Buskes" /></meta><meta name="dc.Creator" content="Naimee  Mehta" /></meta><meta name="dc.Creator" content="Scott  Tanghe" /></meta><meta name="dc.Creator" content="Jeremiah D.  Momper" /></meta><meta name="dc.Creator" content="Richard J.  Sciotti" /></meta><meta name="dc.Creator" content="Ana  Rodriguez" /></meta><meta name="dc.Creator" content="Kojo  Mensa-Wilmot" /></meta><meta name="dc.Creator" content="Michael P.  Pollastri" /></meta><meta name="dc.Creator" content="Lori  Ferrins" /></meta><meta name="dc.Description" content="Lapatinib, an approved epidermal growth factor receptor inhibitor, was explored as a starting point for the synthesis of new hits against Trypanosoma brucei, the causative agent of human African tr..." /></meta><meta name="Description" content="Lapatinib, an approved epidermal growth factor receptor inhibitor, was explored as a starting point for the synthesis of new hits against Trypanosoma brucei, the causative agent of human African tr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 19, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01365" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01365" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01365" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01365" /></link>
        
    
    

<title>Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01365" /></meta><meta property="og:title" content="Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0017.jpeg" /></meta><meta property="og:description" content="Lapatinib, an approved epidermal growth factor receptor inhibitor, was explored as a starting point for the synthesis of new hits against Trypanosoma brucei, the causative agent of human African trypanosomiasis (HAT). Previous work culminated in 1 (NEU-1953), which was part of a series typically associated with poor aqueous solubility. In this report, we present various medicinal chemistry strategies that were used to increase the aqueous solubility and improve the physicochemical profile without sacrificing antitrypanosomal potency. To rank trypanocidal hits, a new assay (summarized in a cytocidal effective concentration (CEC50)) was established, as part of the lead selection process. Increasing the sp3 carbon content of 1 resulted in 10e (0.19 μM EC50 against T. brucei and 990 μM aqueous solubility). Further chemical exploration of 10e yielded 22a, a trypanocidal quinolinimine (EC50: 0.013 μM; aqueous solubility: 880 μM; and CEC50: 0.18 μM). Compound 22a reduced parasitemia 109 fold in trypanosome-infected mice; it is an advanced lead for HAT drug development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01365"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01365">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01365&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01365&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01365&amp;href=/doi/10.1021/acs.jmedchem.8b01365" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 665-687</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01330" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01366" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Kelly A. Bachovchin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kelly A. Bachovchin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kelly%0AA.++Bachovchin">Kelly A. Bachovchin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amrita Sharma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amrita Sharma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cellular Biology, Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia 30602, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amrita++Sharma">Amrita Sharma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Seema Bag</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Seema Bag</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Seema++Bag">Seema Bag</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dana M. Klug</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dana M. Klug</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dana+M.++Klug">Dana M. Klug</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katherine M. Schneider</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katherine M. Schneider</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+M.++Schneider">Katherine M. Schneider</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Baljinder Singh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Baljinder Singh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Baljinder++Singh">Baljinder Singh</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2828-5768" title="Orcid link">http://orcid.org/0000-0003-2828-5768</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hitesh B. Jalani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hitesh B. Jalani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hitesh+B.++Jalani">Hitesh B. Jalani</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2442-9798" title="Orcid link">http://orcid.org/0000-0002-2442-9798</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa J. Buskes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa J. Buskes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+J.++Buskes">Melissa J. Buskes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Naimee Mehta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naimee Mehta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naimee++Mehta">Naimee Mehta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Tanghe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Tanghe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Anti-Infectives Screening Core, New York University School of Medicine, 430 East 29th Street, New York, New York 10016, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Tanghe">Scott Tanghe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeremiah D. Momper</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeremiah D. Momper</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeremiah+D.++Momper">Jeremiah D. Momper</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard J. Sciotti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard J. Sciotti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Therapeutics, Walter Reed Army Institute for Research, 2460 Linden Lane, Silver Spring, Maryland 20910, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+J.++Sciotti">Richard J. Sciotti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ana Rodriguez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ana Rodriguez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Anti-Infectives Screening Core, New York University School of Medicine, 430 East 29th Street, New York, New York 10016, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ana++Rodriguez">Ana Rodriguez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kojo Mensa-Wilmot</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kojo Mensa-Wilmot</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cellular Biology, Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia 30602, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#b5d8d0dbc6d4c2dcd9f5c0d2d49bd0d1c0"><span class="__cf_email__" data-cfemail="e489818a9785938d88a4918385ca818091">[email protected]</span></a> (K.M.-W.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kojo++Mensa-Wilmot">Kojo Mensa-Wilmot</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael P. Pollastri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael P. Pollastri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+P.++Pollastri">Michael P. Pollastri</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9943-7197" title="Orcid link">http://orcid.org/0000-0001-9943-7197</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lori Ferrins</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lori Ferrins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#3955175f5c4b4b50574a7957564b4d515c584a4d5c4b57175c5d4c"><span class="__cf_email__" data-cfemail="432f6d252631312a2d30032d2c31372b2622303726312d6d262736">[email protected]</span></a> (L.F.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lori++Ferrins">Lori Ferrins</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8992-0919" title="Orcid link">http://orcid.org/0000-0001-8992-0919</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01365&amp;href=/doi/10.1021%2Facs.jmedchem.8b01365" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 665–687</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 19, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 August 2018</li><li><span class="item_label"><b>Published</b> online</span>19 December 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 January 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01365" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01365</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D665%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKelly%250AA.%2BBachovchin%252C%2BAmrita%2BSharma%252C%2BSeema%2BBag%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D2%26contentID%3Dacs.jmedchem.8b01365%26title%3DImprovement%2Bof%2BAqueous%2BSolubility%2Bof%2BLapatinib-Derived%2BAnalogues%253A%2BIdentification%2Bof%2Ba%2BQuinolinimine%2BLead%2Bfor%2BHuman%2BAfrican%2BTrypanosomiasis%2BDrug%2BDevelopment%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D687%26publicationDate%3DJanuary%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01365"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2702</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01365" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kelly\nA.&quot;,&quot;last_name&quot;:&quot;Bachovchin&quot;},{&quot;first_name&quot;:&quot;Amrita&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;Seema&quot;,&quot;last_name&quot;:&quot;Bag&quot;},{&quot;first_name&quot;:&quot;Dana&quot;,&quot;last_name&quot;:&quot;M. Klug&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;M. Schneider&quot;},{&quot;first_name&quot;:&quot;Baljinder&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;Hitesh&quot;,&quot;last_name&quot;:&quot;B. Jalani&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;J. Buskes&quot;},{&quot;first_name&quot;:&quot;Naimee&quot;,&quot;last_name&quot;:&quot;Mehta&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Tanghe&quot;},{&quot;first_name&quot;:&quot;Jeremiah&quot;,&quot;last_name&quot;:&quot;D. Momper&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;J. Sciotti&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;Rodriguez&quot;},{&quot;first_name&quot;:&quot;Kojo&quot;,&quot;last_name&quot;:&quot;Mensa-Wilmot&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;P. Pollastri&quot;},{&quot;first_name&quot;:&quot;Lori&quot;,&quot;last_name&quot;:&quot;Ferrins&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;665-687&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01365&quot;},&quot;abstract&quot;:&quot;Lapatinib, an approved epidermal growth factor receptor inhibitor, was explored as a starting point for the synthesis of new hits against Trypanosoma brucei, the causative agent of human African trypanosomiasis (HAT). Previous work culminated in 1 (NEU-1953), which was part of a series typically associated with poor aqueous solubility. In this report, we present various medicinal chemistry strategies that were used to increase the aqueous solubility and improve the physicochemical profile without sacrificing antitrypanosomal potency. To rank trypanocidal hits, a new assay (summarized in a cytocidal effective concentration (CEC50)) was established, as part of the lead selection process. Increasing the sp3 carbon content of 1 resulted in 10e (0.19 μM EC50 against T. brucei and 990 μM aqueous solubility). Further chemical exploration of 10e yielded 22a, a trypanocidal quinolinimine (EC50: 0.013 μM; aqueous solubility: 880 μM; and CEC50: 0.18 μM). Compound 22a reduced parasitemia 109 fold in trypanosome-infected &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01365&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01365" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01365&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01365" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01365&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01365" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01365&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01365&amp;href=/doi/10.1021/acs.jmedchem.8b01365" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01365" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01365" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01365%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DBachovchin%26date%3D2019%26atitle%3DImprovement%2Bof%2BAqueous%2BSolubility%2Bof%2BLapatinib-Derived%2BAnalogues%253A%2BIdentification%2Bof%2Ba%2BQuinolinimine%2BLead%2Bfor%2BHuman%2BAfrican%2BTrypanosomiasis%2BDrug%2BDevelopment%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D2%26spage%3D665%26epage%3D687%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290888" title="Liquid liquid equilibrium">Liquid liquid equilibrium</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/jmcmar.2019.62.issue-2/20190124/jmcmar.2019.62.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Lapatinib, an approved epidermal growth factor receptor inhibitor, was explored as a starting point for the synthesis of new hits against <i>Trypanosoma brucei</i>, the causative agent of human African trypanosomiasis (HAT). Previous work culminated in <b>1</b> (<b>NEU-1953</b>), which was part of a series typically associated with poor aqueous solubility. In this report, we present various medicinal chemistry strategies that were used to increase the aqueous solubility and improve the physicochemical profile without sacrificing antitrypanosomal potency. To rank trypanocidal hits, a new assay (summarized in a cytocidal effective concentration (CEC<sub>50</sub>)) was established, as part of the lead selection process. Increasing the sp<sup>3</sup> carbon content of <b>1</b> resulted in <b>10e</b> (0.19 μM EC<sub>50</sub> against <i>T. brucei</i> and 990 μM aqueous solubility). Further chemical exploration of <b>10e</b> yielded <b>22a</b>, a trypanocidal quinolinimine (EC<sub>50</sub>: 0.013 μM; aqueous solubility: 880 μM; and CEC<sub>50</sub>: 0.18 μM). Compound <b>22a</b> reduced parasitemia 10<sup>9</sup> fold in trypanosome-infected mice; it is an advanced lead for HAT drug development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Human African trypanosomiasis (HAT) is a neglected tropical disease that is caused by the protozoan parasite <i>Trypanosoma brucei</i>.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> The two subspecies responsible for human infection, <i>T.b. gambiense</i> (western and central Africa) and <i>T.b. rhodesiense</i> (eastern and southern Africa), cause chronic and acute forms of the disease, respectively, and infection is considered 100% fatal if left untreated.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> HAT is a threat to over 70 million people in sub-Saharan Africa, where the tsetse fly vector can be found, and is endemic in many rural areas.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> In 2015, less than 3000 cases were reported, largely due to disease elimination efforts set by the World Health Organization (WHO), which include vector control, case reporting, and availability of treatments.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Vaccines are not available for HAT prevention, due to extensive antigenic variation of the major surface protein, variant surface glycoprotein.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Chemotherapy for HAT is specific to the stage of disease as well as the subspecies of <i>T. brucei</i>. The disease occurs in two stages: the first stage starts with trypanosomes in the blood and lymphatic systems, causing influenza-like symptoms and the second stage is coincident with parasites crossing the blood–brain barrier, which is associated with disrupted sleep patterns, leading to coma and death.<a onclick="showRef(event, 'ref2 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref4 ref5">(2,4,5)</a> Current drugs for HAT have significant shortcomings in terms of toxicity, efficacy, and convenience of dosing; treatment failure that could be a result of drug resistance has also emerged.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Two orally administered leads, fexinidazole<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> and acoziborole (<b>SCYX-7158</b>),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> are in the midst of clinical trials. Because of well-documented high failure rates in drug development,<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> and the possibility of drug resistance,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> we believe that it is prudent to continue populating the pipeline of antitrypanosome leads with backup compounds that meet the target-product profile (TPP) set by WHO and the Drugs for Neglected Diseases <i>initiative</i> (DND<i>i</i>).<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><div class="NLM_p">To streamline our antitrypanosome drug discovery effort, we used a target class repurposing approach<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> to improve the efficacy against <i>T. brucei</i> of the US Food and Drug Administration-approved drug lapatinib. A series of medicinal chemistry optimization campaigns produced the highly potent <b>NEU-617</b>;<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> subsequent work led to <b>1</b> (<b>NEU-1953</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a>), a compound that was moderately potent against <i>T. brucei</i>, but had limited aqueous solubility and high microsomal clearance (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18−21)</a> Side-stepping the daunting task of simultaneously improving antitrypanosome potency, aqueous solubility, and metabolic clearance of these hits, we began efforts to improve the physicochemical properties with a focus on increasing solubility of the compounds.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Criteria Used To Select an Advanced Lead Compound<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">properties</th><th class="colsep0 rowsep0" align="center">desired values</th><th class="colsep0 rowsep0" align="center"><b>1</b> (<b>NEU-1953</b>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T.b. brucei</i> EC<sub>50</sub></td><td class="colsep0 rowsep0" align="left"><0.03 μM, cidal</td><td class="colsep0 rowsep0" align="left">0.43 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2 TC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">>100× EC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">>30 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human liver microsome intrinsic clearance (HLM Cl<sub>int</sub>)</td><td class="colsep0 rowsep0" align="left"><8.6 μL/min/mg</td><td class="colsep0 rowsep0" align="left">180 μL/min/mg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human plasma protein binding (PPB)</td><td class="colsep0 rowsep0" align="left"><95%</td><td class="colsep0 rowsep0" align="left">87%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">thermodynamic solubility (pH = 7)</td><td class="colsep0 rowsep0" align="left">>100 μM</td><td class="colsep0 rowsep0" align="left">44 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pharmacokinetics</td><td class="colsep0 rowsep0" align="left">>10× EC<sub>50</sub> > 6 h</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CNS exposure</td><td class="colsep0 rowsep0" align="left">>10× EC<sub>50</sub> > 6 h</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse efficacy, bloodstream HAT model</td><td class="colsep0 rowsep0" align="left"><50 mg/kg p.o. × 10 days; >90% cure</td><td class="colsep0 rowsep0" align="left">failed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse efficacy, CNS HAT model</td><td class="colsep0 rowsep0" align="left"><100 mg/kg p.o. × 10 days; >90% cure</td><td class="colsep0 rowsep0" align="left">nd</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">nd = not determined.</p></div></div></div><div class="NLM_p">Several medicinal chemistry strategies can be employed to increase the aqueous solubility of compounds. These include increasing charge and polarity (through salt formation<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> or introduction of hydrophilic functional groups), reducing planarity by increasing sp<sup>3</sup> carbon content,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> or reducing the aromatic ring content.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> We present our application of different strategies to improve the aqueous solubility and overall absorption, distribution, metabolism, and excretion (ADME) profile of compound <b>1</b>, as part of an ongoing effort to produce an advanced lead that meets the criteria shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The progression of our hit-to-lead optimization process followed the schematic highlighted in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, wherein compounds were filtered through a series of selection parameters that were reflective of the TPP.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Given that the TPP for HAT indicates a preference for compounds that act irreversibly against the trypanosome, we developed a cidality assay that we used to prioritize compounds that exhibited such an effect. Compounds were progressed into mouse model studies based on these combined results.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Hit-to-lead screening cascade employed in this project, along with the goal values used for the various parameters, as determined when considering the TPP for HAT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74482" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74482" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our goal was to improve the physicochemical properties, specifically focusing on the aqueous solubility, of the previously reported compound <b>1</b><a onclick="showRef(event, 'ref17 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref20">(17,20)</a> whose liabilities as an antitrypanosome hit are presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. We also paid close attention to the lipophilic ligand efficiency (LLE) of each analogue, in comparison to <b>1</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Calculated as the difference between the pEC<sub>50</sub> and <i>c</i> Log <i>P</i>, LLE is now a frequently used metric in medicinal chemistry campaigns that normalizes the potency of an inhibitor to its lipophilicity; this allows easier comparison of compound quality as the optimization program proceeds.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Furthermore, given that compound lipophilicity can adversely impact the pharmacokinetic properties, employment of LLE helps to ensure that the best balance of lipophilicity and potency is struck to identify molecules with a good ADME profile.</div><div class="NLM_p">The approaches we pursued can be categorized as either increasing charge and polarity at biological pH or decreasing planarity of the hits. Thermodynamic solubility (extent to which a compound dissolves) is a more useful metric in guiding the optimization of compounds than kinetic solubility (the extent to which a compound precipitates from a solution).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Furthermore, thermodynamic solubility of a compound is more relevant in the biological assays used in the assessment of potency of our hits. As such, our hit optimization campaign tracked thermodynamic solubility throughout instead of the kinetic solubility of compounds, although we have assessed kinetic solubility where necessary.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Increasing Charge and Polarity</h3><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> Salt Screening</h4><div class="NLM_p">A common strategy used to increase the kinetic aqueous solubility of a series is through the formation of salts at acidic or basic centers on compounds.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Initially, a range of salts of <b>1</b> were studied (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), taking advantage of the basic nitrogen atoms within the compound. The hydrochloride (<b>1a</b>) and sulfate (<b>1b</b>) salt forms remained unchanged in both potency and kinetic solubility, whereas the citrate salt (<b>1c</b>) showed a modest increase in kinetic solubility. The methanesulfonate salt (<b>1d</b>) demonstrated a 4-fold increase in the kinetic solubility. However, the thermodynamic solubility decreased 2-fold for the methanesulfonate (<b>1d</b>) salt form, remained unchanged for the hydrochloride (<b>1a</b>) and sulfate (<b>1b</b>) salt forms, and increased modestly for the citrate (<b>1c</b>) (25%).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Salts of <b>1</b>: Potency against <i>T. brucei</i>, Thermodynamic and Kinetic Solubility, and Metabolic Stability</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">salt form</th><th class="colsep0 rowsep0" align="center">salt ratio</th><th class="colsep0 rowsep0" align="center" char="±"><i>T. brucei</i> EC<sub>50</sub> (μM) ± SEM</th><th class="colsep0 rowsep0" align="center" char=".">thermodynamic solubility (μM)</th><th class="colsep0 rowsep0" align="center" char=".">kinetic solubility (μM)</th><th class="colsep0 rowsep0" align="center" char=".">HLM Cl<sub>int</sub> (μL/min/mg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">free base</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">0.43 ± 0.015</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hydrochloride (<b>1a</b>)</td><td class="colsep0 rowsep0" align="left">4:1</td><td class="colsep0 rowsep0" align="char" char="±">0.33 ± 0.025</td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">160</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sulfate (<b>1b</b>)</td><td class="colsep0 rowsep0" align="left">1:1</td><td class="colsep0 rowsep0" align="char" char="±">0.45 ± 0.024</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">170</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">citrate (<b>1c</b>)</td><td class="colsep0 rowsep0" align="left">2:1</td><td class="colsep0 rowsep0" align="char" char="±">0.51 ± 0.027</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">190</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">methanesulfonate (<b>1d</b>)</td><td class="colsep0 rowsep0" align="left">2:1</td><td class="colsep0 rowsep0" align="char" char="±">0.18 ± 0.023</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">170</td></tr></tbody></table></div></div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> Modification of Ionizable Groups</h4><div class="NLM_p">A second strategy employed was introduction of functional groups that are charged at physiological pH. For this purpose, we added ionizable groups to the piperazine. A general synthetic scheme for these analogues is presented in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Briefly, 5-bromo-2-chloropyrimidine (<b>2</b>) was substituted with the appropriate amines in good to excellent yields. The resulting bromide intermediates <b>3a–y</b> were subjected to Miyaura borylation to give the corresponding boronic acid pinacol ester <b>4a</b>–<b>p</b> that, in a Suzuki reaction with <b>5</b>,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> led to the desired products <b>6a</b>–<b>j</b> and <b>10a–j</b> in acceptable to excellent yields.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Scheme for Addition of Ionizable Groups or Increased sp<sup>3</sup> Carbon Content as New Tail Groups for Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) various substituted amines, Et<sub>3</sub>N, EtOH, ambient temperature, 18 h (32–72%); (b) various substituted amines, DIPEA, <i>tert</i>-butanol, 150 °C, microwave, 30 min (57–97%); (c) B<sub>2</sub>pin<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, dioxane, 145 °C, 1 h (49%-assumed quant.); (d) K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/H<sub>2</sub>O, 130 °C, microwave, 30 min (21–99%).</p></p></figure><div class="NLM_p">Replacement of the piperazine ring with ethylene diamine (<b>6a</b>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) led to a loss of activity against <i>T. brucei</i> and decreased aqueous solubility although the LLE remained high due to the reduced <i>c</i> Log <i>P</i> (0.81 compared to 2.1 for compound <b>1</b>). The synthetic precursor <i>tert</i>-butyl carbamate (<b>6b</b>) was predictably less soluble. The methylated acyclic tail (<b>6d</b>) raised aqueous solubility but dropped antitrypanosomal potency ∼4-fold compared to <b>1</b>; however, this was also accompanied by an improvement in the human liver microsome intrinsic clearance (HLM Cl<sub>int</sub>: 45 μL/min/mg), although this was still outside of our targeted range. The demethylated piperazine derivative <b>6f</b> displayed a 6-fold loss in potency, the solubility remained unchanged, and the HLM Cl<sub>int</sub> was significantly improved (30 μL/min/mg) suggesting demethylation of the piperazine as one of the major metabolites in this series. The <i>tert</i>-butyl carbamate precursor (<b>6e</b>) was far less soluble than <b>1</b>, with retention of moderate antitrypanosome activity. Substitution of the piperazine with methylene carboxylic acid (<b>6h</b>, presumably present as a zwitterion in vitro), and the corresponding methyl ester (<b>6g</b>), made as a potentially more cell-permeable prodrug of <b>6h</b>, lost potency and aqueous solubility compared to <b>1</b>. Finally, the piperazine was replaced by proline (<b>6i</b>) and its methyl ester derivative (<b>6j</b>); both were inactive against <i>T. brucei</i>, and no improvement in the ADME profile compared to <b>1</b> was evident. Thus, analogues that are charged at biological pH do not consistently have better aqueous solubility than <b>1</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effect of Incorporation of Ionizable Groups on <b>1</b> Potency against <i>T. brucei</i>, Metabolic Stability, and Aqueous Solubility<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">nd = no data.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last"><b>SCYX-7158</b> was used as a control, EC<sub>50</sub>: 0.29 μM.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Compound lost, likely due to unspecific binding.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Compound detected in only the first sample.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Not tested initially and a combination of poor properties and potency meant that the compound was not considered for progression.</p></div></div><div></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Reductions in Planarity</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Pseudo-ring Analogues</h4><div class="NLM_p">We looked to increase the conformational flexibility of the quinoline series by breaking one of the rings of the central core; we hoped to maintain <i>T. brucei</i> activity by taking advantage of a possible intramolecular hydrogen bond (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S7</a>). This scaffold also has the advantage of incorporating additional hydrogen bond donors, increasing its potential interactions with water. Applying this strategy to a compound related to <b>1</b>, compound <b>7</b>, led to compound <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). However, despite breaking the bicyclic aromatic system (<b>8</b>), this strategy did not show any significant improvement in the aqueous solubility of the series or potency against <i>T. brucei</i>. An improvement in the HLM metabolic stability was observed (24 μL/min/mg) and was representative of this series of analogues; however, due to the lack of potency against <i>T. brucei</i> (associated with a decreased LLE), this strategy was not pursued further.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pseudo-ring analogues of the previously reported compound <b>7</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Methylation of the Quinoline Core</h4><div class="NLM_p">Methylation reduces planarity in biaryl motifs,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and we hypothesized that such a conformational change would increase solubility. Synthesis of compounds followed an analogous route to a previously reported procedure,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> the details of which are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Scheme S1</a>, Supporting Information. However, introduction of the methyl groups led to a significant decrease in the potency against <i>T. brucei</i>, causing a reduction in the LLE of the compounds accompanied by increased toxicity toward HepG2 (human liver) cells and a substantial decrease in aqueous solubility (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Methylation of the Quinoline Reduces Antitrypanosome Potency and Increases Toxicity of Analogues of <b>1</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0011.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char="±"><i>T. brucei</i> EC<sub>50</sub> (μM) ± SEM<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">aq sol (μM)</th><th class="colsep0 rowsep0" align="center" char=".">human PPB (%)</th><th class="colsep0 rowsep0" align="center" char=".">HLM Cl<sub>int</sub> (μL/min/mg)</th><th class="colsep0 rowsep0" align="center">HepG2 TC<sub>50</sub> (μM) (R<sup>2</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">LLE</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">-H</td><td class="colsep0 rowsep0" align="left">-H</td><td class="colsep0 rowsep0" align="char" char="±">0.43 ± 0.015</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="char" char=".">180</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">-H</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.30</td><td class="colsep0 rowsep0" align="left"><0.02</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">130</td><td class="colsep0 rowsep0" align="left">5.9 (0.98)</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="left">-H</td><td class="colsep0 rowsep0" align="left">-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">15 ± 1.4</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="left">9.6 (0.98)</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn2"><div class="footnote" id="t4fn2"><sup><sup>a</sup></sup><p class="last"><b>SCYX-7158</b> was used as a control, EC<sub>50</sub>: 0.29 μM.</p></div></div></div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Increased sp<sup>3</sup> Atom Content</h4><div class="NLM_p">We explored increasing the sp<sup>3</sup> content of the tail group (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), replacing the piperazine ring with groups that have increased three-dimensionality. Bridged piperazines in <b>10a</b> and <b>10b</b> improved aqueous solubility 20-fold, compared to <b>1</b>, conferred a slight improvement in potency against <i>T. brucei</i>, and exhibited an improved LLE and a 4-fold increase in metabolic stability. Ethyl- and propyl-substituted piperazines (<b>10c</b> and <b>10d</b>, respectively) were ineffective at improving aqueous solubility, although potencies were comparable to or better than <b>1</b>. Swapping the piperazine moiety for alkyl-substituted homopiperazines (<b>10e</b>–<b>g</b>) yielded highly soluble compounds coupled with a 2- to 4-fold improvement in antitrypanosome potency. In the case of <b>10f</b> and <b>10g</b>, there was a noticeable decrease in metabolic stability that makes these hits less attractive for antitrypanosome drug development, compared to <b>10e</b>. Similarly, the spirocyclic derivatives <b>10i</b> and <b>10j</b> showed 2- to 3-fold improvement in potency compared to <b>1</b> and were both highly soluble. By far, the bridged piperazine (<b>10a</b>), the methylhomopiperazine (<b>10e</b>), and the spirocyclic derivatives (<b>10i</b> and <b>10j</b>) were the most improved compounds in terms of antitrypanosome potency, LLE, metabolic stability, and aqueous solubility. For <b>10e</b>, we also obtained calculated p<i>K</i><sub>a</sub> data and compared it with <b>1</b> (see Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S4</a>), and the aliphatic nitrogen on the homopiperazine was found to be between 0.8 and 1.2 log units more basic than the analogous nitrogen of <b>1</b>. A closer examination of the Log <i>D</i> values (see Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S3</a>) for this set of analogues revealed that the addition of a one-carbon bridge to the piperazine (<b>10a</b> and <b>10b</b>) and replacement with spirocyclic derivatives (<b>10i</b> and <b>10j</b>) led to a decrease in the Log <i>D</i> compared to <b>1</b>, which is consistent with a recent report from AstraZeneca.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> We also observed a similar trend with two of the homopiperazine analogues (<b>10e</b> and <b>10f</b>), while <b>10g</b> had the same Log <i>D</i> value as <b>1</b>, despite the addition of 3 methylenes.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Increased sp<sup>3</sup> Carbon Content in the Tail Region Can Improve Metabolic Stability and Aqueous Solubility of 1<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">nd = no data.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last"><b>SCYX-7158</b> was used as a control, EC<sub>50</sub>: 0.29 μM.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Compound detected in only the first sample.</p></div></div><div></div></div><div class="NLM_p">Saturated rings were also used to replace the pyrazine head group of <b>1</b> to explore the solubility effect of increasing sp<sup>3</sup> carbon content in this region. While the synthesis initially employed a Buchwald amination to install the saturated primary amines (required for the preparation of compounds <b>15b</b> and <b>15d</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Scheme S2</a>, Supporting Information), subsequent optimization led to an alternative route, where the dihalogenated intermediate <b>11</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> was subjected to S<sub>N</sub>Ar conditions with various primary amines to give compounds <b>12a</b>–<b>h</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). A subsequent Suzuki coupling utilizing both the <i>N</i>-methylpiperazine pyrimidine boronic acid, pinacol ester (<b>14</b>, prepared from the bromo precursor <b>13</b>),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and the <i>N</i>-methylhomopiperazine pyrimidine boronic acid, pinacol ester (<b>4p</b>, prepared from <b>3m</b>), provided desired compounds <b>15a</b>, <b>15c</b>, <b>15e</b>–<b>g</b>, and <b>17a</b>–<b>c</b>.</div><div class="NLM_p">The analogue bearing the cyclohexylamine, <b>15a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), showed a modest improvement in solubility and potency over <b>1</b>, but was less metabolically stable and showed a reduction in LLE due to an increase in the <i>c</i> Log <i>P</i> (3.8 compared to 2.1 for compound <b>1</b>). Tertiary amines (<b>15b</b>, <b>15c</b>, and <b>15d</b>) all exhibited improved solubility with moderate to excellent antitrypanosome potencies. Compound <b>15d</b> is 20-fold more potent than <b>1</b> with a 10-fold improvement in aqueous solubility and significantly improved LLE (5.3). However, its high plasma protein binding (PPB; 100%) and toxicity against HepG2 cells are liabilities that make it less desirable for progression. Replacement of the head group with the tetrahydropyrans (<b>15e</b> and <b>15f</b>) maintained activity against <i>T. brucei</i> compared to <b>1</b>, and improved aqueous solubility 15-fold, but again increased toxicity against HepG2 cells.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Increase in sp<sup>3</sup> Carbon Content of the Head Group Region of <b>1</b>: Effect of Antitrypanosome Potency, Toxicity to HepG2, Aqueous Solubility, and Metabolic Stability<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0013.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">nt = not tested.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">nd = not determined.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last"><b>SCYX-7158</b> was used as a control, EC<sub>50</sub>: 0.29 μM.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Compound lost, likely due to unspecific binding.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Assay failed due to poor curve fitting.</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">Poor MS response.</p></div><div class="footnote" id="t6fn7"><sup><sup>g</sup></sup><p class="last">Low recovery.</p></div><div class="footnote" id="t6fn8"><sup><sup>h</sup></sup><p class="last">Not tested initially and compounds with a superior profile overall had already been identified.</p></div></div><div></div></div><div class="NLM_p last">In summary, modulation of the aqueous solubility of <b>1</b> could be achieved through increasing the sp<sup>3</sup> content of the head group. However, these analogues typically exhibited increased toxicity in HepG2 cells and were less metabolically stable than those presented in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>.</div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Insertion of −NH linker</h4><div class="NLM_p">Addition of an −NH linker between ring systems in the molecule was explored using a previously described synthetic route<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and led to an increase in the aqueous solubility in a position-dependent manner (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Placing a nitrogen atom between the aromatic rings of the tail and core groups of the molecule increased the aqueous solubility. For example, comparing <b>1</b> to the matched analogue <b>16c</b> showed a ∼12-fold reduction in potency, although a 3-fold improvement in aqueous solubility occurred. Moving the amine linker from the 5- to 4-position of the pyrimidine (<b>16d</b>) restored some of the potency compared to <b>16c</b>, but at a loss of aqueous solubility. Shifting the pyrimidine nitrogen (<b>16e</b>) restores some of the aqueous solubility that was lost in <b>16d</b> and retains potency compared to <b>1</b>. Inclusion of the nitrogen between the phenyl ring of the tail group and the quinoline core (<b>16b</b>) greatly improved the solubility while maintaining potency compared to <b>16a</b>. The addition of a nitrogen atom between the piperazine and pyrimidine rings (<b>16f</b>) increased solubility over 20-fold, decreased plasma protein binding to 51%, and increased metabolic stability 10-fold but dropped antitrypanosomal potency 5-fold. Given the lack of broad applicability of this strategy to the series, we sought other avenues by which to increase the aqueous solubility.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Influence of Adding −NH Linkers to Analogues on Metabolic Stability, Solubility, and Potency against <i>T. brucei</i><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">nd = no data.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last"><b>SCYX-7158</b> was used as a control, EC<sub>50</sub>: 0.29 μM.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Low MS/MS signal.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">Not tested initially and compounds with a superior profile overall had already been identified.</p></div></div><div></div></div><div class="NLM_p">At this point, <b>10e</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) emerged as the preferred chemotype for optimization because of its improved metabolic stability, aqueous solubility, plasma protein binding, and potent antitrypanosomal activity. To further explore the SAR, we performed a methyl scan on the pyrazine head group (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). These analogues are matched pairs with <b>10e</b> and were synthesized following the procedure outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Addition of a methyl group at R<sup>1</sup> (<b>17a</b>) or R<sup>3</sup> (<b>17c</b>) was tolerated, while maintaining excellent aqueous solubility. Conversely, substitution with a methyl group at the R<sup>2</sup> position (<b>17b</b>) reduced antitrypanosomal potency 2-fold, compared to <b>10e</b>, and reduced aqueous solubility, although it is still significantly higher than our starting point (<b>1</b>) and the targeted threshold of 100 μM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Finally, alkylation of the endocyclic nitrogen (<b>18</b>) was detrimental to antitrypanosomal potency, while the physicochemical features were relatively unchanged compared to <b>10e</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route for Various Head Group Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span><i>Reagents and conditions:</i> a) saturated primary amine, DIPEA, <i>n</i>-butanol, 200 °C, microwave, 3 h (22–98%); b) aryl primary amine, NaH, DMF, 60 °C (38–75%); c) B<sub>2</sub>pin<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, dioxane, 145 °C, microwave, 1 h (assumed quantitative); d) Cs<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 3:1 dioxane/H<sub>2</sub>O, 80 °C, 48 h (11–44%); e) K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/H<sub>2</sub>O, 130 °C, microwave, 30 min (7–29%).</p></p></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Head Group Modifications of <b>10e</b>: Effect on Antitrypanosome Potency, Metabolic Stability, Aqueous Solubility, and Plasma Protein Binding</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0015.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center" char="±"><i>T. brucei</i> EC<sub>50</sub> (μM) ± SEM<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">aq sol (μM)</th><th class="colsep0 rowsep0" align="center" char=".">human PPB (%)</th><th class="colsep0 rowsep0" align="center" char=".">HLM Cl<sub>int</sub> (μL/min/mg)</th><th class="colsep0 rowsep0" align="center">HepG2 TC<sub>50</sub> (μM) (<i>R</i><sup>2</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">LLE</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">0.19 ± 0.008</td><td class="colsep0 rowsep0" align="left">990</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="left">-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">0.31 ± 0.009</td><td class="colsep0 rowsep0" align="left">830</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">0.46 ± 0.049</td><td class="colsep0 rowsep0" align="left">650</td><td class="colsep0 rowsep0" align="char" char=".">78</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.027</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">72</td><td class="colsep0 rowsep0" align="left">18 (0.90)</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" colspan="3" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.070</td><td class="colsep0 rowsep0" align="left">810</td><td class="colsep0 rowsep0" align="char" char=".">67</td><td class="colsep0 rowsep0" align="char" char=".">170</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last"><b>SCYX-7158</b> was used as a control, EC<sub>50</sub>: 0.29 μM.</p></div></div></div><div class="NLM_p">Alkylation of the −NH was attempted using the conditions outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>a; however, alkylation occurred on the quinoline nitrogen (<b>19a</b>) rather than the exocyclic nitrogen as expected. Alkylation on the quinoline nitrogen and the <i>E</i> configuration of the imine were confirmed by X-ray crystallography (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Figure S2</a>, Supporting Information). A compound with a related structure has previously been reported utilizing reaction conditions similar to those employed here,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and there are only a few other examples of the quinolinimine scaffold available in the literature.<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34−36)</a> Further, analysis of the proton NMR reveals a characteristic chemical shift (∼6.8 ppm) for the proton at the 3-position of the quinolinimine. A Suzuki coupling with the relevant boronic acid was used to obtain the final product <b>22a</b>, whose hydrolytic stability was confirmed under both acidic and basic conditions. Further, the stability of <b>22a</b> was assessed in the presence of a hard and soft nucleophile; it was found to be stable in the presence of both glutathione and cyanide (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Supporting Information</a>). To access the originally desired analogue (<b>18</b>, <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>b), methylation of 2-aminopyrazine (<b>23</b>) was readily achieved to give <b>24</b>, which could be used to displace the chloro <b>11</b> before a Suzuki coupling to provide <b>18</b> in good yield.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthetic Route to Quinolinimine Core Analogues, and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, R-I, THF, 0 °C to ambient temperature (27–63%); (b) <b>3m</b>, B<sub>2</sub>pin<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, dioxane, 145 °C, microwave, 1 h; (c) K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/H<sub>2</sub>O, 130 °C, microwave, 30 min (36–53% over two steps); (d) 2-aminopyrazine, NaH, CH<sub>3</sub>I, THF, 0 °C to ambient temperature (49%); (e) <b>11</b>, NaH, DMF, ambient temperature (82%).</p></p></figure><div class="NLM_p">Alkylation of the quinoline nitrogen with the methyl, ethyl, and propyl groups (<b>22a</b>, <b>22b</b>, and <b>22c</b>, respectively) maintained excellent aqueous solubility, reduced PPB, and increased metabolic stability (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). Compound <b>22a</b> demonstrated a significant boost in potency (∼15-fold) compared to <b>10e</b>, which translated to an improved LLE (5.4 compared with 4.6 for <b>10e</b>). The ethyl and propyl derivatives (<b>22b</b> and <b>22c</b>) proved to be more metabolically labile, although they were improved over our original compound <b>1</b>.</div><div class="NLM_p last">A comparison of the melting points of <b>1</b> (aqueous solubility: 44 μM), <b>10e</b> (aqueous solubility: 990 μM), and <b>22a</b> (aqueous solubility: 880 μM) (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S2</a>, Supporting Information) revealed a lower melting point range with the increased solubility of <b>10e</b> and <b>22a</b>. This suggests that one of the factors influencing the increased solubility of <b>10e</b> and <b>22a</b> is the disruption of the crystal packing in these analogues.</div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Cidal Effective Concentration (CEC<sub>50</sub>) Can Inform Selection of Hits for Advancement</h3><div class="NLM_p">Given that the TPP for HAT indicates a preference for compounds that act irreversibly against the trypanosome,<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> an assessment of trypanocidality was undertaken for hits with EC<sub>50</sub> ≤ 200 nM. Here, trypanosomes (1 × 10<sup>5</sup>/mL) were incubated with hit (concentration 25 times EC<sub>50</sub>, i.e., 25 × EC<sub>50</sub>) for 6 h (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) or 12 h (data not shown). The number of trypanosomes used in this cidal assay was adjusted to maintain the ratio of trypanosome density-to-hit concentration as was used in the 48 h proliferation assay employed to determine EC<sub>50</sub>. At the end of incubation, cell density was checked, compound was washed off, and trypanosomes were incubated in fresh drug-free medium at a density of 10<sup>4</sup>/mL. After 48 h culture in the absence of hits, trypanosomes were enumerated using a hemocytometer.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Trypanocidal effect of test compounds. Log-phase <i>T.b. brucei</i> (1 × 10<sup>5</sup>/mL) were incubated with the hit (at 25 × EC<sub>50</sub> concentration) for 6 h and transferred into drug-free HMI-9 medium for 48 h at a starting cell density of 1 × 10<sup>4</sup> cells/mL. Trypanosomes were enumerated with a hemocytometer after 48 h (*indicates Student’s <i>T</i>-test <i>p</i> < 0.01; the error bars indicate standard deviation). The dashed line corresponds to expected density of cells if 50% were killed in the earlier 6 h exposure to a hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Data presented on the left-hand side of <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows that in the first 6 h of incubation with hits, trypanosomes were viable. For cells treated with cidal hits, the expected density of trypanosomes is 50% of the control (i.e., dimethyl sulfoxide (DMSO)-treated) at the end of 48 h culture at the next stage of this cidal assay. Trypanosomes treated with <b>22c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) had a density above 50% of the control value, meaning that the compound is not cidal at 6 h, based on data expected from the EC<sub>50</sub> values. Trypanosomes treated with <b>22b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) had densities that were approximately 50% of the controls, implying that the hit is cidal. The most trypanocidal compounds using the parameters presented above was <b>22a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>); for this compound, trypanosome density was 25% that of the controls. In comparison to the clinical candidate, acoziborole (<b>SCYX-7158</b>), compound <b>22a</b> appears to exhibit less of a cidal effect. However, because the antitrypanosomal potency of acoziborole (<i>T. brucei</i> EC<sub>50</sub>: 0.29 μM) is higher than the other compounds, a significantly higher concentration of acoziborole (7.2 μM) was used in the cidal assay compared to <b>22a</b> (0.33 μM), making a direct comparison difficult.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Quinolinimine Derivatives of <b>10e</b>: Potency against <i>T. brucei</i>, Metabolic Stability, Aqueous Solubility, and Plasma Protein Binding<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t9fnb" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0016.gif" alt="" id="fx8" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center"><i>T. brucei</i> EC<sub>50</sub> (μM) ± SEM</th><th class="colsep0 rowsep0" align="center" char=".">aq sol (μM)</th><th class="colsep0 rowsep0" align="center" char=".">human PPB (%)</th><th class="colsep0 rowsep0" align="center" char=".">HLM Cl<sub>int</sub> (μL/min/mg)</th><th class="colsep0 rowsep0" align="center">HepG2 TC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">LLE</th><th class="colsep0 rowsep0" align="center">25 × EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">6 h CEC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.19 ± 0.008</td><td class="colsep0 rowsep0" align="char" char=".">990</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="left">nt</td><td class="colsep0 rowsep0" align="left">nt</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" align="left">-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.013 ± 0.001</td><td class="colsep0 rowsep0" align="char" char=".">880</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="left">0.33</td><td class="colsep0 rowsep0" align="left">180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">-CH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.069 ± 0.010</td><td class="colsep0 rowsep0" align="char" char=".">1000</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">1700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22c</b></td><td class="colsep0 rowsep0" align="left">-(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.15 ± 0.00</td><td class="colsep0 rowsep0" align="char" char=".">890</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t9fn2" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>SCYX-7158</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="left">1100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">nt = not tested.</p></div><div class="footnote" id="t9fnb"><sup><sup>b</sup></sup><p class="last">nd = not determined.</p></div><div class="footnote" id="t9fn2"><sup><sup>c</sup></sup><p class="last">Compound did not meet the threshold of 50% cidality in either of 6 or 12 h (data not shown) assays using 25 × EC<sub>50.</sub></p></div></div></div><div class="NLM_p">To obtain a more robust measure of cidality, the study summarized in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> was performed. Using the protocol described in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, we tested several concentrations of hits around the amount used in the single-point assay (25 × EC<sub>50</sub>), to arrive at CEC<sub>50</sub>, the drug concentration at which 50% of trypanosomes are killed after a 6 h exposure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). When comparing CEC<sub>50</sub> with 25 × EC<sub>50</sub> for multiple hits, a linear relationship is expected in a plot because the assumption behind the 48 h proliferation assay, used routinely in the field, is that trypanosome growth arrest occurs because a drug kills the parasite cells. For a drug development project, it is preferable that killing of the trypanosome takes place within one cell division cycle (6 h) of drug treatment. Compounds that kill in >6 h are revealed by significant deviation of a compound’s data point from an idealized linear correlation between 25 × EC<sub>50</sub> and CEC<sub>50</sub> (see trend line in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). For <b>22a</b> and <b>22b</b>, the CEC<sub>50</sub> values fall on the trend line (CEC<sub>50</sub>/25 × EC<sub>50</sub> is between 0.95 and 1.1), indicating that they are cidal after trypanosomes are exposed to them for 6 h.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plot of 25× <i>T. brucei</i> EC<sub>50</sub> against CEC<sub>50</sub> of hits.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Efficacy of 22a in a Mouse Model of HAT</h4><div class="NLM_p">Recognizing that it is difficult to attain a concentration in blood above 500 nM for most drugs administered orally to vertebrates, we considered <b>22a</b> as a candidate for testing in a murine model of HAT because of its low CEC<sub>50</sub> (175 nM), potency (<i>T. brucei</i> EC<sub>50</sub> = 0.013 μM), selectivity over mammalian cells (selectivity index > 2000), low PPB (15%), excellent aqueous solubility (880 μM), and reasonable metabolic stability (22 μL/min/mg; <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). A preliminary toxicity study with <b>22a</b> showed no adverse effects when dosed orally to mice at 100 mg/kg. Pharmacokinetic (PK) parameters were measured in plasma following oral administration of 100 mg/kg of <b>22a</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S6</a>, Supporting Information). To achieve efficacy in a mouse model of HAT, we aimed to exceed 10 × EC<sub>50</sub> for 6–8 h (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), and at this dose, we were in excess of 10 × EC<sub>50</sub> for 13 h in blood (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Figure S4</a>, Supporting Information).</div><div class="NLM_p">In a mouse efficacy study of <b>22a</b> (dose: 100 mg/kg, p.o., <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), the compound was administered 1 day post-infection, once daily for 5 days, and then on day 6, they received an additional dose of 50 mg/kg of <b>22a</b>. In control (untreated) mice, parasitemia reached 10<sup>8</sup>/mL (mean parasitemia = 4.1 × 10<sup>8</sup>/mL) by day 4 and they were sacrificed. For mice treated with <b>22a</b>, parasitemia decreased (compared to that recorded in control mice) from day 2 post-infection. On day 4, the difference in parasitemia between untreated (control) and <b>22a</b>-treated animals was 100-fold, which met the benchmark for classification of <b>22a</b> as a lead compound for HAT.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In mice treated with <b>22a</b>, parasitemia peaked on day 5 (3.7 × 10<sup>6</sup>/mL) and then declined to a mean of 2 × 10<sup>4</sup>/mL, before becoming undetectable in three mice by day 9 (cell density < 4 × 10<sup>4</sup>/mL), although treatment was terminated on day 7. Had the control (untreated) mice lived until day 9, the projected mean parasitemia would be 10<sup>13</sup>/mL, as density of trypanosomes in blood rises 10-fold every 24 h. Thus, the estimated difference in parasitemia between <b>22a-</b>treated and control mice is 10<sup>9</sup>-fold on day 9. However, as trypanosomes were detected in the blood of the treated mice on day 11, the mice were not deemed to have been cured in this study (which is defined as no parasitemia on day 30). Through this study, compound <b>22a</b> has been identified as a promising lead for further optimization. Future studies will attempt to find a dosing protocol that may lead to cure of the trypanosome infection in mice by <b>22a</b>.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of <b>22a</b> on trypanosomes in a mouse model of HAT. Mice (four per group) were each infected with 10<sup>5</sup><i>T.b. brucei</i> (day 0). Compound <b>22a</b> (100 mg/kg) was administered p.o. for 6 days (an additional 50 mg/kg was dosed on day 6). Control mice received vehicle. Different shapes represent individual mice, and the horizontal lines in each group indicate mean parasitemia. Parasitemia was determined with a hemocytometer. UND = undetectable.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Safety Profiling of 22a</h4><div class="NLM_p">Given the promising outcome of the efficacy study into <b>22a</b>, we sought to gain a better understanding of the human kinase inhibition profile of this compound compared to <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Figure S5</a>, Supporting Information). While <b>1</b> showed moderate to potent inhibition of 28 out of the 45 human kinases tested in the Eurofins ExpreS Diversity kinase panel, <b>22a</b> demonstrated potent inhibition of only 3 out of the 45 kinases tested. This indicates a significant improvement in the overall selectivity of this compound compared to the starting point for this work (full data for <b>22a</b> are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S9</a>, Supporting Information).</div><div class="NLM_p">To assess the genotoxicity of <b>22a</b>, we used an Ames fluctuation assay offered by Eurofins to detect frameshift mutations and base-pair substitutions in <i>Salmonella typhimurium</i> strains treated with <b>22a</b> (full data are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S10</a>, Supporting Information). We also tested major metabolites identified through metabolic activation using rat liver S9 fraction. Neither <b>22a</b> nor its metabolites were found to be genotoxic under these conditions.</div><div class="NLM_p last">Finally, given the improved selectivity profile of <b>22a</b>, it was further assessed in a HitProfilingScreen (Eurofins) consisting of 30 GPCRs and ion channels. Significant responses (>50% inhibition at 10 μM) were recorded in five of these assays, against: muscarinic M2, muscarinic M3, nicotinic acetylcholine α1, hERG, and the norepinephrine transporter (full data are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S11</a>, Supporting Information). The activity of <b>22a</b> against these receptors is the major liability of this compound and is the subject of ongoing optimization efforts, which will be reported in due course.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30855" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30855" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Previous studies focused on the optimization of lapatinib against <i>T. brucei</i> and led to the identification of <b>1</b>, a potent and selective antitrypanosomal compound. The work presented herein describes a number of strategies that were employed to improve the ADME profile of <b>1</b>, and it was found that increasing the sp<sup>3</sup> carbon content of the molecule was a highly successful approach. Increasing the sp<sup>3</sup> content in the tail portion of the molecule led to <b>10e</b>, which reduced parasitemia in vivo. Further exploration of the <b>10e</b> chemotype led to <b>22a</b>, a quinolinimine that renders parasitemia undetectable in vivo in 75% of mice following 7 days of treatment (summarized in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). Further profiling of <b>22a</b> reveals that it has an improved kinase selectivity profile versus the starting compound and neither this compound nor its metabolites are genotoxic. We have identified an hERG liability, which we are conscious of correcting as our efforts to further optimize this chemotype for efficacy in the murine model of HAT continue. We conclude that <b>22a</b> is a promising lead for HAT drug development, with an improved ADME profile and potent antitrypanosomal activity over starting compound <b>1</b>.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Biological Assay Protocols</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>Trypanosoma brucei</i> Proliferation</h4><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> New York University (<b>NYU</b>)</h5><div class="NLM_p last">In a 96-well plate, compounds were added in triplicates at 50 μM and in serial dilutions 1:2 in HMI-9 medium. To each well, 2.5 × 10<sup>3</sup><i>T.b. brucei</i> (strain 427) were added and incubated at 37 °C, 5% CO<sub>2</sub> for 48 h. Following incubation, 20 μL of PrestoBlue were added to each well and incubated for additional 4 h. Fluorescence was read at 530 nm excitation and 590 nm emission. Suramin at 100 μM was used as positive control and reference for calculation of IC<sub>50</sub>.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> University of Georgia (<b>UGA</b>)</h5><div class="NLM_p">The high-throughput trypanosome proliferation inhibition assay was performed and analyzed as previously described.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a></div><div class="NLM_p last">A comparison of the biological readouts from NYU and UGA revealed a good correlation between the results (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S1</a>). As such, the readouts have not been distinguished in the text of the manuscript.</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Mouse Infection with <i>T.b. brucei</i></h5><div class="NLM_p last">Bloodstream form (BSF) <i>T.b. brucei</i> CA427 parasites were maintained at densities below 1 × 10<sup>6</sup> cells/mL in HMI-9 media supplemented with 10% fetal bovine serum (Atlanta Biologicals), 10% Serum PLUS (Sigma), and 1% Antibiotic-Antimycotic Solution (Corning Cellgro) at 37 °C, 5% CO<sub>2</sub>. Parasites were centrifuged at 5000<i>g</i> for 3 min at room temperature and resuspended in cold 1× PBS containing 1% glucose to yield a suspension of 1 × 10<sup>6</sup> cells/mL. Correct cell density following resuspension was confirmed using a Z2 Coulter Counter (Beckman). Parasite viability was observed by motility with a Neubauer Bright-line hemocytometer. Cells were kept on ice until infection. Animals were infected with 100 μL of cell suspension (10<sup>5</sup> trypanosomes per mouse).</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Compound 22a (NEU-4438) Treatment of Trypanosome-Infected Mice</h5><div class="NLM_p">Compound <b>22a</b> (NEU-4438) treatment was initiated 1 day after trypanosome infection and continued for 7 days. Mice in the treatment groups were dosed orally (by gavage) 100 mg/kg <b>22a</b> (NEU-4438) each day for 7 days, and an additional dose of 50 mg/kg on day 6. Control mice received vehicle (10% NMP and 90% PEG 300). Parasitemia was checked daily from day 2 to day 7 and on alternate days thereafter.</div><div class="NLM_p">The mice were monitored daily for changes in body weight and overt signs of drug toxicity. To check parasitemia, 3 μL of blood obtained from a tail prick was diluted eightfold into red blood cell (RBC) lysis solution (Qiagen) and the trypanosomes were counted with a hemocytometer. When parasitemia reached 10<sup>7</sup>/mL, dilutions of blood were made with PBS/G (KH<sub>2</sub>PO<sub>4</sub> 0.144 g/L, NaCl 9 g/L, Na<sub>2</sub>PO<sub>4</sub> 0.795 g/L with glucose 10 mM, pH 7.4) to facilitate counting. The mice were euthanized for humane reasons, when parasitemia exceeded 10<sup>8</sup>/mL. Data obtained were plotted with GraphPad Prism (GraphPad Software, La Jolla, CA).</div><div class="NLM_p last">Humane euthanasia by CO<sub>2</sub> overdose followed by incision to form a bilateral pneumothorax was conducted on mice at study termination. All animal experimental protocols were approved and performed in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at the University of Georgia.</div></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Trypanocidal Effect of Hits (Cidal Assay)</h4><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Methods</h5><div class="NLM_p">Compounds with antitrypanosome proliferation potency EC<sub>50</sub> ≤ 200 nM (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S3</a>) were assessed for cidal activity. Mid-logarithmic growth-phase parasites were seeded at 1 × 10<sup>5</sup> cell/mL in HMI-9 medium. Control parasites were treated with 0.1% DMSO (vehicle). Drug treatment was performed for 6 or 12 h at 37 °C/5% CO<sub>2</sub>. HMI-9 medium used for drug treatment was washed off by centrifuging trypanosomes (3000<i>g</i>, 5 min), and the trypanosome pellet was rinsed with drug-free HMI-9 medium. Trypanosomes were suspended (1 × 10<sup>4</sup> cells/mL) in drug-free HMI-9 medium, incubated for 48 h at 37 °C/5% CO<sub>2</sub>, and counted with a hemocytometer. The data presented were obtained from three independent biological replicates each with duplicate determinations. Student’s <i>t</i>-test was used to determine if the mean of cell densities in drug-treated samples varied significantly (<i>p</i> < 0.01) from control samples. Compounds that were ≥50% trypanocidal (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) in either of the assays were retested to determine drug concentrations that yielded 50% trypanocidality in 6 h (6 h CEC<sub>50</sub>) or 12 h (12 h CEC<sub>50</sub>) (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">Table S5</a>, Supplementary Information).</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Summary Table Showing Progress from <b>1</b> to <b>22a</b><a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">properties</th><th class="colsep0 rowsep0" align="center">targeted lead values</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>22a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T. brucei</i> EC<sub>50</sub></td><td class="colsep0 rowsep0" align="left"><0.03 μM, cidal</td><td class="colsep0 rowsep0" align="left">0.43 μM</td><td class="colsep0 rowsep0" align="left">0.013 μM, cidal</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2 TC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">>100× EC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">>30 μM</td><td class="colsep0 rowsep0" align="left">>30 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human liver microsome intrinsic clearance (HLM Cl<sub>int</sub>)</td><td class="colsep0 rowsep0" align="left"><8.6 μL/min/mg</td><td class="colsep0 rowsep0" align="left">180</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding</td><td class="colsep0 rowsep0" align="left"><95%</td><td class="colsep0 rowsep0" align="left">87%</td><td class="colsep0 rowsep0" align="left">15%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (pH = 7)</td><td class="colsep0 rowsep0" align="left">>100 μM</td><td class="colsep0 rowsep0" align="left">44 μM</td><td class="colsep0 rowsep0" align="left">880 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pharmacokinetics</td><td class="colsep0 rowsep0" align="left">>10× EC<sub>50</sub> for >6 h</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">pass at 100 mg/kg, p.o.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse efficacy, bloodstream stage</td><td class="colsep0 rowsep0" align="left"><50 mg/kg p.o. × 5 days; >90% cure</td><td class="colsep0 rowsep0" align="left">failed</td><td class="colsep0 rowsep0" align="left">100 mg/kg, p.o., 7 days, 75% UND parasitemia</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">nd = no data.</p></div></div></div><div class="NLM_p last">To determine CEC<sub>50</sub>, a 2 mL culture of log-phase trypanosomes in HMI-9 medium was inoculated at 1 × 10<sup>5</sup>/mL in 24-well plates and incubated with different concentration of hits for 6 or 12 h at 37 °C/5% CO<sub>2</sub>. The treatment medium was washed off by centrifuging trypanosomes (3000<i>g</i>) and aspiration of the supernatant. Trypanosomes were washed with HMI-9 medium, inoculated at 1 × 10<sup>4</sup>/mL, incubated at 37 °C for 48 h, and cell density determined with a hemocytometer. The data presented were obtained from two independent biological samples (with duplicate determinations) and analyzed with GraphPad Prism software. The CEC<sub>50</sub> values were obtained by nonlinear regression analysis of the data.</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Drug Toxicity to HepG2 Cells<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></h5><div class="NLM_p last">HepG2 cells were cultured in complete minimal essential medium (MEM) prepared by supplementing MEM with 0.19% sodium bicarbonate, 10% heat-inactivated FBS, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 0.1 mM MEM nonessential amino acids, 0.009 mg/mL insulin, 1.76 mg/mL bovine serum albumin, 20 units/mL penicillin–streptomycin, and 0.05 mg/mL gentamycin. HepG2 cells cultured in complete MEM were first washed with 1× Hank’s Balanced Salt Solution (Invitrogen #14175095), trypsinized using a 0.25% trypsin/EDTA solution, assessed for viability using trypan blue, and resuspended at 250 000 cells/mL. Using a Tecan EVO Freedom robot, 38.3 μL of cell suspension was added to each well of clear, cell culture-treated 384-well microtiter plates for a final concentration of 9570 liver cells per well, and plated cells were incubated overnight in 5% CO<sub>2</sub> at 37 °C. Drug plates were prepared with the Tecan EVO Freedom using sterile 96-well plates containing 12 duplicate 1.6-fold serial dilutions of each test compound suspended in DMSO. Diluted test compound (4.25 μL) was then added to 38.3 μL of media in each well providing a 10-fold final dilution of compound. Compounds were tested in the range of 57–10 000 ng/mL for all assays. Mefloquine was used as a plate control for all assays with concentration ranging from 113 to 20 000 ng/mL. After a 48 h incubation period, 8 μL of a 1.5 mg/mL solution of MTT diluted in complete MEM media was added to each well. All plates were subsequently incubated in the dark for 1 h at room temperature. After incubation, the media and drugs in each well were removed by shaking the plate over sink, and the plates were left to dry in a fume hood for 15 min. Next, 30 μL of isopropanol acidified by addition of HCl at a final concentration of 0.36% was added to dissolve the formazan dye crystals created by reduction of MTT. The plates are put on a three-dimensional rotator for 15–30 min. Absorbance was determined in all wells using a Tecan iControl 1.6 Infinite plate reader. The 50% toxic concentrations (TC<sub>50</sub>) were then generated for each toxicity dose–response test using GraphPad Prism (GraphPad Software Inc., San Diego, CA) by nonlinear regression (sigmoidal dose–response/variable slope) equation.</div></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> ADME Experiment Protocols</h4><div id="sec4_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Aqueous pH 7.4 Solubility</h5><div class="NLM_p last">Compounds are dried down from 10 mM DMSO solutions using the centrifugal evaporation technique. Phosphate buffer (0.1 M, pH 7.4) was added, and StirStix was inserted in the glass vials. Shaking was then performed at a constant temperature of 25 °C for 20–24 h. This step was followed by double centrifugation with a tip wash in between, to ensure that no residues of the dried compound interfere. The solutions are diluted before analysis, and quantification using LC/MS/MS is performed.</div></div><div id="sec4_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Log <i>D</i><sub>7.4</sub></h5><div class="NLM_p last">The distribution coefficient between 1-octanol and aqueous buffer, Log <i>D</i>, at pH 7.4, is based on the traditional shake flask technique, but with the modification of measuring compounds in mixtures of 10 at a time using ultra-performance liquid chromatography with quantitative MS to measure the relative octanol and aqueous concentrations of compounds. The buffer solution used is 10 mM sodium phosphate (pH 7.4). The method has been validated for Log <i>D</i><sub>7.4</sub> ranging from −2 to 5.0.</div></div><div id="sec4_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Human Plasma Protein Binding (<b>PPB</b>)</h5><div class="NLM_p last">PPB is determined using equilibrium dialysis (RED device) to separate free compound from bound compound. The amount of compound in plasma (1 mM initial concentration in DMSO) and in dialysis buffer (pH 7.4 phosphate buffer) is measured by LC-MS/MS after 18 h in a dialysis chamber at 37 °C. Sample levels are quantified using a seven-point calibration curve in plasma. The fraction unbound (fu%) is reported.</div></div><div id="sec4_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Human Liver Microsomal Cl<sub>int</sub></h5><div class="NLM_p last">In vitro intrinsic clearance was determined from human liver microsomes using a standard approach.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Following incubation and preparation, the samples are analyzed using LC/MS/MS. Refined data are uploaded to IBIS and are displayed as Cl<sub>int</sub> (intrinsic clearance) in μL/min/mg.</div></div><div id="sec4_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Rat Hepatocyte Cl<sub>int</sub></h5><div class="NLM_p last">In vitro intrinsic clearance was determined from rat han wistar hepatocytes at a final concentration of 1 million cells/mL. The cells were preincubated at 37 °C for 15 min before addition of a test compound (as a 50 μM stock solution) to a final concentration of 1 μM. The samples were analyzed using LC/MSMS at predefined time points. Refined data were uploaded to IBIS and are displayed as Cl<sub>int</sub> (intrinsic clearance) μL/min/1 million cells.</div></div><div id="sec4_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Calculated Log <i>P</i> and Log <i>D</i> Values</h5><div class="NLM_p last">Both Log <i>P</i> and Log <i>D</i> predictions are based on a modified version of the method<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> where the predicted partition coefficients are composed of the molecules’ atomic increments.</div></div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Chemistry Experimental</h4><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> General Chemistry</h5><div class="NLM_p last">All starting materials were commercially procured and were used without further purification, unless specified. The reaction solvents were purified by passage through alumina columns on a purification system manufactured by Innovative Technology (Newburyport, MA). For all microwave reactions, a Biotage Initiator + was used and the absorbance was set in accordance with the recommendations set by the manufacturer. NMR spectra were obtained on Varian NMR systems, operating at 400 or 500 MHz for 1H acquisitions. LCMS analysis was performed using a Waters Alliance reverse-phase HPLC (columns Waters SunFire C18 4.6 × 50 mm<sup>2</sup>, 3.5 μm, or Waters SunFire C8 4.6 × 50 mm<sup>2</sup>, 3.5 μm), with a single-wavelength UV–visible detector and an LCT Premier time-of-flight mass spectrometer (electrospray ionization) or a Waters Micromass ZQ detector (electrospray ionization). Optical rotations were obtained on a Jasco P-2000. Purification of intermediates and final compounds was performed using silica gel chromatography on a Biotage Isolera One Flash purification system. Where required, final compounds were purified by preparative reverse-phase HPLC (columns Waters Symmetry RP8 30 × 50 mm<sup>2</sup>, 5 μm column, or OBD RP18 30 × 50 mm<sup>2</sup>, 5 μm), with a single-wavelength UV–visible detector and Waters Micromass ZQ (electrospray ionization). All final compounds have purities greater than 95% based on LC/MS analysis.</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> General Procedure Gor Salt Formation</h4><div class="NLM_p">The qualitative solubility of <b>1</b> was determined in various solvents (methanol, ethanol, isopropanol, tetrahydrofuran, acetonitrile, ethyl acetate, and water). For each of the solvents, 2.0 mg of <b>1</b> as added to vials. Solvents were added in 200 μL increments until the solid was completely dissolved. With a solubility of about 2.75 mg/mL, ethanol was chosen as the solvent for the salt screen.</div><div class="NLM_p">Compound <b>1</b> (20 mg, 0.05 mmol) was dissolved in ethanol (4 mL) using sonication and heat. Stock solutions of various acids were made (1 M in ethanol). Acid solution was added to solution of <b>1</b> until a precipitate formed (different amounts needed for each acid). The precipitate was collected by vacuum filtration and washed with ethanol.</div><div id="sec4_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Hydrochloride Salt (<b>1a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.04 (s, 2H), 8.91 (s, 1H), 8.81–8.86 (m, 1H), 8.78 (d, <i>J</i> = 5.9 Hz, 1H), 8.38–8.44 (m, 2H), 8.27–8.34 (m, 2H), 8.08–8.13 (m, 1H), 7.52–7.65 (m, 2H), 2.79 (s, 3H).</div></div><div id="sec4_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Sulfate Salt (<b>1b</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.79–11.01 (m, 1H), 9.07 (s, 2H), 8.86–8.94 (m, 3H), 8.53–8.59 (m, 2H), 8.50 (d, <i>J</i> = 2.9 Hz, 1H), 8.28–8.34 (m, 2H), 3.34–3.40 (m, 2H), 3.17 (s, 3H), 2.88 (s, 3H).</div></div><div id="sec4_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Citrate Salt (<b>1c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.77–9.85 (m, 1H), 8.98 (s, 2H), 8.73 (s, 2H), 8.57 (d, <i>J</i> = 8.8 Hz, 1H), 8.31–8.35 (m, 2H), 8.23–8.26 (m, 1H), 8.17–8.20 (m, 1H), 7.96–8.02 (m, 1H), 4.34 (br. s., 13H), 3.85–3.96 (m, 4H), 3.72–3.83 (m, 7 H), 3.40–3.48 (m, 8 H), 2.53–2.71 (m, 14H), 2.42 (s, 4H).</div></div><div id="sec4_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Methanesulfonate Salt (<b>1d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.63–10.88 (m, 1H), 9.62–9.94 (m, 1H), 9.07 (s, 2H), 8.77–8.96 (m, 4H), 8.41–8.62 (m, 3H), 8.30 (d, <i>J</i> = 1.5 Hz, 2H), 4.62–4.98 (m, 2H), 2.87 (s, 4H), 2.32 (s, 6 H).</div></div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> General Procedure A</h4><div class="NLM_p last">To a solution of 5-bromo-2-chloro-pyrimidine (<b>2</b>) in ethanol (0.2–0.3 M) was added triethylamine (3 equiv) followed by appropriate amine (1.3 equiv). The reaction mixture was stirred at ambient temperature overnight. The reaction was monitored by LCMS analysis.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> General Procedure B</h4><div class="NLM_p last">Compounds <b>3a–d</b>, <b>3f</b>, <b>3h–m</b>, <b>3p–r</b>, <b>3u</b>, <b>3x</b>, or <b>3y</b>, bis(pinacolato)diboron (1.5 equiv), potassium acetate (3.5 equiv), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv) were combined in a microwave vial filled with nitrogen and evacuated three times. Anhydrous dioxane (0.1 M) was added, and the reaction mixture was degassed. The vial was transferred to the microwave at 145 °C (low absorbance) for 1 h. The reaction was monitored by LCMS analysis and, once complete, the reaction mixture was filtered through celite and all of the volatiles were removed in vacuo. The crude material was used directly without further purification unless otherwise specified.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> General Procedure C</h4><div class="NLM_p last">The appropriate boronate (1.2 equiv) was dissolved in a 3:1 dioxane/water (0.13 M) mixture. To this was added <b>5</b>, <b>12a</b>, <b>12f</b>, <b>25</b>, <b>19a–c</b>, 7-bromoquinolin-4(1<i>H</i>)-one (1 equiv), potassium carbonate (3 equiv), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), and the reaction mixture was degassed before being transferred to the microwave for 30 min at 130 °C (high absorbance). The reaction was monitored by LCMS analysis and, once complete, the reaction mixture was filtered through celite and the crude material was purified by column chromatography, eluting with the specified mobile phase.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> General Procedure D</h4><div class="NLM_p">Compound <b>3b</b> or <b>3m</b>, bis(pinacolato)diboron (1.5 equiv), potassium acetate (3.5 equiv), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv) were combined in a microwave vial that was filled with nitrogen and evacuated three times. Anhydrous dioxane (0.13 M) was added and the reaction mixture was degassed. The vial was transferred to the microwave at 145 °C (low absorbance) for 1 h. The reaction was monitored by LCMS analysis.</div><div class="NLM_p last">Once complete, compound <b>5</b>, <b>12 g</b>, or <b>12 h</b> (1.0 equiv) was added directly to the reaction mixture along with a 1.8 M aqueous potassium carbonate solution (0.33 M). The reaction mixture was degassed again before being returned to the microwave at 130 °C for 10 min (high absorbance). The reaction was monitored by LCMS analysis and, once complete, the reaction mixture was filtered through celite and the crude material was purified by column chromatography, eluting with the specified mobile phase.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> General Procedure E</h4><div class="NLM_p last">To a solution of 5-bromo-2-chloro-pyrimidine (<b>2</b>) in <i>tert</i>-butanol (0.2–0.3 M) was added diisopropylethylamine (1.3–3 equiv), followed by appropriate amine (or appropriate dihydrobromide salt where appropriate) (1.2 equiv). The reaction mixture was stirred and heated in the microwave at 150 °C for 30 min. The reaction was monitored by LCMS analysis.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> General Procedure F</h4><div class="NLM_p last">The appropriate boronate (1.2 equiv) was dissolved in a 1:2 water/ethanol (0.13 M) mixture. To this was added <b>5</b>, <b>31</b>, <b>37</b>, or <b>12b–e</b> (1 equiv), cesium carbonate (4 equiv), and tetrakis(triphenylphosphine)palladium(0) (5 mol %), and the reaction mixture was degassed before being transferred to the microwave for 10 min at 130 °C (high absorbance). The reaction was monitored by LCMS analysis and, once complete, the reaction mixture was filtered through celite and the crude material was purified by column chromatography, eluting with the specified mobile phase.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> General Procedure G</h4><div class="NLM_p last">To a suspension of sodium hydride (3.5 equiv) in anhydrous dimethylformamide (1 M) was added appropriate aryl primary amine (2.4 equiv) under nitrogen, upon which the reaction mixture changed color. To this was added a solution of <b>11</b>, <b>30</b>, or <b>36</b> (1 equiv) in anhydrous dimethylformamide (0.4 M), which was also accompanied by a color change. The reaction was monitored by LCMS and, upon completion, quenched with a saturated aqueous ammonium chloride solution. A precipitate was observed and collected by vacuum filtration (washed with water).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> General Procedure H</h4><div class="NLM_p last">Compound <b>11</b> was dissolved in <i>n</i>-butanol (0.1 M). Appropriate saturated primary amine (4 equiv) and diisopropylethylamine (10 equiv) were added. The reaction was heated in the microwave at 200 °C for 3 h. <i>n</i>-Butanol was removed in vacuo, and the reaction mixture was purified by column chromatography, eluting with specified mobile phase.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> General Procedure I</h4><div class="NLM_p last">Compound <b>5</b>, <b>12h–j</b>, or 2-aminopyrazine (<b>23</b>) was added to a cooled suspension of sodium hydride (2.9 equiv) in anhydrous tetrahydrofuran (0.16 M concentration to the relative amine). After 15 min, the appropriate iodoalkane (1.7 equiv) was added to the reaction mixture, which was allowed to gradually warm to ambient temperature. The reaction mixture was stirred under nitrogen and monitored by LCMS analysis. Upon completion, sodium hydride was neutralized by addition of methanol until no further effervescence was observed. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography, eluting with the gradient specified.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>tert</i>-Butyl (2-((5-Bromopyrimidin-2-yl)amino)ethyl)carbamate (<b>3a</b>)</h4><div class="NLM_p last">Prepared via general procedure A. The crude material was purified by column chromatography, eluting with 1–5% methanol/dichloromethane to obtain the title compound as a colorless solid (297 mg, 72%). LCMS [M + H]<sup>+</sup> 317.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 319.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.35 (s, 2H), 7.40 (s, 1H), 6.85 (s, 1H), 3.26 (q, <i>J</i> = 6.4 Hz, 2H), 3.07 (q, <i>J</i> = 6.5 Hz, 2H), 1.36 (s, 9 H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>tert</i>-Butyl (2-((5-Bromopyrimidin-2-yl)amino)ethyl)(methyl)carbamate (<b>3b</b>)</h4><div class="NLM_p last">Prepared via general procedure A. The crude material was purified by column chromatography, eluting with 1% methanol/dichloromethane to obtain the title compound as a colorless solid (123 mg, 32%). LCMS [M + H]<sup>+</sup> 331.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 333.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.36 (s, 2H), 7.39–7.60 (m, 1H), 3.34 (br. s., 2H), 2.76 (s, 2H), 1.36 (br. s., 3H), 1.23 (s, 6 H).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i><sup>1</sup>-(5-Bromopyrimidin-2-yl)-<i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>,<i>N</i><sup>2</sup>-trimethylethane-1,2-diamine (<b>3c</b>)</h4><div class="NLM_p last">Prepared via general procedure A. All of the volatiles were removed, and the residue was dissolved in ethyl acetate and washed with an aqueous solution of 1 M sodium hydroxide. The aqueous phase was back-extracted with ethyl acetate three times, and the organic phases were combined, washed with a saturated solution of sodium chloride, and dried with magnesium sulfate. The material was then purified by column chromatography, eluting with 1% methanol/dichloromethane to obtain the title compound as a yellow oil (302 mg, 68%). LCMS [M + H]<sup>+</sup> 259.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 261.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.41 (d, <i>J</i> = 5.1 Hz, 2H), 3.65 (td, <i>J</i> = 7.3, 5.9 Hz, 2H), 3.07 (d, <i>J</i> = 4.4 Hz, 3H), 2.40 (dt, <i>J</i> = 7.3, 5.9 Hz, 2H), 2.16 (d, <i>J</i> = 4.4 Hz, 6 H).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>tert</i>-Butyl 4-(5-Bromopyrimidin-2-yl)piperazine-1-carboxylate (<b>3d</b>)</h4><div class="NLM_p last">Prepared via general procedure E. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography, eluting 0–5% ethyl acetate/hexanes to obtain the title compound as a colorless solid (819 mg, 92%). LCMS [M + H]<sup>+</sup> 343.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 345.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.30 (s, 2H), 3.76 (t, <i>J</i> = 4.9 Hz, 4H), 3.48 (t, <i>J</i> = 5.4 Hz, 4H), 1.48 (s, 9 H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 5-Bromo-2-(piperazin-1-yl)pyrimidine (<b>3e</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate (<b>3d</b>) (819 mg, 2.39 mmol) was dissolved in 4.0 M hydrochloric acid in dioxane (6.0 mL) and stirred at ambient temperature. After 5 min, the reaction mixture became thick with precipitation. Thin-layer chromatography (TLC) after 1 h indicated that no starting material remained. The volatiles were removed in vacuo, and the residue was redissolved in water. Si carbonate was added, and the reaction mixture was stirred at ambient temperature for 3 h. Si carbonate was removed by filtration, and the volatiles were removed in vacuo to obtain the title compound as a colorless solid (501 mg, 86%). LCMS [M + H]<sup>+</sup> 243.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 245.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.93 (br. s., 2H), 8.55 (s, 2H), 3.91 (t, <i>J</i> = 5.4 Hz, 4H), 3.18 (br. s., 4H).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Ethyl 2-(4-(5-Bromopyrimidin-2-yl)piperazin-1-yl)acetate (<b>3f</b>)</h4><div class="NLM_p last">5-Bromo-2-(piperazin-1-yl)pyrimidine (<b>3e</b>) (250 mg, 1.03 mmol) was dissolved in acetonitrile (20 mL, 0.05 M) prior to the addition of potassium carbonate (171 mg, 1.23 mmol) and ethyl bromoacetate (137 μL, 1.23 mmol). The resulting reaction mixture was heated to reflux and monitored by TLC and LCMS. LCMS analysis after 8 h revealed no remaining starting material. The volatiles were removed in vacuo, and the resulting residue was dissolved in ethyl acetate and washed with water (three times) and a saturated aqueous sodium chloride solution (once) before being dried with magnesium sulfate, filtered, and the volatiles were removed in vacuo. The crude material was purified by column chromatography, eluting with 10–15% ethyl acetate/hexanes to obtain the title compound as a pale yellow solid (314 mg, 93%). LCMS [M + H]<sup>+</sup> 329.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 331.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.45 (s, 2H), 4.08 (q, <i>J</i> = 7.1 Hz, 2H), 3.70 (t, <i>J</i> = 5.1 Hz, 2H), 3.27 (s, 2H), 2.55 (t, <i>J</i> = 5.1 Hz, 4H), 1.19 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (5-Bromopyrimidin-2-yl)proline (<b>3g</b>)</h4><div class="NLM_p last">5-Bromo-2-chloropyrimidine (<b>2</b>) (500 mg, 2.58 mmol) was dissolved in ethanol (100 mL) prior to the addition of <span class="smallcaps smallerCapital">d</span>-proline (327 mg, 2.84 mmol) and triethylamine (1.08 mL, 7.75 mmol). The resultant mixture was heated to 75 °C, and the reaction was monitored by LCMS. After 8 h, product was evident by LCMS analysis. The reaction mixture was concentrated in vacuo before the residue was partitioned between 1 M hydrochloric acid and ethyl acetate. The aqueous phase was back-extracted with ethyl acetate two more times. The organic phases were combined, washed once with a saturated aqueous solution of sodium chloride, and dried with sodium sulfate. The volatiles were removed in vacuo to obtain the title compound as a colorless solid (609 mg, 87%). LCMS [M + H]<sup>+</sup> 272.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 274.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.37 (s, 2H), 4.52 (dd, <i>J</i> = 8.1, 2.7 Hz, 1H), 3.70 (ddd, <i>J</i> = 11.0, 7.3, 3.2 Hz, 1H), 3.59 (ddd, <i>J</i> = 10.6, 9.2, 7.1 Hz, 1H), 2.48 (ddt, <i>J</i> = 12.1, 5.9, 2.9, 2.9 Hz, 1H), 2.01–2.23 (m, 4H).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Methyl (5-Bromopyrimidin-2-yl)prolinate (<b>3h</b>)</h4><div class="NLM_p last">Compound <b>3 g</b> (100 mg, 0.368 mmol) was dissolved in anhydrous methanol/toluene (4:1, 500 μL) and cooled to 0 °C under nitrogen. To this was added dropwise a solution of TMS-diazomethane in hexanes (550 μL, 1.10 mmol). The reaction mixture was allowed to gradually warm to ambient temperature overnight. LCMS analysis revealed no remaining starting material and a mass consistent with the desired product. The reaction mixture was concentrated in vacuo, and the crude material was purified by column chromatography, eluting with 10% ethyl acetate/hexanes to obtain the title compound as a colorless solid (90 mg, 86%). LCMS [M + H]<sup>+</sup> 286.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 288.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.50 (br. s., 1H), 8.43 (br. s., 1H), 4.48 (dd, <i>J</i> = 8.8, 3.4 Hz, 1H), 3.51–3.66 (m, 5H), 2.27–2.40 (m, 1H), 1.88–2.05 (m, 3H).</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (1<i>S</i>,4<i>S</i>)-2-(5-Bromopyrimidin-2-yl)-5-methyl-2,5-diazabicyclo[2.2.1]heptane (<b>3i</b>)</h4><div class="NLM_p last">Prepared via general procedure E using (1<i>S</i>,4<i>S</i>)-2-methyl-2,5-diazabicyclo[2.2.1]heptane dihydrobromide. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography, eluting first with 20–50% ethyl acetate/hexanes before switching to 0–30% methanol/dichloromethane to obtain the title compound as a yellow solid (205 mg, 97%). [α]<sub>D</sub><sup>27</sup> −134 ± 0.34 (<i>c</i> 0.45, CH<sub>3</sub>OH); LCMS [M + H]<sup>+</sup> 269.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 271.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.34 (s, 2H), 4.81 (br. s, 1H), 3.65–3.73 (m, 2H), 3.44 (dd, <i>J</i> = 11.2, 1.9 Hz, 1H), 2.91–2.97 (m, 1H), 2.84 (dd, <i>J</i> = 10.2, 1.5 Hz, 1H), 2.51 (s, 3H), 2.03–2.11 (m, 1H), 1.90–1.96 (m, 1H).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (1<i>R</i>,4<i>R</i>)-2-(5-Bromopyrimidin-2-yl)-5-methyl-2,5-diazabicyclo[2.2.1]heptane (<b>3j</b>)</h4><div class="NLM_p last">Prepared via general procedure E using (1<i>R</i>,4<i>R</i>)-2-methyl-2,5-diazabicyclo[2.2.1]heptane dihydrobromide. The reaction mixture was stirred and heated in the microwave at 150 °C for 0.5 h. Upon cooling, a precipitate was observed and collected by vacuum filtration (washed with MeOH) to afford the title compound as a tan solid (134 mg, 57%). [α]<sub>D</sub><sup>27</sup> + 27 ± 0.42 (<i>c</i> 0.56, CH<sub>3</sub>OH); LCMS [M + H]<sup>+</sup> 268.99 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 271.01 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.55–9.86 (m, 1H), 8.54 (s, 2H), 4.87 (s, 1H), 4.37 (br. s., 1H), 3.72 (d, <i>J</i> = 12.7 Hz, 1H), 3.59 (dd, <i>J</i> = 12.2, 1.9 Hz, 2H), 2.85 (br. s., 3H), 2.17 (d, <i>J</i> = 9.8 Hz, 1H), 1.31–1.38 (m, 2H).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 5-Bromo-2-(4-ethylpiperazin-1-yl)pyrimidine (<b>3k</b>)</h4><div class="NLM_p last">Compound <b>3e</b> (280 mg, 1.15 mmol) was dissolved in methanol (4.6 mL, 0.25 M). To this mixture was added triethylamine (1.61 mL, 11.52 mmol) and iodoethane (461 μL, 5.76 mmol). The reaction mixture was stirred at ambient temperature for 43 h. LCMS analysis revealed no remaining starting material and a mass consistent with the desired product. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography, eluting with 1% methanol (+5% ammonium hydroxide)/dichloromethane. The fractions were combined and the volatiles were removed before the material was redissolved in dichloromethane, washed with water (twice), and washed with a saturated aqueous solution of sodium chloride (twice). The organic phase was collected, dried with magnesium sulfate, and concentrated in vacuo to obtain the title compound as a pale yellow solid (201 mg, 64%). LCMS [M + H]<sup>+</sup> 271.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 273.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.57 (s, 2H), 4.64 (d, <i>J</i> = 14.2 Hz, 2H), 3.56 (d, <i>J</i> = 11.7 Hz, 2H), 3.26 (t, <i>J</i> = 12.5 Hz, 2H), 3.16 (qd, <i>J</i> = 6.3, 4.9 Hz, 2H), 3.02 (td, <i>J</i> = 11.2, 9.8 Hz, 2H), 1.24 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 5-Bromo-2-(4-propylpiperazin-1-yl)pyrimidine (<b>3l</b>)</h4><div class="NLM_p last">Compound <b>3e</b> (280 mg, 1.15 mmol) was dissolved in methanol (4.6 mL, 0.25 M). To this was added triethylamine (1.61 mL, 11.52 mmol) and 1-bromopropane (520 μL, 5.76 mmol). The reaction mixture was stirred at ambient temperature and monitored by TLC and LCMS analysis. Once the reaction was complete, all of the volatiles were removed in vacuo and the residue was redissolved in dichloromethane. The organic layer was washed with water (twice) and dried with magnesium sulfate before being concentrated in vacuo to obtain the title compound as a pale yellow solid (279 mg, 85%). LCMS [M + H]<sup>+</sup> 285.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 287.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.44 (s, 2H), 3.68 (t, <i>J</i> = 4.9 Hz, 4H), 2.38 (t, <i>J</i> = 5.1 Hz, 4H), 2.25 (t, <i>J</i> = 7.3 Hz, 2H), 1.45 (sxt, <i>J</i> = 7.4 Hz, 2H), 0.86 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 1-(5-Bromopyrimidin-2-yl)-4-methyl-1,4-diazepane (<b>3m</b>)</h4><div class="NLM_p last">Prepared via general procedure E. All volatiles were removed, and the crude material was dissolved in dichloromethane and washed with a saturated aqueous solution of sodium bicarbonate. The aqueous phase was back-extracted with dichloromethane, and the organic phases were combined, washed once with a saturated solution of sodium chloride, and dried with magnesium sulfate before being concentrated in vacuo to obtain the title compound as an off-white solid (1.28 g, 91%). LCMS [M + H]<sup>+</sup> 271.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 273.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.50 (s, 2H), 3.95 (br. s., 2H), 3.74 (br. s., 2H), 3.16 (d, <i>J</i> = 4.9 Hz, 4H), 2.66 (br. s., 3H), 2.13 (br. s., 2H).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>tert</i>-Butyl 4-(5-bromopyrimidin-2-yl)-1,4-diazepane-1-carboxylate (<b>3n</b>)</h4><div class="NLM_p last">The <sup>1</sup>H NMR spectra contains two rotamers in a 1:1 ratio. Prepared via general procedure E. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography, eluting 0–10% ethyl acetate/hexanes to obtain the title compound as a colorless solid (810 mg, 88%). LCMS [M + H]<sup>+</sup> 357.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 359.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.45 (s, 2H), 8.44 (s, 2H), 3.78 (td, <i>J</i> = 5.9, 2.9 Hz, 4H), 3.68 (q, <i>J</i> = 6.3 Hz, 4H), 3.52 (t, <i>J</i> = 5.9 Hz, 2H), 3.46 (t, <i>J</i> = 5.6 Hz, 2H), 3.30 (t, <i>J</i> = 5.6 Hz, 2H), 3.25 (t, <i>J</i> = 5.9 Hz, 2H), 1.77 (quin, <i>J</i> = 6.0 Hz, 2H), 1.70 (quin, <i>J</i> = 5.6 Hz, 2H), 1.30 (s, 9 H), 1.26 (s, 9 H).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 1-(5-Bromopyrimidin-2-yl)-1,4-diazepane, Trifluoroacetic Acid Salt (<b>3o</b>)</h4><div class="NLM_p last">Compound <b>3n</b> (810 mg, 2.27 mmol) was dissolved in dichloromethane (11.4 mL, 0.2M) and trifluoroacetic acid (1.74 mL, 22.67 mmol) was added. The reaction mixture was stirred at ambient temperature and monitored by TLC and LCMS analysis. Once complete, all of the volatiles were removed in vacuo and the material was used directly, without further purification. LCMS [M + H]<sup>+</sup> 257.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 250.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.79 (br. s., 2H), 8.50 (s, 2H), 3.93 (t, <i>J</i> = 4.9 Hz, 2H), 3.79 (t, <i>J</i> = 6.1 Hz, 2H), 3.26 (quin, <i>J</i> = 5.0 Hz, 2H), 3.12–3.22 (m, 2H), 2.00 (dt, <i>J</i> = 11.4, 5.8 Hz, 2H).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 1-(5-Bromopyrimidin-2-yl)-4-ethyl-1,4-diazepane (<b>3p</b>)</h4><div class="NLM_p last">Compound <b>3o</b> (291 mg, 1.13 mmol) was dissolved in methanol (4.5 mL, 0.25M). To this was added triethylamine (1.58 mL, 11.32 mmol) and iodoethane (453 μL, 5.66 mmol). The reaction mixture was stirred at ambient temperature and monitored by TLC and LCMS analysis. Once the reaction was complete, all of the volatiles were removed in vacuo and the crude material was purified by column chromatography, eluting with 1% methanol (+5% ammonium hydroxide)/dichloromethane. Material was dissolved in dichloromethane and washed with a saturated aqueous solution of sodium bicarbonate. The aqueous phase was back-extracted with dichloromethane and the organic phases were combined, washed once with a saturated solution of sodium chloride, and dried with magnesium sulfate before being concentrated in vacuo to obtain the title compound as a colorless solid (85 mg, 26%). LCMS [M + H]<sup>+</sup> 285.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 287.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.51 (s, 2H), 4.19 (dd, <i>J</i> = 15.9, 3.7 Hz, 1H), 3.69–3.79 (m, 3H), 3.58 (d, <i>J</i> = 13.7 Hz, 1H), 3.47 (dd, <i>J</i> = 12.9, 5.6 Hz, 1H), 3.12–3.19 (m, 4H), 1.99–2.22 (m, 2H), 1.19 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 1-(5-Bromopyrimidin-2-yl)-4-propyl-1,4-diazepane (<b>3q</b>)</h4><div class="NLM_p last">Compound <b>3o</b> (291 mg, 1.13 mmol) was dissolved in methanol (4.5 mL, 0.25 M). To this was added triethylamine (1.58 mL, 11.32 mmol) and 1-bromopropane (511 μL, 5.66 mmol). The reaction mixture was stirred at ambient temperature and monitored by TLC and LCMS analysis. Once the reaction was complete, all of the volatiles were removed in vacuo and the residue was redissolved in dichloromethane. The organic layer was washed with water (twice), a saturated aqueous solution of sodium bicarbonate (once), a saturated solution of sodium chloride (once), and dried with magnesium sulfate. All of the volatiles were removed in vacuo to obtain the title compound as a pale yellow oil (172 mg, 51%). LCMS [M + H]<sup>+</sup> 299.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 301.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.42 (s, 2H), 3.75 (t, <i>J</i> = 5.4 Hz, 2H), 3.69 (t, <i>J</i> = 6.1 Hz, 2H), 2.68 (br. s., 2H), 2.54 (br. s., 2H), 2.37 (t, <i>J</i> = 6.3 Hz, 2H), 1.80 (quin, <i>J</i> = 5.7 Hz, 2H), 1.39 (sxt, <i>J</i> = 7.3 Hz, 2H), 0.80 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 1-(5-Bromopyrimidin-2-yl)azepane (<b>3r</b>)</h4><div class="NLM_p last">Prepared via general procedure E. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography, eluting first with 50% ethyl acetate/hexanes before switching to 0–20% methanol/dichloromethane to obtain the title compound as a colorless solid (605 mg, 91%). LCMS [M + H]<sup>+</sup> 256.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 258.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.32–8.46 (m, 2H), 3.66 (t, <i>J</i> = 5.9 Hz, 4H), 1.61–1.77 (m, 4H), 1.47 (dt, <i>J</i> = 6.5, 2.9 Hz, 4H).</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>tert</i>-Butyl 6-(5-bromopyrimidin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (<b>3s</b>)</h4><div class="NLM_p last">Prepared via general procedure E. The crude material was purified by column chromatography, eluting with 20% ethyl acetate/hexanes to afford the title compound as an off-white solid (268 mg, 94%). LCMS [M + H]<sup>+</sup> 369.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 371.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.31 (s, 2H), 3.93 (d, <i>J</i> = 8.3 Hz, 2H), 3.88 (d, <i>J</i> = 8.8 Hz, 2H), 3.69 (s, 2H), 3.59 (t, <i>J</i> = 6.8 Hz, 2H), 2.20 (t, <i>J</i> = 6.8 Hz, 2H), 1.46 (s, 9 H).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 6-(5-Bromopyrimidin-2-yl)-2,6-diazaspiro[3.4]octane (<b>3t</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 6-(5-bromopyrimidin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (<b>3s</b>) (268 mg, 0.726 mmol) was taken up in 4.0 M HCl in dioxane (1.0 mL, 4.00 mmol). The reaction was stirred at room temperature overnight. All volatiles were removed in vacuo to afford a white solid. The crude material was used directly in the next reaction without further purification. LCMS [M + H]<sup>+</sup> 269.03 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 271.05 <i>m</i>/<i>z</i> (Br<sup>81</sup>).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 6-(5-Bromopyrimidin-2-yl)-2-methyl-2,6-diazaspiro[3.4]octane (<b>3u</b>)</h4><div class="NLM_p last">6-(5-Bromopyrimidin-2-yl)-2,6-diazaspiro[3.4]octane (<b>3t</b>) (195 mg, 0.724 mmol) was dissolved in methanol (3.0 mL, 0.25 M) and triethylamine (1.0 mL, 7.17 mmol) was added, followed by the addition of methyl iodide (68 μL, 1.09 mmol). The reaction was stirred overnight at ambient temperature. All volatiles were removed in vacuo, and the resulting residue was dissolved in dichloromethane and washed with a saturated aqueous solution of sodium bicarbonate. The aqueous layer was extracted once more with dichloromethane, then the combined organic layers were washed once with a saturated solution of sodium chloride and dried with sodium sulfate. The crude material was purified by column chromatography, eluting with 5–10–20% methanol (+10% ammonium hydroxide)/ethyl acetate to afford the title compound as an orange oil (20 mg, 10%). LCMS [M + H]<sup>+</sup> 283.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 285.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.29 (s, 2H), 3.61 (s, 2H), 3.54 (t, <i>J</i> = 7.1 Hz, 2H), 3.30 (d, <i>J</i> = 7.8 Hz, 2H), 3.16 (d, <i>J</i> = 7.8 Hz, 2H), 2.35 (s, 3H), 2.19 (t, <i>J</i> = 6.8 Hz, 2H).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>tert</i>-Butyl 7-(5-Bromopyrimidin-2-yl)-2,7-diazaspiro[4.4]nonane-2-carboxylate (<b>3v</b>)</h4><div class="NLM_p last">Prepared via general procedure E. The crude material was purified by column chromatography, eluting with 20% ethyl acetate/hexanes to afford the title compound as a colorless solid (554 mg, 93%). LCMS [M + H]<sup>+</sup> 383.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 385.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.31 (s, 2H), 3.58–3.71 (m, 2H), 3.25–3.56 (m, 6H), 1.83–2.08 (m, 4H), 1.47 (s, 9H).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 2-(5-Bromopyrimidin-2-yl)-2,7-diazaspiro[4.4]nonane (<b>3w</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 7-(5-bromopyrimidin-2-yl)-2,7-diazaspiro[4.4]nonane-2-carboxylate (<b>3v</b>) (554 mg, 1.45 mmol) was taken up in 4.0 M HCl in dioxane (1.8 mL, 7.20 mmol). The reaction was stirred at room temperature overnight. All volatiles were removed in vacuo to afford a white solid. The crude material was used directly in the next reaction without further purification. LCMS [M + H]<sup>+</sup> 283.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 285.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 2-(5-Bromopyrimidin-2-yl)-7-methyl-2,7-diazaspiro[4.4]nonane (<b>3x</b>)</h4><div class="NLM_p last">2-(5-Bromopyrimidin-2-yl)-2,7-diazaspiro[4.4]nonane (<b>3w</b>) (350 mg, 1.24 mmol) was dissolved in methanol (5.0 mL, 0.25 M) and triethylamine (1.7 mL, 12.20 mmol) was added, followed by the addition of methyl iodide (115 μL, 1.85 mmol). The reaction was stirred overnight at ambient temperature. All volatiles were removed in vacuo and the resulting residue was dissolved in dichloromethane and washed with a saturated aqueous solution of sodium bicarbonate. The aqueous layer was extracted once more with dichloromethane, then the combined organic layers were washed once with a saturated solution of sodium chloride and dried with sodium sulfate. The crude material was purified by column chromatography, eluting with 5–10–20% methanol (+10% ammonium hydroxide)/ethyl acetate to afford the title compound as an orange oil (56 mg, 15%). LCMS [M + H]<sup>+</sup> 297.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 299.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.29 (s, 2H), 3.52–3.63 (m, 3H), 3.46 (d, <i>J</i> = 11.2 Hz, 1H), 2.72 (q, <i>J</i> = 7.8 Hz, 1H), 2.55–2.64 (m, 2H), 2.51 (d, <i>J</i> = 9.8 Hz, 1H), 2.37 (s, 3H), 2.02 (tdd, <i>J</i> = 19.1, 19.1, 12.3, 7.1 Hz, 2H), 1.87 (sxt, <i>J</i> = 6.6 Hz, 2H).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 5-Bromo-<i>N</i>-(4-methylpiperazin-1-yl)pyrimidin-2-amine (<b>3y</b>)</h4><div class="NLM_p last">1-Amino-4-methylpiperazine (404 μL, 3.36 mmol) was added to a solution of 5-bromo-2-chloro-pyrimidine (<b>2</b>) (500 mg, 2.58 mmol) and triethylamine (1.01 mL, 7.24 mmol) in ethanol (10 mL). The reaction mixture was stirred at ambient temperature overnight. LCMS analysis revealed no remaining starting material and a mass consistent with the desired product. The crude material was purified by column chromatography, eluting with 1–5% methanol (+5% ammonium hydroxide)/dichloromethane. The material was further purified by column chromatography, eluting first with 50–95% ethyl acetate/hexanes, 0–5% methanol/dichloromethane, and finally 5% methanol (+5% ammonium hydroxide)/dichloromethane to obtain the title compound as a colorless solid (57 mg, 8%). LCMS [M + H]<sup>+</sup> 272.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 274.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.41 (s, 1H), 8.40 (s, 2H), 2.78 (t, <i>J</i> = 4.9 Hz, 4H), 2.30–2.48 (m, 4H), 2.18 (s, 3H).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (2-((2-((<i>tert</i>-Butoxycarbonyl)amino)ethyl)amino)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4a</b>)</h4><div class="NLM_p last">Prepared via general procedure B. The crude material was redissolved in ethyl acetate and washed with water and then a saturated aqueous solution of sodium chloride. The material was used directly in the next reaction without further purification. LCMS [M + H]<sup>+</sup> 365.2 <i>m</i>/<i>z</i> (Boronic acid, pinacol ester), 283.1 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (2-((2-(Dimethylamino)ethyl)(methyl)amino)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4b</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 307.2 <i>m</i>/<i>z</i> (boronic acid, pinacol ester), 225.0 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (2-(4-(<i>tert</i>-Butoxycarbonyl)piperazin-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4c</b>)</h4><div class="NLM_p last">Prepared via general procedure B (heating time was 3 h instead of 1 h). The crude material was purified by column chromatography, eluting with 5–10% ethyl acetate/hexanes to obtain the title compound as a colorless solid (140 mg, 49%). LCMS [M + H]<sup>+</sup> 391.3 <i>m</i>/<i>z</i> (boronic acid pinacol ester), 309.2 <i>m</i>/<i>z</i> (boronic acid); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.35–8.40 (m, 2H), 3.71 (t, <i>J</i> = 4.9 Hz, 4H), 3.39 (t, <i>J</i> = 5.4 Hz, 5H), 1.42 (s, 12H), 1.17 (s, 9 H).</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> (2-(4-(2-Ethoxy-2-oxoethyl)piperazin-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4d</b>)</h4><div class="NLM_p last">Prepared via general procedure B (heating time was 15 min). The reaction mixture was filtered through celite and purified by column chromatography, eluting with 30–80% ethyl acetate/hexanes to obtain the title compound as a yellow solid (206 mg, 72%). LCMS [M + H]<sup>+</sup> 377.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.47 (s, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.79 (t, <i>J</i> = 5.4 Hz, 4H), 3.27 (s, 2H), 2.55 (t, <i>J</i> = 5.4 Hz, 4H), 1.27 (s, 12H), 1.18 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (2-(2-(Methoxycarbonyl)pyrrolidin-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4e</b>)</h4><div class="NLM_p last">Prepared via general procedure B (heating time was 3 h instead of 1 h). The crude material was purified by column chromatography, eluting with 10–25% ethyl acetate/hexanes to obtain the title compound as a colorless solid (102 mg, 99%). LCMS [M + H]<sup>+</sup> 334.2 <i>m</i>/<i>z</i> (boronic acid, pinacol ester), 252.1 <i>m</i>/<i>z</i> (boronic acid); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.51 (d, <i>J</i> = 2.9 Hz, 1H), 8.40 (d, <i>J</i> = 2.4 Hz, 1H), 4.55 (dd, <i>J</i> = 8.8, 3.4 Hz, 1H), 3.60–3.70 (m, 5H), 2.28–2.38 (m, 1H), 1.99–2.04 (m, 1H), 1.91–1.98 (m, 2H), 1.27 (d, <i>J</i> = 2.4 Hz, 12H).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> (2-((1<i>S</i>,4<i>S</i>)-5-Methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyrimidin-5-yl)boronic Acid, Boronic Acid (<b>4f</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 317.1 <i>m</i>/<i>z</i>.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> (2-((1<i>R</i>,4<i>R</i>)-5-Methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4g</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 317.2 <i>m</i>/<i>z</i>.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> (2-(4-Ethylpiperazin-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4h</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 319.2 <i>m</i>/<i>z</i> (boronic acid, pinacol ester), 237.1 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (2-(4-Propylpiperazin-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4i</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 333.2 <i>m</i>/<i>z</i> (boronic acid pinacol ester), 251.1 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> (2-(4-Ethyl-1,4-diazepan-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4j</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 333.2 <i>m</i>/<i>z</i> (boronic acid, pinacol ester), 251.1 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> (2-(4-Propyl-1,4-diazepan-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4k</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 347.3 <i>m</i>/<i>z</i> (boronic acid, pinacol ester), 265.2 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> (2-(Azepan-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4l</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 222.1 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> (2-(2-Methyl-2,6-diazaspiro[3.4]octan-6-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4m</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 249.1 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> (2-(7-Methyl-2,7-diazaspiro[4.4]nonan-2-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4n</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 263.2 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> (2-((4-Methylpiperazin-1-yl)amino)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4o</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 238.1 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> (2-(4-Methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)boronic Acid, Pinacol Ester (<b>4p</b>)</h4><div class="NLM_p last">Prepared via general procedure B and used directly in the next reaction without purification. LCMS [M + H]<sup>+</sup> 319.3 <i>m</i>/<i>z</i> (boronic acid, pinacol ester), 237.1 <i>m</i>/<i>z</i> (boronic acid).</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> <i>N</i><sup>1</sup>-(5-(4-(Pyrazin-2-ylamino)quinolin-7-yl)pyrimidin-2-yl)ethane-1,2-diamine (<b>6a</b>)</h4><div class="NLM_p last">Compound <b>6b</b> (37.2 mg, 0.081 mmol) was dissolved in dichloromethane (3 mL) and trifluoroacetic acid (93 μL, 1.22 mmol) was added. The reaction mixture was stirred at ambient temperature overnight. TLC and LCMS analyses showed incomplete conversion to the desired product. Additional trifluoroacetic acid (186 μL, 2.44 mmol) was added, and the reaction mixture was stirred at ambient temperature for 3 h. LCMS analysis revealed no remaining starting material and a mass consistent with the desired product. All of the volatiles were removed in vacuo, and the crude material was purified by prep HPLC (method: 95-5_6p5 min) to obtain the title compound as a pale yellow solid (22 mg, 76%). LCMS [M + H]<sup>+</sup> 359.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.76–10.89 (m, 1H), 8.95 (s, 2H), 8.90 (d, <i>J</i> = 1.0 Hz, 1H), 8.84–8.88 (m, 2H), 8.51–8.56 (m, 1H), 8.46 (d, <i>J</i> = 2.4 Hz, 1H), 8.29 (d, <i>J</i> = 2.0 Hz, 1H), 8.26 (d, <i>J</i> = 8.3 Hz, 1H), 7.85 (br. s., 2H), 7.76 (t, <i>J</i> = 5.6 Hz, 1H), 3.62 (q, <i>J</i> = 6.3 Hz, 2H), 3.06 (dq, <i>J</i> = 11.9, 5.8 Hz, 2H).</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> <i>tert</i>-Butyl (2-((5-(4-(Pyrazin-2-ylamino)quinolin-7-yl)pyrimidin-2-yl)amino)ethyl)carbamate (<b>6b</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with a step gradient of 2–5–7–10% methanol/dichloromethane to obtain the title compound as a brown solid (50 mg, 41%). LCMS [M + H]<sup>+</sup> 459.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.81 (s, 1H), 8.86 (s, 2H), 8.73 (d, <i>J</i> = 1.0 Hz, 1H), 8.72 (d, <i>J</i> = 5.4 Hz, 1H), 8.56 (d, <i>J</i> = 9.3 Hz, 1H), 8.33 (m, 2H), 8.20 (d, <i>J</i> = 1.0 Hz, 1H), 8.18 (d, <i>J</i> = 2.9 Hz, 1H), 7.97 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 7.43 (t, <i>J</i> = 5.9 Hz, 1H), 6.91 (t, <i>J</i> = 5.6 Hz, 1H), 3.39 (q, <i>J</i> = 6.3 Hz, 2H), 3.16 (dd, <i>J</i> = 7.1, 5.6 Hz, 2H), 1.38 (s, 9 H).</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> <i>tert</i>-Butyl Methyl(2-((4-(4-(pyrazin-2-ylamino)quinolin-7-yl)phenyl)amino)ethyl)carbamate (<b>6c</b>)</h4><div class="NLM_p last">Prepared via general procedure D. The initial Miyaura was complete in 15 min, and the subsequent Suzuki reaction was complete in 20 min. The crude material was purified by column chromatography, eluting with 1–10% methanol/dichloromethane. Further purification was required, and was performed by column chromatography, eluting with 1–7% methanol/dichloromethane to obtain the title compound as a yellow solid (29 mg, 41% over two steps). LCMS [M + H]<sup>+</sup> 473.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.80 (s, 1H), 8.87 (s, 2H), 8.73 (d, <i>J</i> = 1.5 Hz, 1H), 8.72 (d, <i>J</i> = 4.9 Hz, 1H), 8.56 (d, <i>J</i> = 8.8 Hz, 1H), 8.31–8.35 (m, 2H), 8.18 (d, <i>J</i> = 2.9 Hz, 2H), 7.96 (d, <i>J</i> = 8.3 Hz, 1H), 7.43–7.59 (m, 1H), 3.44 (d, <i>J</i> = 7.8 Hz, 4H), 2.79–2.89 (m, 3H), 1.24–1.41 (m, 9 H).</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-Trimethyl-<i>N</i><sup>2</sup>-(5-(4-(pyrazin-2-ylamino)quinolin-7-yl)pyrimidin-2-yl)ethane-1,2-diamine (<b>6d</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 10–20% methanol (+5% ammonium hydroxide)/ethyl acetate to obtain the title compound as a yellow solid (82 mg, 64%). LCMS [M + H]<sup>+</sup> 401.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.82 (br. s., 2H), 8.97 (s, 2H), 8.75 (s, 1H), 8.72 (d, <i>J</i> = 5.1 Hz, 1H), 8.59 (d, <i>J</i> = 8.8 Hz, 2H), 8.33 (br. s., 2H), 8.23 (s, 1H), 8.18 (d, <i>J</i> = 2.2 Hz, 1H), 7.99 (d, <i>J</i> = 8.8 Hz, 1H), 3.93 (t, <i>J</i> = 6.2 Hz, 2H), 3.21 (s, 3H), 2.91–3.08 (m, 2H), 2.60 (br. s., 6 H).</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> <i>tert</i>-Butyl 4-(5-(4-(Pyrazin-2-ylamino)quinolin-7-yl)pyrimidin-2-yl)piperazine-1-carboxylate (<b>6e</b>)</h4><div class="NLM_p last">Prepared via general procedure F. The crude material was purified by column chromatography, eluting with 1–5% methanol/dichloromethane to obtain the title compound as a pale yellow solid (108 mg, 74%). LCMS [M + H]<sup>+</sup> 485.3 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.80 (s, 1H), 8.97 (s, 2H), 8.66–8.82 (m, 2H), 8.57 (d, <i>J</i> = 8.8 Hz, 1H), 8.33 (dd, <i>J</i> = 2.7, 1.2 Hz, 2H), 8.24 (d, <i>J</i> = 1.5 Hz, 1H), 8.18 (d, <i>J</i> = 2.9 Hz, 1H), 7.99 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 3.82 (dd, <i>J</i> = 6.3, 4.4 Hz, 4H), 3.45 (t, <i>J</i> = 5.4 Hz, 4H), 1.44 (s, 9 H).</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 7-(2-(Piperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>6f</b>)</h4><div class="NLM_p last">Compound <b>6e</b> (110 mg, 0.227 mmol) was suspended in 4.0 M hydrochloric acid in dioxane (4 mL) and was stirred at ambient temperature. After 1 h, the reaction was complete by LCMS and TLC analysis. All of the volatiles were removed, and the crude material was redissolved in water (2 mL) and Si carbonate was added. The suspension was stirred at ambient temperature for ∼2 h. The Si carbonate was collected by vacuum filtration, and the filtrate was concentrated in vacuo to obtain the desired product as a yellow solid (70 mg, 80%). LCMS [M + H]<sup>+</sup> 385.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.16 (br. s, 1H), 9.03 (s, 2H), 8.94–8.99 (m, 2H), 8.85 (d, <i>J</i> = 6.3 Hz, 1H), 8.52 (s, 1H), 8.51 (dd, <i>J</i> = 3.9, 1.5 Hz, 1H), 8.43 (d, <i>J</i> = 2.4 Hz, 1H), 8.33 (d, <i>J</i> = 2.0 Hz, 1H), 8.21–8.26 (m, 1H), 4.08 (t, <i>J</i> = 5.4 Hz, 4H), 3.23 (br. s., 4H).</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Methyl 2-(4-(5-(4-(Pyrazin-2-ylamino)quinolin-7-yl)pyrimidin-2-yl)piperazin-1-yl)acetate (<b>6g</b>)</h4><div class="NLM_p">Prepared via general procedure F. The crude material was purified by column chromatography, eluting with 1–5% methanol/dichloromethane to obtain the title compound as a pale yellow solid (24 mg, 64%). LCMS [M + H]<sup>+</sup> 457.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.81–9.86 (m, 1H), 8.95 (s, 2H), 8.73 (d, <i>J</i> = 1.5 Hz, 2H), 8.55–8.60 (m, 1H), 8.33 (dd, <i>J</i> = 2.9, 1.5 Hz, 2H), 8.23 (s, 1H), 8.19 (d, <i>J</i> = 2.9 Hz, 1H), 7.96–8.02 (m, 1H), 3.81–3.87 (m, 4H), 3.63 (s, 3H), 2.61 (t, <i>J</i> = 4.9 Hz, 4H).</div><div class="NLM_p last">*Note that the methyl ester was obtained following purification.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> 2-(4-(5-(4-(Pyrazin-2-ylamino)quinolin-7-yl)pyrimidin-2-yl)piperazin-1-yl)acetic Acid (<b>6h</b>)</h4><div class="NLM_p">Prepared via general procedure F. The crude material was purified by column chromatography, eluting with 5–10% methanol/dichloromethane to obtain the title compound as a yellow solid (28 mg, 99%). LCMS [M + H]<sup>+</sup> 443.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.83 (br. s., 1H), 8.95 (s, 2H), 8.69–8.76 (m, 2H), 8.57 (d, <i>J</i> = 8.8 Hz, 1H), 8.33 (dd, <i>J</i> = 2.4, 1.5 Hz, 2H), 8.23 (d, <i>J</i> = 1.5 Hz, 1H), 8.18 (d, <i>J</i> = 2.9 Hz, 1H), 7.98 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 3.85 (t, <i>J</i> = 4.9 Hz, 4H), 3.18 (s, 2H), 2.64 (t, <i>J</i> = 4.9 Hz, 4H).</div><div class="NLM_p last">*The carboxylic acid peak is too rapidly exchanging to be seen in the <sup>1</sup>H NMR spectra.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> (5-(4-(Pyrazin-2-ylamino)quinolin-7-yl)pyrimidin-2-yl)proline (<b>6i</b>)</h4><div class="NLM_p">Prepared via general procedure F. The crude material was purified by column chromatography, eluting with 40–80% ethyl acetate/hexanes before switching to 0–40% methanol/dichloromethane to obtain the title compound as a yellow solid (27 mg, 53%). LCMS [M + H]<sup>+</sup> 414.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.90 (br. s., 1H), 8.91 (br. s., 1H), 8.87 (br. s., 2H), 8.74 (s, 1H), 8.70 (d, <i>J</i> = 5.4 Hz, 1H), 8.57 (d, <i>J</i> = 8.8 Hz, 1H), 8.32 (dd, <i>J</i> = 2.4, 1.5 Hz, 2H), 8.19 (s, 1H), 8.17 (d, <i>J</i> = 2.4 Hz, 1H), 7.94 (d, <i>J</i> = 8.8 Hz, 1H), 4.50 (dd, <i>J</i> = 8.5, 3.2 Hz, 1H), 3.59–3.76 (m, 2H), 2.20–2.33 (m, 2H), 2.02–2.11 (m, 1H), 1.92–2.02 (m, 2H).</div><div class="NLM_p">*The carboxylic acid peak is too rapidly exchanging to be seen in the <sup>1</sup>H NMR spectra.</div><div class="NLM_p last">**Note ester hydrolysis was observed under the reaction conditions.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Methyl (5-(4-(Pyrazin-2-ylamino)quinolin-7-yl)pyrimidin-2-yl)prolinate (<b>6j</b>)</h4><div class="NLM_p last">Prepared via general procedure F (except that the reaction was run in anhydrous dioxane). The crude material was purified by column chromatography, eluting first with 40–80% ethyl acetate/hexanes before switching to 0–5% methanol/dichloromethane to obtain the title compound as a pale yellow solid (20 mg, 38%). LCMS [M + H]<sup>+</sup> 428.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.81 (br. s., 1H), 8.98 (br. s., 2H), 8.92 (br. s., 2H), 8.69–8.76 (m, 2H), 8.57 (d, <i>J</i> = 9.3 Hz, 1H), 8.31–8.37 (m, 2H), 8.23 (s, 1H), 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 7.99 (d, <i>J</i> = 8.3 Hz, 1H), 4.61 (dd, <i>J</i> = 8.5, 3.2 Hz, 1H), 3.68–3.79 (m, 2H), 3.66 (s, 3H), 2.38 (dd, <i>J</i> = 11.7, 7.8 Hz, 1H), 1.93–2.10 (m, 3H).</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 6-Methyl-7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>9a</b>)</h4><div class="NLM_p last">Prepared via general procedure F. The reaction mixture was concentrated, ethyl acetate was added, and the suspension was filtered. The filtrate was washed with water and brine and dried with sodium sulfate. The crude product was purified via prep HPLC in basic mode using water (+0.1% ammonium hydroxide)/acetonitrile (30–100%) to obtain the title compound as a pale yellow solid (17 mg, 43%). LCMS [M + H]<sup>+</sup> 413.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.74 (s, 1H), 8.72 (s, 1H), 8.67 (d, <i>J</i> = 5.0 Hz, 1H), 8.55 (s, 2H), 8.39 (s, 1H), 8.32 (s, 1H), 8.31 (d, <i>J</i> = 5.5 Hz, 1H), 8.17 (d, <i>J</i> = 2.5 Hz, 1H), 7.81 (s, 1H), 3.81 (t, <i>J</i> = 5.0 Hz, 4H), 2.51 (d, <i>J</i> = 6.0 Hz, 3H), 2.40 (t, <i>J</i> = 5.0 Hz, 4H), 2.24 (s, 3H).</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 8-Methyl-7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>9b</b>)</h4><div class="NLM_p last">Prepared via general procedure F. The reaction mixture was then concentrated, ethyl acetate was added, and the suspension was filtered. The filtrate was washed with water and brine and dried with sodium sulfate. The crude product was purified via prep HPLC in basic mode using water 30–100% acetonitrile (+0.1% ammonium hydroxide)/water to obtain the title compound as a yellow solid (16 mg, 61%). LCMS [M + H]<sup>+</sup> 413.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.77 (s, 1H), 8.79 (d, <i>J</i> = 5.5 Hz, 1H), 8.72 (s, 1H), 8.54 (s, 2H), 8.40 (d, <i>J</i> = 9.0 Hz, 1H), 8.36 (d, <i>J</i> = 5.0 Hz, 1H), 8.32 (dd, <i>J</i> = 1.5, 2.5 Hz, 1H), 8.17 (d, <i>J</i> = 3.0 Hz, 1H), 7.54 (d, <i>J</i> = 9.0 Hz, 1H), 3.82 (t, <i>J</i> = 5.0 Hz, 4H), 2,70 (s, 3H), 2.44 (t, <i>J</i> = 5.0 Hz, 4H), 2.26 (s, 3H).</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 7-(2-((1<i>S</i>,4<i>S</i>)-5-Methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10a</b>)</h4><div class="NLM_p">Prepared via general procedure C (except that the reaction mixture was heated conventionally at 100 °C overnight). The crude material was purified by column chromatography, eluting with 1–20% methanol (+10% ammonium hydroxide)/dichloromethane. A second purification was necessary, and this was done by column chromatography, eluting first with 20–25% methanol/dichloromethane, before switching to 5–20% methanol (+10% ammonium hydroxide)/dichloromethane to afford the title compound as a yellow solid (16 mg, 21%). [α]<sub>D</sub><sup>22</sup> −77 ± 3.8 (<i>c</i> 0.38, CH<sub>3</sub>OH); LCMS [M + H]<sup>+</sup> 411.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.67 (s, 2H), 8.58 (d, <i>J</i> = 5.4 Hz, 1H), 8.55 (d, <i>J</i> = 1.5 Hz, 1H), 8.37 (d, <i>J</i> = 5.4 Hz, 1H), 8.33 (d, <i>J</i> = 8.8 Hz, 1H), 8.29 (dd, <i>J</i> = 2.4, 1.5 Hz, 1H), 8.10 (d, <i>J</i> = 2.9 Hz, 1H), 7.97 (d, <i>J</i> = 2.0 Hz, 1H), 7.73 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 4.86 (s, 1H), 3.76 (dd, <i>J</i> = 10.7, 1.5 Hz, 1H), 3.62 (s, 1H), 3.47 (dd, <i>J</i> = 11.0, 2.2 Hz, 1H), 3.35 (s, 5H), 2.91 (dd, <i>J</i> = 10.0, 2.2 Hz, 1H), 2.75 (d, <i>J</i> = 10.3 Hz, 1H), 2.45 (s, 3H), 2.04 (d, <i>J</i> = 9.8 Hz, 1H), 1.91 (d, <i>J</i> = 9.8 Hz, 1H).</div><div class="NLM_p last">*The −NH peak is too rapidly exchanging to be seen in the <sup>1</sup>H NMR spectra.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 7-(2-((1<i>R</i>,4<i>R</i>)-5-Methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10b</b>)</h4><div class="NLM_p">Prepared via general procedure C (except that the reaction mixture was heated conventionally at 100 °C overnight). The crude material was purified by column chromatography, eluting first with 50–100% ethyl acetate/hexanes, before switching to 0–30% methanol/dichloromethane. A second purification was necessary, and this was done by column chromatography, eluting with 20% methanol (+10% ammonium hydroxide)/dichloromethane to afford the title compound as an orange-yellow solid (63 mg, 35%). [α]<sub>D</sub><sup>27</sup> + 17 ± 0.42 (<i>c</i> 0.46, CH<sub>3</sub>OH); LCMS [M + H]<sup>+</sup> 411.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.82 (s, 2H), 8.68 (d, <i>J</i> = 5.4 Hz, 1H), 8.61 (s, 1H), 8.49 (d, <i>J</i> = 8.8 Hz, 1H), 8.46 (d, <i>J</i> = 5.4 Hz, 1H), 8.35 (dd, <i>J</i> = 2.4, 1.5 Hz, 1H), 8.15 (d, <i>J</i> = 2.4 Hz, 1H), 8.12 (d, <i>J</i> = 1.5 Hz, 1H), 7.88 (d, <i>J</i> = 7.8 Hz, 1H), 5.01 (s, 1H), 3.91 (br. s., 1H), 3.84 (d, <i>J</i> = 11.7 Hz, 1H), 3.63 (d, <i>J</i> = 12.2 Hz, 1H), 3.09 (s, 2H), 2.64 (s, 3H), 2.18 (d, <i>J</i> = 10.7 Hz, 1H), 2.08 (d, <i>J</i> = 11.2 Hz, 1H).</div><div class="NLM_p last">*The −NH peak is too rapidly exchanging to be seen in the <sup>1</sup>H NMR spectra.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> 7-(2-(4-Ethylpiperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10c</b>)</h4><div class="NLM_p last">Prepared via general procedure C (except that the reaction mixture was heated conventionally at 100 °C overnight). The crude material was purified by column chromatography, eluting with 2–5–10–15% methanol (+5% ammonium hydroxide)/ethyl acetate to obtain the title compound as a yellow solid (25 mg, 40%). LCMS [M + H]<sup>+</sup> 413.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.80 (s, 1H), 8.95 (s, 2H), 8.72 (d, <i>J</i> = 5.4 Hz, 2H), 8.56 (d, <i>J</i> = 8.8 Hz, 1H), 8.33 (d, <i>J</i> = 4.9 Hz, 2H), 8.23 (d, <i>J</i> = 1.5 Hz, 1H), 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 7.98 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 3.82 (t, <i>J</i> = 4.9 Hz, 4H), 2.45 (t, <i>J</i> = 4.9 Hz, 4H), 2.38 (q, <i>J</i> = 7.2 Hz, 2H), 1.05 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> 7-(2-(4-Propylpiperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10d</b>)</h4><div class="NLM_p last">Prepared via general procedure C (except 0.1 equiv of catalyst was used instead of 0.05 equiv). The crude material was purified by column chromatography, eluting with 2–5–10% methanol (+5% ammonium hydroxide)/ethyl acetate to obtain the title compound as a gold solid (64 mg, 51%). LCMS [M + H]<sup>+</sup> 427.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.80 (s, 1H), 8.94 (s, 2H), 8.69–8.76 (m, 2H), 8.56 (d, <i>J</i> = 8.8 Hz, 1H), 8.30–8.36 (m, 2H), 8.23 (d, <i>J</i> = 2.0 Hz, 1H), 8.18 (d, <i>J</i> = 2.9 Hz, 1H), 7.98 (dd, <i>J</i> = 9.0, 1.7 Hz, 1H), 3.82 (t, <i>J</i> = 4.9 Hz, 4H), 2.44 (t, <i>J</i> = 4.4 Hz, 4H), 2.29 (t, <i>J</i> = 7.3 Hz, 2H), 1.49 (sxt, <i>J</i> = 7.3 Hz, 2H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> 7-(2-(4-Methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10e</b>)</h4><div class="NLM_p last">Prepared via general procedure D. The crude material was purified by column chromatography, eluting with 1–5% methanol/dichloromethane to obtain the title compound as a yellow solid (73 mg, 48% over two steps). LCMS [M + H]<sup>+</sup> 413.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.82 (s, 1H), 8.94 (s, 2H), 8.75 (d, <i>J</i> = 1.0 Hz, 1H), 8.72 (d, <i>J</i> = 5.4 Hz, 1H), 8.58 (d, <i>J</i> = 8.8 Hz, 1H), 8.30–8.34 (m, 2H), 8.22 (d, <i>J</i> = 2.0 Hz, 1H), 8.17 (d, <i>J</i> = 2.9 Hz, 1H), 7.98 (dd, <i>J</i> = 9.0, 1.7 Hz, 1H), 3.92 (t, <i>J</i> = 4.4 Hz, 2H), 3.83 (t, <i>J</i> = 6.1 Hz, 2H), 2.72 (br. s., 2H), 2.58 (br. s., 2H), 1.91–1.97 (m, 2H), 1.90 (s, 3H).</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> 7-(2-(4-Ethyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10f</b>)</h4><div class="NLM_p">Prepared via general procedure C, eluting with 2–5% methanol (+5% ammonium hydroxide)/dichloromethane. Further purification was required and was performed by prep HPLC (method: 99-90_6p5 min) to obtain the title compound as a yellow solid (32 mg, 30%). LCMS [M + H]<sup>+</sup> 427.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.83 (br. s., 1H), 8.93 (s, 2H), 8.73 (s, 1H), 8.71 (d, <i>J</i> = 5.1 Hz, 1H), 8.57 (d, <i>J</i> = 8.8 Hz, 1H), 8.30–8.38 (m, 2H), 8.26–8.30 (m, 1H), 8.22 (d, <i>J</i> = 1.5 Hz, 1H), 8.17 (d, <i>J</i> = 2.9 Hz, 1H), 7.98 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 3.89 (t, <i>J</i> = 5.1 Hz, 2H), 3.83 (t, <i>J</i> = 6.2 Hz, 2H), 2.74 (t, <i>J</i> = 5.1 Hz, 2H), 2.58 (t, <i>J</i> = 5.1 Hz, 2H), 1.88 (qd, <i>J</i> = 6.6, 5.1 Hz, 2H), 0.99 (t, <i>J</i> = 7.0 Hz, 3H). <sup>1</sup>H NMR (399 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.68 (br. s., 2H), 8.52–8.61 (m, 2H), 8.36 (d, <i>J</i> = 5.1 Hz, 1H), 8.29 (br. s., 1H), 8.10 (d, <i>J</i> = 2.2 Hz, 1H), 7.94 (s, 1H), 7.72 (br. s., 1H), 4.03 (br. s., 2H), 3.88 (t, <i>J</i> = 6.2 Hz, 2H), 3.10 (br. s., 2H), 2.99 (t, <i>J</i> = 4.4 Hz, 1H), 2.88 (q, <i>J</i> = 7.1 Hz, 2H), 2.11 (td, <i>J</i> = 6.6, 4.4 Hz, 2H), 1.22 (t, <i>J</i> = 7.3 Hz, 3H).</div><div class="NLM_p last">*In DMSO, one of the methylenes is overlapping with the solvent signal</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 7-(2-(4-Propyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10g</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 2–5–10–15–20% methanol (+5% ammonium hydroxide)/ethyl acetate. Further purification was performed by column chromatography, eluting with 20% acetonitrile (+5% ammonium hydroxide)/dichloromethane to obtain the title compound as a pale brown solid (27 mg, 22%). LCMS [M + H]<sup>+</sup> 441.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.81 (s, 1H), 8.93 (s, 2H), 8.74 (s, 1H), 8.72 (d, <i>J</i> = 5.4 Hz, 1H), 8.57 (d, <i>J</i> = 8.8 Hz, 1H), 8.33 (s, 2H), 8.22 (s, 1H), 8.17 (d, <i>J</i> = 2.9 Hz, 1H), 7.98 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 3.86–3.91 (m, 2H), 3.83 (t, <i>J</i> = 6.1 Hz, 2H), 2.71–2.77 (m, 2H), 2.54–2.60 (m, 2H), 2.39 (t, <i>J</i> = 7.3 Hz, 2H), 1.86 (quin, <i>J</i> = 5.7 Hz, 2H), 1.42 (sxt, <i>J</i> = 7.3 Hz, 2H), 0.83 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> 7-(2-(Azepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10h</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 2–5–7–10% methanol/dichloromethane. Further purification was required by prep HPLC (method: 95-5_6p5 min) to obtain the title compound as a yellow solid (18 mg, 14%). LCMS [M + H]<sup>+</sup> 398.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.81 (br. s., 1H), 8.92 (s, 2H), 8.73 (s, 1H), 8.71 (d, <i>J</i> = 4.9 Hz, 1H), 8.56 (d, <i>J</i> = 8.8 Hz, 1H), 8.32 (dd, <i>J</i> = 2.4, 1.5 Hz, 2H), 8.21 (d, <i>J</i> = 1.5 Hz, 1H), 8.17 (d, <i>J</i> = 2.9 Hz, 1H), 7.97 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 3.80 (t, <i>J</i> = 5.9 Hz, 4H), 1.70–1.81 (m, 4H), 1.52 (quin, <i>J</i> = 2.4 Hz, 4H).</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> 7-(2-(2-Methyl-2,6-diazaspiro[3.4]octan-6-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10i</b>)</h4><div class="NLM_p last">Prepared via general procedure C with one exception, i.e., the reaction was run at 0.1 M. The crude material was purified by column chromatography, eluting with 10–20% methanol (+10% ammonium hydroxide)/ethyl acetate (step gradient) to afford the title compound as a yellow solid (8 mg, 28%). LCMS [M + H]<sup>+</sup> 425.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.83 (s, 2H), 8.69 (d, <i>J</i> = 5.4 Hz, 1H), 8.62 (d, <i>J</i> = 1.0 Hz, 1H), 8.51 (d, <i>J</i> = 8.8 Hz, 1H), 8.47 (d, <i>J</i> = 5.4 Hz, 1H), 8.36 (s, 1H), 8.17 (d, <i>J</i> = 2.4 Hz, 1H), 8.14 (d, <i>J</i> = 2.0 Hz, 1H), 7.90 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 4.12 (q, <i>J</i> = 9.3 Hz, 4H), 3.91 (s, 2H), 3.73 (t, <i>J</i> = 7.1 Hz, 2H), 2.91 (s, 3H), 2.38 (t, <i>J</i> = 7.1 Hz, 2H).</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> 7-(2-(7-Methyl-2,7-diazaspiro[4.4]nonan-2-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>10j</b>)</h4><div class="NLM_p last">Prepared via general procedure C with one exception, i.e., the reaction was run at 0.1 M. The crude material was purified by column chromatography, eluting with 10–20% methanol (+10% ammonium hydroxide)/ethyl acetate (step gradient) to afford the title compound as a tan solid (23 mg, 32%). LCMS [M + H]<sup>+</sup> 439.3 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.79 (s, 2H), 8.68 (d, <i>J</i> = 5.4 Hz, 1H), 8.61 (s, 1H), 8.48 (d, <i>J</i> = 8.8 Hz, 1H), 8.45 (d, <i>J</i> = 5.4 Hz, 1H), 8.35 (s, 1H), 8.15 (d, <i>J</i> = 2.4 Hz, 1H), 8.12 (s, 1H), 7.87 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 3.58–3.74 (m, 4H), 2.76 (t, <i>J</i> = 7.1 Hz, 2H), 2.68 (td, <i>J</i> = 9.8, 4.9 Hz, 2H), 2.42 (s, 3H), 2.02–2.15 (m, 2H), 1.95 (quind, <i>J</i> = 5.9, 5.9, 5.9, 5.9, 4.4 Hz, 2H).</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> 7-Bromo-<i>N</i>-cyclohexylquinolin-4-amine (<b>12a</b>)</h4><div class="NLM_p last">Prepared via general procedure H. The crude material was purified by column chromatography, eluting with 1–20% methanol/dichloromethane to afford the title compound as an off-white solid (26 mg, 41%). LCMS [M + H]<sup>+</sup> 305.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 307.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.49 (d, <i>J</i> = 5.9 Hz, 1H), 8.12 (d, <i>J</i> = 1.5 Hz, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (dd, <i>J</i> = 9.0, 1.7 Hz, 1H), 6.44 (d, <i>J</i> = 5.4 Hz, 1H), 4.93 (d, <i>J</i> = 6.8 Hz, 1H), 3.43–3.56 (m, 1H), 2.08–2.21 (m, 2H), 1.78–1.89 (m, 2H), 1.66–1.76 (m, 1H), 1.39–1.52 (m, 2H), 1.22–1.38 (m, 3H).</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> <i>N</i><sup>1</sup>-(7-Bromoquinolin-4-yl)-<i>N</i><sup>4</sup>,<i>N</i><sup>4</sup>-dimethylcyclohexane-1,4-diamine (<b>12b</b>)</h4><div class="NLM_p last">Prepared via general procedure H. The crude material was purified by column chromatography, eluting with 1–20% methanol/dichloromethane to afford the title compound as an off-white solid (15.8 mg, 22%). LCMS [M + H]<sup>+</sup> 348.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 350.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.51 (d, <i>J</i> = 4.9 Hz, 1H), 8.13 (d, <i>J</i> = 2.0 Hz, 1H), 7.56 (d, <i>J</i> = 8.8 Hz, 1H), 7.48 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.45 (d, <i>J</i> = 5.4 Hz, 1H), 4.83 (d, <i>J</i> = 6.8 Hz, 1H), 3.39–3.49 (m, 1H), 2.33 (s, 6 H), 2.24–2.32 (m, 2H), 2.12–2.22 (m, 1H), 2.04 (d, <i>J</i> = 12.7 Hz, 2H), 1.27–1.51 (m, 4H).</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> 7-Bromo-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)quinolin-4-amine (<b>12c</b>)</h4><div class="NLM_p last">Prepared via general procedure H. The crude material was purified by column chromatography, eluting with 1–20% methanol/dichloromethane to afford the title compound as a yellow solid (46 mg, 74%). LCMS [M + H]<sup>+</sup> 307.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 309.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.28 (d, <i>J</i> = 5.4 Hz, 1H), 7.95 (d, <i>J</i> = 2.0 Hz, 1H), 7.73 (d, <i>J</i> = 9.3 Hz, 1H), 7.42 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.39 (d, <i>J</i> = 5.9 Hz, 1H), 3.98 (dt, <i>J</i> = 11.5, 3.3 Hz, 2H), 3.75 (s, 1H), 3.66 (tt, <i>J</i> = 10.7, 4.2 Hz, 1H), 3.50 (td, <i>J</i> = 11.8, 2.2 Hz, 2H), 1.98–2.05 (m, 2H), 1.56–1.67 (m, 2H).</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> 7-Bromo-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-4-yl)methyl)quinolin-4-amine (<b>12d</b>)</h4><div class="NLM_p last">Prepared via general procedure H. The crude material was purified by column chromatography, eluting with 5–15% methanol/dichloromethane. The resulting residue was washed with hexanes, after which the title compound was collected by vacuum filtration as a yellow solid (47 mg, 71%). LCMS [M + H]<sup>+</sup> 321.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 323.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.37 (d, <i>J</i> = 5.4 Hz, 1H), 8.22 (d, <i>J</i> = 8.8 Hz, 1H), 7.93 (d, <i>J</i> = 2.0 Hz, 1H), 7.55 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.39 (t, <i>J</i> = 5.4 Hz, 1H), 6.52 (d, <i>J</i> = 5.4 Hz, 1H), 3.85 (dd, <i>J</i> = 11.2, 2.9 Hz, 2H), 3.24–3.30 (m, 2H), 1.91–2.01 (m, 1H), 1.68 (d, <i>J</i> = 12.7 Hz, 2H), 1.25 (qd, <i>J</i> = 12.2, 4.4 Hz, 2H), 1.07 (s, 2H).</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> (1<i>R</i>,2<i>R</i>)-2-((7-Bromoquinolin-4-yl)amino)cyclohexan-1-ol (<b>12e</b>)</h4><div class="NLM_p last">Prepared via general procedure H. The heating temperature was 180 °C instead of 200 °C. The crude material was purified by column chromatography, eluting with 1–8% methanol (+10% ammonium hydroxide)/dichloromethane, to afford the product compound as an off-white solid (95 mg, 98%). [α]<sub>D</sub><sup>21</sup> −0.79 ± 0.38 (<i>c</i> 1.1, 1:5 CH<sub>3</sub>OH/DCM); LCMS [M + H]<sup>+</sup> 321.3 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 323.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.58 (d, <i>J</i> = 9.3 Hz, 1H), 8.41 (d, <i>J</i> = 6.8 Hz, 2H), 8.11 (d, <i>J</i> = 2.0 Hz, 1H), 7.76 (dd, <i>J</i> = 9.3, 2.0 Hz, 1H), 6.86 (d, <i>J</i> = 6.3 Hz, 1H), 5.00 (br. s., 1H), 3.53–3.66 (m, 2H), 2.84–3.06 (m, 1H), 1.86–1.97 (m, 2H), 1.64–1.76 (m, 2H), 1.28–1.51 (m, 3H).</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> 7-Bromo-<i>N</i>-(3-methylpyrazin-2-yl)quinolin-4-amine (<b>12f</b>)</h4><div class="NLM_p last">Prepared via general procedure G. There was no precipitate evident so the aqueous phase was extracted twice with dichloromethane. The organic layers were combined and washed once with a saturated aqueous sodium chloride solution before being dried with magnesium sulfate. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography, eluting with 50–65% ethyl acetate/hexanes before switching to 0–10% methanol/dichloromethane to obtain the title compound as an orange solid (264 mg, 41%). LCMS [M + H]<sup>+</sup> 314.9 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 317.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.87 (s, 1H), 8.70 (d, <i>J</i> = 4.9 Hz, 1H), 8.21 (d, <i>J</i> = 9.3 Hz, 1H), 8.12–8.18 (m, 3H), 7.71 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 7.61 (d, <i>J</i> = 4.9 Hz, 1H), 2.63 (s, 3H).</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> 7-Bromo-<i>N</i>-(5-methylpyrazin-2-yl)quinolin-4-amine (<b>12g</b>)</h4><div class="NLM_p last">Prepared via general procedure G. The solid was collected and purified by column chromatography, eluting with 0–15% methanol/dichloromethane to obtain the title compound as a pale orange solid (250 mg, 38%). LCMS [M + H]<sup>+</sup> 314.9 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 317.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.73 (s, 1H), 8.68 (d, <i>J</i> = 5.4 Hz, 1H), 8.61 (d, <i>J</i> = 1.5 Hz, 1H), 8.47 (d, <i>J</i> = 8.8 Hz, 1H), 8.30 (d, <i>J</i> = 5.4 Hz, 1H), 8.23 (s, 1H), 8.14 (d, <i>J</i> = 2.0 Hz, 1H), 7.77 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 2.44 (s, 3H).</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> 7-Bromo-<i>N</i>-(6-methylpyrazin-2-yl)quinolin-4-amine (<b>12h</b>)</h4><div class="NLM_p last">Prepared via general procedure G. The crude material was purified by column chromatography, eluting with 0–15% methanol/dichloromethane to obtain the title compound as a pale yellow solid (486 mg, 75%). LCMS [M + H]<sup>+</sup> 314.9 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 316.9 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.77 (s, 1H), 8.72 (d, <i>J</i> = 5.4 Hz, 1H), 8.50 (s, 1H), 8.47 (d, <i>J</i> = 9.3 Hz, 1H), 8.43 (d, <i>J</i> = 5.4 Hz, 1H), 8.15 (d, <i>J</i> = 2.0 Hz, 1H), 8.09 (s, 1H), 7.78 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 2.46 (s, 3H).</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> <i>N</i>-Cyclohexyl-7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)quinolin-4-amine, Monoformate Salt (<b>15a</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 1–20% methanol/dichloromethane. The material was further purified by prep HPLC (method: 95-70_6p5 min). The residue was triturated with dichloromethane, and the subsequent precipitate was isolated by vacuum filtration, to obtain the title compound as a tan solid (7.3 mg, 11%). LCMS [M + H]<sup>+</sup> 403.3 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.88 (s, 2H), 8.45 (d, <i>J</i> = 9.3 Hz, 1H), 8.40 (d, <i>J</i> = 5.4 Hz, 1H), 8.15 (s, 2H), 8.00 (s, 1H), 7.81 (d, <i>J</i> = 8.8 Hz, 1H), 7.31–7.40 (m, 1H), 6.60 (d, <i>J</i> = 5.4 Hz, 1H), 3.82 (br. s., 4H), 2.41 (t, <i>J</i> = 4.6 Hz, 4H), 2.24 (s, 3H), 2.00 (br. s., 2H), 1.80 (br. s., 2H), 1.67 (d, <i>J</i> = 11.7 Hz, 1H), 1.35–1.48 (m, 4H), 1.13–1.26 (m, 1H). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.87 (s, 2H), 8.55 (d, <i>J</i> = 8.8 Hz, 1H), 8.38 (br. s., 2H), 8.35 (d, <i>J</i> = 6.8 Hz, 1H), 7.99 (br. s., 1H), 7.96 (d, <i>J</i> = 9.3 Hz, 1H), 6.90 (d, <i>J</i> = 6.8 Hz, 1H), 4.13 (br. s., 4H), 3.78–3.90 (m, 1H), 3.08 (br. s., 4H), 2.74 (s, 3H), 2.12 (d, <i>J</i> = 9.8 Hz, 2H), 1.92 (d, <i>J</i> = 10.7 Hz, 2H), 1.78 (d, <i>J</i> = 12.7 Hz, 1H), 1.46–1.64 (m, 4H), 1.32 (d, <i>J</i> = 10.7 Hz, 1H).</div></div><div id="sec4_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> 7-(2-(4-Methylpiperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-(1-methylpiperidin-4-yl)quinolin-4-amine, Triformate Salt (<b>15b</b>)</h4><div class="NLM_p last">4-Chloro-7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)quinoline (<b>39</b>) (20 mg, 0.059 mmol), 1-methylpiperidin-4-amine (14.8 μL, 0.12 mmol), tris(dibenzylideneacetone)dipalladium(0) (2.7 mg, 0.003 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (2.8 mg, 0.006 mmol), and potassium <i>tert-</i>butoxide (19.8 mg, 0.177 mmol) were added to a vial that was filled with nitrogen and evacuated three times. Dry, degassed dioxane (1 mL) was then added. The reaction mixture was heated at 90 °C overnight. LCMS analysis revealed no remaining starting material and a mass consistent with the desired product. The reaction mixture was filtered through celite and purified by column chromatography, eluting with 0–20% (10% ammonium hydroxide/methanol)/dichloromethane. The material was further purified by prep HPLC (method: 99-95_6p5 min) to afford the title compound as a yellow solid (11.7 mg, 47%). LCMS [M + H]<sup>+</sup> 418.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.82 (s, 2H), 8.52 (d, <i>J</i> = 8.8 Hz, 1H), 8.47 (s, 3H), 8.41 (d, <i>J</i> = 6.8 Hz, 1H), 8.01 (s, 1H), 7.93 (d, <i>J</i> = 8.8 Hz, 1H), 6.94 (d, <i>J</i> = 7.3 Hz, 1H), 4.06 (br. s., 5H), 3.50 (br. s., 2H), 3.06 (br. s., 2H), 2.95 (t, <i>J</i> = 5.1 Hz, 4H), 2.62 (s, 6H), 2.27 (d, <i>J</i> = 12.7 Hz, 2H), 2.03–2.17 (m, 2H).</div></div><div id="sec4_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-Dimethyl-<i>N</i><sup>4</sup>-(7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)quinolin-4-yl)cyclohexane-1,4-diamine (<b>15c</b>)</h4><div class="NLM_p last">Prepared via general procedure F with some exceptions. The reaction mixture was run in a 3:1 mixture of degassed dioxane/water (0.08 M), and the reaction was heated for 48 h at 80 °C. The crude material was purified by column chromatography, eluting with 4–10% methanol (10% ammonium hydroxide)/dichloromethane to afford the title compound as an off-white solid, 28 mg (27%). LCMS [M + H]<sup>+</sup> 446.3 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.86 (s, 2H), 8.37 (d, <i>J</i> = 5.4 Hz, 1H), 8.34 (d, <i>J</i> = 8.8 Hz, 1H), 7.99 (d, <i>J</i> = 2.0 Hz, 1H), 7.71 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.79 (d, <i>J</i> = 7.8 Hz, 1H), 6.48 (d, <i>J</i> = 5.4 Hz, 1H), 3.78–3.83 (m, 4H), 3.41–3.50 (m, 1H), 2.39 (t, <i>J</i> = 5.1 Hz, 4H), 2.23 (s, 3H), 2.20 (s, 7 H), 2.08 (d, <i>J</i> = 10.7 Hz, 2H), 1.87 (d, <i>J</i> = 11.2 Hz, 2H), 1.39 (m, 4H).</div></div><div id="sec4_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> 7-(2-(4-Methylpiperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-(2-(pyrrolidin-1-yl)ethyl)quinolin-4-amine (<b>15d</b>)</h4><div class="NLM_p last">4-Chloro-7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)quinoline (<b>39</b>) (20 mg, 0.059 mmol), 2-(pyrrolidin-1-yl)ethan-1-amine (14.8 μL, 0.12 mmol), tris(dibenzylideneacetone)dipalladium(0) (2.7 mg, 0.003 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (2.8 mg, 0.006 mmol), and potassium <i>tert-</i>butoxide (19.8 mg, 0.177 mmol) were added to a vial that was filled with nitrogen and evacuated three times. Dry, degassed dioxane (1.5 mL) was then added. The reaction mixture was heated at 90 °C overnight. LCMS analysis revealed no remaining starting material and a mass consistent with the desired product. The reaction mixture was filtered through celite and purified by column chromatography, eluting with 2–20% (5% ammonium hydroxide/methanol)/dichloromethane to afford the title compound as a yellow solid (36 mg, 59%). LCMS [M + H]<sup>+</sup> 418.3 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.87 (s, 2H), 8.40 (d, <i>J</i> = 5.9 Hz, 1H), 8.25 (d, <i>J</i> = 8.8 Hz, 1H), 8.01 (s, 1H), 7.75 (d, <i>J</i> = 8.8 Hz, 1H), 7.20 (br. s., 1H), 6.45 (d, <i>J</i> = 5.1 Hz, 1H), 3.81 (m, 1H), 3.38–3.47 (m, 1H), 2.73 (t, <i>J</i> = 6.6 Hz, 2H), 2.55 (br. s., 4H), 2.38 (t, <i>J</i> = 4.8 Hz, 4H), 2.18–2.26 (m, 3H), 1.70 (br. s., 4H).</div></div><div id="sec4_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> 7-(2-(4-Methylpiperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)quinolin-4-amine (<b>15e</b>)</h4><div class="NLM_p last">Prepared via general procedure F. The crude material was purified by column chromatography, eluting with 1–20% methanol (+50% ammonium hydroxide)/dichloromethane. The resulting product was triturated with ether and the precipitate was collected by vacuum filtration to afford the title compound as a light brown solid (22 mg, 36%). LCMS [M + H]<sup>+</sup> 405.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.74 (s, 2H), 8.36 (d, <i>J</i> = 5.9 Hz, 1H), 8.27 (d, <i>J</i> = 8.8 Hz, 1H), 7.92 (s, 1H), 7.69 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 6.65 (d, <i>J</i> = 5.9 Hz, 1H), 3.99–4.08 (m, 2H), 3.85–3.95 (m, 5H), 3.60 (m, 2H), 2.52 (t, <i>J</i> = 5.1 Hz, 4H), 2.34 (s, 3H), 2.01–2.11 (m, 2H), 1.68–1.82 (m, 2H).</div></div><div id="sec4_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> 7-(2-(4-Methylpiperazin-1-yl)pyrimidin-5-yl)-<i>N</i>-((tetrahydro-2<i>H</i>-pyran-4-yl)methyl)quinolin-4-amine (<b>15f</b>)</h4><div class="NLM_p last">Prepared via general procedure F with some exceptions. The reaction mixture was run in a 3:1 mixture of degassed dioxane/water (0.08 M), and the reaction was heated for 18 h at 80 °C. The crude material was purified by column chromatography, eluting with 2–20% methanol/dichloromethane. The compound was further purified by column chromatography, eluting with 1–8% methanol (+5% ammonium hydroxide)/dichloromethane to afford the title compound as a colorless solid, (26 mg, 44%). LCMS [M + H]<sup>+</sup> 419.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.86 (s, 2H), 8.38 (d, <i>J</i> = 5.4 Hz, 1H), 8.31 (d, <i>J</i> = 8.8 Hz, 1H), 8.00 (d, <i>J</i> = 1.5 Hz, 1H), 7.72 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.25 (t, <i>J</i> = 5.6 Hz, 1H), 6.46 (d, <i>J</i> = 5.9 Hz, 1H), 3.86 (dd, <i>J</i> = 11.2, 2.9 Hz, 2H), 3.77–3.83 (m, 4H), 3.28 (m, 2H), 3.18 (t, <i>J</i> = 6.1 Hz, 2H), 2.38 (t, <i>J</i> = 4.9 Hz, 4H), 2.22 (s, 3H), 1.93–2.03 (m, 1H), 1.69 (dd, <i>J</i> = 12.5, 1.2 Hz, 2H), 1.26 (qd, <i>J</i> = 12.2, 3.9 Hz, 2H).</div></div><div id="sec4_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> (1<i>R</i>,2<i>R</i>)-2-((7-(2-(4-Methylpiperazin-1-yl)pyrimidin-5-yl)quinolin-4-yl)amino)cyclohexan-1-ol (<b>15g</b>)</h4><div class="NLM_p last">Prepared via general procedure F with some exceptions. The reaction mixture was run in a 3:1 mixture of degassed dioxane/water (0.08 M), and the reaction was heated for 48 h at 80 °C. The crude material was purified by column chromatography, eluting with 4–8% methanol (+10% ammonium hydroxide)/dichloromethane to afford the title compound as a light brown solid (46 mg, 38%). [α]<sub>D</sub><sup>22</sup> + 0.57 ± 0.28 (<i>c</i> 1.1, 1:10 DCM/CH<sub>3</sub>OH); LCMS [M + H]<sup>+</sup> 419.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.87 (s, 2H), 8.35 (d, <i>J</i> = 2.0 Hz, 1H), 8.34 (s, 1H), 7.99 (d, <i>J</i> = 2.0 Hz, 1H), 7.72 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.72 (d, <i>J</i> = 7.8 Hz, 1H), 6.51 (d, <i>J</i> = 5.9 Hz, 1H), 4.74 (br. s., 1H), 3.92 (br. s., 1H), 3.74–3.85 (m, 4H), 3.52–3.62 (m, 1H), 2.35–2.43 (m, 4H), 2.23 (s, 3H), 1.98 (m, 2H), 1.68 (m, 2H), 1.31 (m, 4H).</div></div><div id="sec4_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> <i>N</i><sup>7</sup>-(4-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i><sup>4</sup>-(pyrazin-2-yl)quinoline-4,7-diamine (<b>16b</b>)</h4><div class="NLM_p last">Compound <b>5</b> (150 mg, 0.498 mmol), 4-(4-methylpiperazin-1-yl)aniline (114 mg, 0.598 mmol), cesium carbonate (325 mg, 0.996 mmol), palladium acetate (11 mg, 0.050 mmol), and XANTPhos (58 mg, 0.100 mmol) were combined in an oven-dried microwave vial with anhydrous dioxane (9 mL). The reaction mixture was degassed and placed in the CEM microwave at 140 °C for 30 min. LCMS analysis revealed no remaining starting material and a mass consistent with the desired product. The crude material was purified by column chromatography, eluting with 5–8% methanol/dichloromethane. The material was further purified by column chromatography, eluting first with 5–15% methanol (+1% ammonium hydroxide)/ethyl acetate, followed by 15–20% methanol (+1% ammonium hydroxide)/dichloromethane. The material was again further purified eluting with 5–15% methanol (+1% ammonium hydroxide)/ethyl acetate to obtain the title compound as an orange solid (112 mg, 55%). LCMS [M + H]<sup>+</sup> 412.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.58 (s, 1H), 8.66 (s, 1H), 8.48 (d, <i>J</i> = 5.37 Hz, 1H), 8.31 (s, 1H), 8.28 (dd, <i>J</i> = 2.44, 1.47 Hz, 1H), 8.24 (d, <i>J</i> = 9.28 Hz, 1H), 8.13 (d, <i>J</i> = 2.44 Hz, 1H), 7.99 (d, <i>J</i> = 4.88 Hz, 1H), 7.27 (d, <i>J</i> = 2.44 Hz, 1H), 7.22 (dd, <i>J</i> = 9.28, 1.95 Hz, 1H), 7.16 (d, <i>J</i> = 8.79 Hz, 2H), 6.98 (d, <i>J</i> = 9.28 Hz, 2H), 3.07–3.15 (m, 4H), 2.44–2.50 (m, 4H), 2.24 (s, 3H).</div></div><div id="sec4_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> 7-(2-((4-Methylpiperazin-1-yl)amino)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>16f</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 2–5–7–10% methanol/dichloromethane before switching to 5–10% methanol (+5% ammonium hydroxide)/dichloromethane to obtain the title compound as a yellow solid (28 mg, 39%). LCMS [M + H]<sup>+</sup> 414.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.90 (br. s., 1H), 8.93 (s, 2H), 8.78 (s, 1H), 8.77 (s, 1H), 8.73 (d, <i>J</i> = 5.4 Hz, 1H), 8.61 (d, <i>J</i> = 8.8 Hz, 1H), 8.31–8.37 (m, 2H), 8.24 (d, <i>J</i> = 2.0 Hz, 1H), 8.20 (d, <i>J</i> = 2.4 Hz, 1H), 7.99 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 3.24 (br. s., 4H), 3.11 (br. s., 3H), 2.75 (br. s., 3H).</div></div><div id="sec4_1_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> 7-(2-(4-Methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(3-methylpyrazin-2-yl)quinolin-4-amine (<b>17a</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 2–5–7–10% methanol/dichloromethane before switching to 5–10–20% methanol (+5% ammonium hydroxide)/dichloromethane to obtain the title compound. Further purification was performed by prep HPLC (method: 95-50_6p5 min) to obtain the title compound as a yellow, oily solid (11 mg, 8%). LCMS [M + H]<sup>+</sup> 427.3 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.83 (s, 2H), 8.63 (d, <i>J</i> = 5.4 Hz, 1H), 8.30 (d, <i>J</i> = 8.8 Hz, 1H), 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 8.14 (d, <i>J</i> = 2.9 Hz, 1H), 8.11 (d, <i>J</i> = 1.0 Hz, 1H), 7.84 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 7.75 (d, <i>J</i> = 5.4 Hz, 1H), 4.16 (t, <i>J</i> = 4.4 Hz, 2H), 3.98 (t, <i>J</i> = 6.3 Hz, 2H), 3.34 (d, <i>J</i> = 4.4 Hz, 2H), 3.25 (t, <i>J</i> = 5.4 Hz, 2H), 2.81 (s, 3H), 2.69 (s, 3H), 2.24 (quin, <i>J</i> = 5.4 Hz, 2H).</div></div><div id="sec4_1_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> 7-(2-(4-Methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(5-methylpyrazin-2-yl)quinolin-4-amine (<b>17b</b>)</h4><div class="NLM_p last">Prepared via general procedure D. The crude material was purified by column chromatography, eluting with 1–10% methanol (+5% ammonium hydroxide)/dichloromethane. A second purification was necessary, and this was done by column chromatography, eluting with 5–10% methanol/dichloromethane to obtain the title compound as a yellow solid (20 mg, 29% over two steps). LCMS [M + H]<sup>+</sup> 427.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.67 (s, 1H), 8.93 (s, 2H), 8.68 (d, <i>J</i> = 5.4 Hz, 1H), 8.64 (d, <i>J</i> = 1.5 Hz, 1H), 8.56 (d, <i>J</i> = 9.3 Hz, 1H), 8.25 (d, <i>J</i> = 5.4 Hz, 1H), 8.23 (s, 1H), 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.96 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 3.91 (t, <i>J</i> = 4.4 Hz, 2H), 3.83 (t, <i>J</i> = 6.1 Hz, 2H), 2.66 (t, <i>J</i> = 4.9 Hz, 2H), 2.52 (m, 2H), 2.44 (s, 3H), 2.28 (s, 3H), 1.91 (quin, <i>J</i> = 5.7 Hz, 2H).</div></div><div id="sec4_1_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> 7-(2-(4-Methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(6-methyl-pyrazin-2-yl)quinolin-4-amine (<b>17c</b>)</h4><div class="NLM_p">Prepared via general procedure D. The crude material was purified by column chromatography, eluting with 1–10% methanol (+5% ammonium hydroxide)/dichloromethane to obtain the title compound as a brown solid (11 mg, 7% over two steps). LCMS [M + H]<sup>+</sup> 427.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.70 (s, 1H), 8.93 (s, 2H), 8.71 (d, <i>J</i> = 4.9 Hz, 1H), 8.56 (d, <i>J</i> = 8.8 Hz, 1H), 8.53 (s, 1H), 8.37 (d, <i>J</i> = 4.9 Hz, 1H), 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 8.08 (s, 1H), 7.96 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 3.90 (t, <i>J</i> = 4.9 Hz, 2H), 3.82 (t, <i>J</i> = 6.3 Hz, 2H), 2.65 (t, <i>J</i> = 5.4 Hz, 2H), 2.47 (s, 3H), 2.27 (s, 3H), 1.91 (dt, <i>J</i> = 11.7, 5.9 Hz, 2H).</div><div class="NLM_p last">*One of the methylenes is under the DMSO signal.</div></div><div id="sec4_1_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> <i>N</i>-Methyl-7-(2-(4-methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>18</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 5–15% methanol (+5% ammonium hydroxide)/ethyl acetate to obtain the title compound as a brown oil (70 mg, 53%). LCMS [M + H]<sup>+</sup> 427.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 9.02 (d, <i>J</i> = 4.9 Hz, 1H), 8.73 (s, 2H), 8.32 (d, <i>J</i> = 1.5 Hz, 1H), 8.19 (dd, <i>J</i> = 2.4, 1.5 Hz, 1H), 7.96 (d, <i>J</i> = 2.4 Hz, 1H), 7.83 (d, <i>J</i> = 8.8 Hz, 1H), 7.73 (d, <i>J</i> = 1.5 Hz, 1H), 7.68 (dd, <i>J</i> = 8.8, 1.5 Hz, 1H), 7.33 (d, <i>J</i> = 4.4 Hz, 1H), 4.02 (br. s., 2H), 3.91 (t, <i>J</i> = 6.1 Hz, 2H), 3.62 (s, 3H), 2.76 (br. s., 2H), 2.62 (br. s., 2H), 2.42 (s, 3H), 2.06 (br. s., 1H).</div></div><div id="sec4_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> (<i>E</i>)-7-Bromo-1-methyl-<i>N</i>-(pyrazin-2-yl)quinolin-4(1<i>H</i>)-imine (<b>19a</b>)</h4><div class="NLM_p last">Prepared via general procedure I. The crude material was purified by column chromatography, eluting with 2–7% methanol (+5% ammonium hydroxide)/dichloromethane (step gradient) to obtain the title product as a yellow solid (663 mg, 63%). LCMS [M + H]<sup>+</sup> 314.9 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 317.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.51 (d, <i>J</i> = 8.8 Hz, 1H), 8.34 (dd, <i>J</i> = 2.4, 1.5 Hz, 1H), 8.31 (s, 1H), 8.15 (d, <i>J</i> = 2.4 Hz, 1H), 7.88 (br. s., 1H), 7.79 (br. s., 1H), 7.63 (d, <i>J</i> = 8.3 Hz, 1H), 6.84–7.05 (m, 1H), 3.81 (s, 3H).</div></div><div id="sec4_1_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> (<i>E</i>)-7-Bromo-1-ethyl-<i>N</i>-(pyrazin-2-yl)quinolin-4(1<i>H</i>)-imine (<b>19b</b>)</h4><div class="NLM_p last">Prepared via general procedure I. The crude material was purified by column chromatography, eluting with 1–10% methanol/dichloromethane to obtain the title compound as a dark orange oil (59 mg, 27%). LCMS [M + H]<sup>+</sup> 329.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 331.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.49 (d, <i>J</i> = 8.8 Hz, 1H), 8.32 (dd, <i>J</i> = 2.4, 1.5 Hz, 1H), 8.27 (d, <i>J</i> = 1.5 Hz, 1H), 8.13 (d, <i>J</i> = 2.9 Hz, 1H), 7.93 (d, <i>J</i> = 1.5 Hz, 1H), 7.75 (d, <i>J</i> = 7.8 Hz, 1H), 7.57 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.84 (d, <i>J</i> = 7.8 Hz, 1H), 4.24 (q, <i>J</i> = 7.0 Hz, 2H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> (<i>E</i>)-7-Bromo-1-propyl-<i>N</i>-(pyrazin-2-yl)quinolin-4(1<i>H</i>)-imine (<b>19c</b>)</h4><div class="NLM_p last">Prepared via general procedure I. The crude material was purified by column chromatography, eluting with 1–10% methanol/dichloromethane to obtain the title compound as an orange oil (91 mg, 40%). LCMS [M + H]<sup>+</sup> 343.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 345.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.52 (d, <i>J</i> = 8.3 Hz, 1H), 8.30–8.37 (m, 2H), 8.16 (d, <i>J</i> = 2.4 Hz, 1H), 8.00 (br. s., 1H), 7.83 (br. s., 1H), 7.61 (d, <i>J</i> = 7.3 Hz, 1H), 6.97 (d, <i>J</i> = 7.8 Hz, 1H), 4.21 (t, <i>J</i> = 6.8 Hz, 2H), 1.74 (sxt, <i>J</i> = 7.3 Hz, 2H), 0.90 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> (<i>E</i>)-1-Methyl-7-(2-(4-methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4(1<i>H</i>)-imine (<b>22a</b>)</h4><div class="NLM_p">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 10–20% methanol/dichloromethane before switching to 10–15% methanol (+5% ammonium hydroxide)/dichloromethane to elute the product. The title compound was obtained as a yellow solid (242 mg, 51% over two steps). LCMS [M + H]<sup>+</sup> 427.1 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.81 (s, 2H), 8.65 (d, <i>J</i> = 8.8 Hz, 1H), 8.31–8.35 (m, 2H), 8.14 (d, <i>J</i> = 2.4 Hz, 1H), 7.76 (s, 1H), 7.70 (dd, <i>J</i> = 8.3, 1.5 Hz, 1H), 7.65 (d, <i>J</i> = 7.8 Hz, 1H), 6.58–6.72 (m, 1H), 4.00 (t, <i>J</i> = 4.9 Hz, 2H), 3.89–3.94 (m, 2H), 3.91 (s, 3H), 2.78 (t, <i>J</i> = 4.9 Hz, 2H), 2.64 (t, <i>J</i> = 5.4 Hz, 2H), 2.40 (s, 3H), 2.05 (dt, <i>J</i> = 11.8, 6.0 Hz, 2H). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.91 (s, 2H), 8.60 (d, <i>J</i> = 8.8 Hz, 1H), 8.30 (dd, <i>J</i> = 2.4, 1.5 Hz, 1H), 8.25 (d, <i>J</i> = 1.5 Hz, 1H), 8.08 (d, <i>J</i> = 2.9 Hz, 1H), 7.78 (d, <i>J</i> = 1.5 Hz, 1H), 7.68–7.75 (m, 2H), 6.84 (d, <i>J</i> = 7.3 Hz, 1H), 3.90 (t, <i>J</i> = 4.9 Hz, 2H), 3.85 (s, 3H), 3.82 (t, <i>J</i> = 6.1 Hz, 2H), 2.64 (t, <i>J</i> = 4.9 Hz, 2H), 2.27 (s, 3H), 1.90 (dt, <i>J</i> = 11.6, 5.7 Hz, 2H).</div><div class="NLM_p last">*One of the methylenes is under the DMSO signal.</div></div><div id="sec4_1_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> (<i>E</i>)-1-Ethyl-7-(2-(4-methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-<i>N</i>-(pyrazin-2-yl)quinolin-4(1<i>H</i>)-imine (<b>22b</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 2–5–7–10% methanol/dichloromethane first before switching to 5–10–20% methanol (+5% ammonium hydroxide)/dichloromethane to obtain the title compound as a glassy brown solid (31 mg, 39% over two steps). LCMS [M + H]<sup>+</sup> 441.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.92 (s, 2H), 8.63 (d, <i>J</i> = 8.3 Hz, 1H), 8.31 (dd, <i>J</i> = 2.4, 1.5 Hz, 1H), 8.29 (s, 1H), 8.11 (d, <i>J</i> = 2.4 Hz, 1H), 7.88 (s, 1H), 7.81 (d, <i>J</i> = 7.8 Hz, 1H), 7.74 (d, <i>J</i> = 8.8 Hz, 1H), 6.93 (d, <i>J</i> = 6.3 Hz, 1H), 4.37 (q, <i>J</i> = 7.0 Hz, 2H), 3.93 (br. s., 2H), 3.84 (t, <i>J</i> = 6.3 Hz, 2H), 2.76 (br. s., 2H), 2.62 (br. s., 1H), 2.35 (br. s., 3H), 1.95 (tt, <i>J</i> = 6.3, 4.9 Hz, 2H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> (<i>E</i>)-7-(2-(4-Methyl-1,4-diazepan-1-yl)pyrimidin-5-yl)-1-propyl-<i>N</i>-(pyrazin-2-yl)quinolin-4(1<i>H</i>)-imine (<b>22c</b>)</h4><div class="NLM_p last">Prepared via general procedure C. The crude material was purified by column chromatography, eluting with 2–5–7–10% methanol/dichloromethane first before switching to 5–10–20% methanol (+5% ammonium hydroxide)/dichloromethane to obtain the title compound as a brown glassy solid (44 mg, 36% over two steps). LCMS [M + H]<sup>+</sup> 455.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.93 (s, 2H), 8.65 (d, <i>J</i> = 8.8 Hz, 1H), 8.29–8.34 (m, 2H), 8.12 (d, <i>J</i> = 2.4 Hz, 1H), 7.89 (s, 1H), 7.84 (d, <i>J</i> = 6.8 Hz, 1H), 7.76 (d, <i>J</i> = 8.8 Hz, 1H), 6.92–7.03 (m, 1H), 4.32 (t, <i>J</i> = 7.3 Hz, 2H), 3.94 (d, <i>J</i> = 6.3 Hz, 2H), 3.84 (t, <i>J</i> = 6.1 Hz, 2H), 2.82 (br. s., 2H), 2.68 (br. s., 2H), 2.40 (br. s., 3H), 1.97 (t, <i>J</i> = 5.4 Hz, 2H), 1.80 (dq, <i>J</i> = 14.3, 7.4 Hz, 2H), 0.92 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_1_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> <i>N</i>-Methylpyrazin-2-amine (<b>24</b>)</h4><div class="NLM_p last">Prepared via general procedure I. The crude material was purified by column chromatography, eluting with 2–5% methanol/dichloromethane to obtain the title compound as a yellow oil (140 mg, 49%). LCMS [M + H]<sup>+</sup> 109.4 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.90 (d, <i>J</i> = 14.7 Hz, 2H), 7.62 (d, <i>J</i> = 2.2 Hz, 1H), 7.00 (br. s., 1H), 2.77 (d, <i>J</i> = 4.4 Hz, 3H). <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub> plus D<sub>2</sub>O) δ ppm 7.91 (br. s., 1H), 7.86 (s, 1H), 7.61 (d, <i>J</i> = 2.2 Hz, 1H), 2.75 (s, 3H).</div></div><div id="sec4_1_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> 7-Bromo-<i>N</i>-methyl-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>25</b>)</h4><div class="NLM_p last">Prepared via general procedure G. The sodium hydride was quenched by addition of methanol until no further effervescence was observed. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography, eluting with 50–75% ethyl acetate/hexanes, before switching to 0–5% methanol/dichloromethane to obtain the title compound as a yellow solid (140 mg, 82%). LCMS [M + H]<sup>+</sup> 315.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 317.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (399 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.00 (d, <i>J</i> = 4.4 Hz, 1H), 8.33 (s, 1H), 8.12 (s, 1H), 7.99 (d, <i>J</i> = 2.2 Hz, 1H), 7.96 (s, 1H), 7.64–7.72 (m, 2H), 7.61 (d, <i>J</i> = 5.1 Hz, 1H), 3.54 (s, 3H).</div></div><div id="sec4_1_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> Diethyl 2-(((3-Bromo-4-methylphenyl)amino)methylene)malonate (<b>26</b>)</h4><div class="NLM_p last">3-Bromo-4-methylaniline (2.0 g, 10.75 mmol) and diethyl 2-(ethoxymethylene)malonate (2.15 mL, 10.75 mmol) were mixed and stirred at ambient temperature until a homogeneous solution was obtained. The reaction mixture was then heated to 100 °C for 2.5 h. The reaction mixture was cooled and a precipitate formed, which was filtered and washed with cold hexanes to obtain the title compound as a yellow solid (3.4 g, 89%). LCMS [M + H]<sup>+</sup> 355.9 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 358.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 10.95 (d, <i>J</i> = 14.0 Hz, 1H), 8.42 (d, <i>J</i> = 13.5 Hz, 1H), 7.33 (d, <i>J</i> = 2.5 Hz, 1H), 7.20 (d, <i>J</i> = 8.5 Hz, 1H), 6.98 (dd, <i>J</i> = 2.5, 8.0 Hz, 1H), 4.30 (q, <i>J</i> = 7.0 Hz, 2H), 4.25 (q, <i>J</i> = 6.5 Hz, 2H), 2.37 (s, 3H), 1.37 (t, <i>J</i> = 7.5 Hz, 3H), 1.33 (t, <i>J</i> = 6.5 Hz, 3H).</div></div><div id="sec4_1_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> Ethyl 7-Bromo-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (<b>27</b>)</h4><div class="NLM_p last">Diethyl 2-(((3-bromo-4-methylphenyl)amino)methylene)malonate <b>26</b> (3.4 g, 9.54 mmol) was suspended in diphenylether (60 mL). The reaction mixture was heated at 250 °C for 3 h before being cooled to ambient temperature. The resulting precipitate was isolated by vacuum filtration and washed with hexanes to obtain the title compound as a beige solid (2.5 g, 84%). LCMS [M + H]<sup>+</sup> 310.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 312.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.54 (s, 1H), 8.06 (s, 1H), 7.86 (s, 1H), 4.20 (q, <i>J</i> = 7.0 Hz, 2H), 2.45 (s, 3H), 1.27 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_1_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> 7-Bromo-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (<b>28</b>)</h4><div class="NLM_p last">Ethyl 7-bromo-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate <b>27</b> (1.0 g, 3.22 mmol) was stirred in a 2.5 M aqueous sodium hydroxide solution (2 mL), and the reaction mixture was heated at 100 °C overnight. The reaction mixture was obtained before being cooled to ambient temperature before being acidified with dilute hydrochloric acid to pH 3–4. The solid precipitate was isolated by vacuum filtration and washed with water. The solid was air dried to obtain the title compound (700 mg, 77%). LCMS [M + H]<sup>+</sup> 282.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 284.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 15.01 (bs, 1H), 13.35 (s, 1H), 8.18 (s, 1H), 8.14 (s, 1H), 7.99 (s, 1H), 2.4 (s, 3H).</div></div><div id="sec4_1_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> 7-Bromo-6-methylquinolin-4(1<i>H</i>)-one (<b>29</b>)</h4><div class="NLM_p last">7-Bromo-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid <b>28</b> (900 mg, 3.19 mmol) was heated in diphenylether (30 mL) at 250 °C for 4 h. The reaction mixture was cooled to ambient temperature and a solid precipitated, which was isolated by vacuum filtration. The solid was washed with hexanes and air-dried to obtain the title compound (699 mg, 92%). LCMS [M + H]<sup>+</sup> 238.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 240.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 12.0 (bs, 1H), 8.01 (s, 1H), 7.95 (d, <i>J</i> = 7.6 Hz, 1H), 7.83 (s, 1H), 6.09 (d, <i>J</i> = 7.2 Hz, 1H), 2.44 (s, 3H).</div></div><div id="sec4_1_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> 7-Bromo-4-chloro-6-methylquinoline (<b>30</b>)</h4><div class="NLM_p last">7-Bromo-6-methylquinolin-4(1<i>H</i>)-one <b>29</b> (698 mg, 2.93 mmol) was refluxed in phosphorous oxychloride for 2 h. The phosphorous oxychloride was removed by distillation, and the resulting residue was cooled in an ice–water bath before being diluted with water. The aqueous phase was neutralized by addition of a saturated sodium bicarbonate solution before being extracted with dichloromethane. The dichloromethane layers were washed with water and saturated sodium chloride solution and dried with sodium sulfate. All of the volatiles were removed in vacuo to obtain the title compound as a cream solid, which was used without further purification (370 mg, 49%). LCMS [M + H]<sup>+</sup> 256.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>/Cl<sup>35</sup>), 258.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>/Cl<sup>37</sup>, Br<sup>81</sup>/Cl<sup>35</sup>), 260.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>/Cl<sup>37</sup>); <sup>1</sup>H NMR (500 MHz chloroform-<i>d</i>) δ ppm 8.71 (d, <i>J</i> = 4.5 Hz, 1H), 8.36 (s, 1H), 8.06 (s, 1H), 7.47 (d, <i>J</i> = 4.5 Hz, 1H), 2.63 (d, 3H).</div></div><div id="sec4_1_112" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> 7-Bromo-6-methyl-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>31</b>)</h4><div class="NLM_p last">Prepared via general procedure G. However, water was used to quench the reaction. The title compound was obtained as a tan solid (714 mg, 86%). LCMS [M + H]<sup>+</sup> 315.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 317.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.77 (s, 1H), 8.69 (d, <i>J</i> = 1.5 Hz, 1H), 8.67 (d, <i>J</i> = 5.5 Hz, 1H), 8.46 (s, 1H), 8.34 (d, <i>J</i> = 5.5 Hz, 1H), 8.33–8.21 (m, 1H), 8.19 (s, 1H), 8.18 (d, <i>J</i> = 2.5 Hz, 1H), 2.59 (s, 3H).</div></div><div id="sec4_1_113" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> Diethyl 2-(((3-Bromo-2-methylphenyl)amino)methylene)malonate (<b>32</b>)</h4><div class="NLM_p last">3-Bromo-2-methylaniline (1.0 g, 5.37 mmol) and diethyl 2-(ethoxymethylene)malonate (1.08 mL, 5.37 mmol) were mixed and stirred at ambient temperature until a homogeneous solution was obtained. The reaction mixture was then heated to 100 °C for 2.5 h. The reaction mixture was cooled and a precipitate formed, which was filtered and washed with cold hexanes to obtain the title compound as a white solid (1.3 g, 68%). LCMS [M + H]<sup>+</sup> 356.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 358.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 11.17 (d, <i>J</i> = 12.5 Hz, 1H), 8.46 (d, <i>J</i> = 14.0 Hz, 1H), 7.38 (d, <i>J</i> = 8.0 Hz, 1H), 7.17 (d, <i>J</i> = 8.5 Hz, 1H), 7.10 (t, <i>J</i> = 8.0 Hz, 1H), 4.32 (q, <i>J</i> = 7.0 Hz, 2H), 4.24 (q, <i>J</i> = 7.0 Hz, 2H), 2.46 (s, 3H), 1.38 (t, <i>J</i> = 7.0 Hz, 3H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_1_114" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> Ethyl 7-Bromo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (<b>33</b>)</h4><div class="NLM_p last">Diethyl 2-(((3-bromo-2-methylphenyl)amino)methylene)malonate <b>32</b> (1 g, 2.81 mmol) and diphenylether were heated at 205 °C for 5 h. The reaction mixture was cooled to ambient temperature and a solid precipitated, which was isolated by vacuum filtration. The solid was washed with hexanes and air-dried to obtain the title compound as a buff solid (501 mg, 57%). LCMS [M + H]<sup>+</sup> 310.1 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 312.1 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.73 (s, 1H), 8.38 (s, 1H), 7.93 (d, <i>J</i> = 9.0 Hz, 1H), 7.62 (d, <i>J</i> = 9.0 Hz, 1H), 4.22 (q, <i>J</i> = 7.0 Hz, 2H), 2.59 (s, 3H), 1.28 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_1_115" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> 7-Bromo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (<b>34</b>)</h4><div class="NLM_p last">Ethyl 7-bromo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate <b>33</b> (500 mg, 1.61 mmol) was stirred in a 2.5 M aqueous sodium hydroxide solution (4 mL), and the reaction mixture was heated at 100 °C overnight. The reaction mixture was obtained before being cooled to ambient temperature before being acidified with dilute hydrochloric acid to pH 3–4. The solid precipitate was isolated by vacuum filtration and washed with water. The solid was air-dried to obtain the title compound as a white solid (420 mg, 93%). LCMS [M + H]<sup>+</sup> 282.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 284.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 12.80 (s, 1H), 8.62 (d, <i>J</i> = 4.5 Hz, 1H), 8.05 (d, <i>J</i> = 8.5 Hz, 1H), 7.80 (d, <i>J</i> = 9.0 Hz, 1H), 2.67 (s, 3H).</div></div><div id="sec4_1_116" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> 7-Bromo-8-methylquinolin-4(1<i>H</i>)-one (<b>35</b>)</h4><div class="NLM_p last">7-Bromo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid <b>34</b> (415 mg, 1.47 mmol) was refluxed in diphenylether (3.75 mL) for 3 h. The reaction mixture was cooled to ambient temperature and a solid precipitated, which was isolated by vacuum filtration. The solid was washed with hexanes and air-dried to obtain the title compound as a white solid (308 mg, 88%). LCMS [M + H]<sup>+</sup> 238.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 240.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.24 (d, <i>J</i> = 4.5 Hz, 1H), 7.87–7.83 (m, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 1H), 6.08 (d, <i>J</i> = 8.5 Hz, 1H), 2.56 (s, 3H).</div></div><div id="sec4_1_117" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> 7-Bromo-4-chloro-8-methylquinoline (<b>36</b>)</h4><div class="NLM_p last">7-Bromo-8-methylquinolin-4(1<i>H</i>)-one <b>35</b> (241 mg, 1.01 mmol) was refluxed in phosphorous oxychloride for 2 h. Phosphorous oxychloride was removed by distillation, and the resulting residue was cooled in an ice–water bath before being diluted with water. The aqueous phase was neutralized by addition of a saturated sodium bicarbonate solution before being extracted with dichloromethane. The dichloromethane layers were washed with water and saturated sodium chloride solution and dried with sodium sulfate. All of the volatiles were removed in vacuo, and the crude material was purified by column chromatography using 5–50% ethyl acetate/hexanes to obtain the title compound as an off-white powder (213 mg, 82%). LCMS [M + H]<sup>+</sup> 256.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>/Cl<sup>35</sup>), 258.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>/Cl<sup>37</sup>, Br<sup>81</sup>/Cl<sup>35</sup>), 260.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>/Cl<sup>37</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.82 (d, <i>J</i> = 4.5 Hz, 1H), 7.98 (d, <i>J</i> = 9.0 Hz, 1H), 7.79 (d, <i>J</i> = 9.0 Hz, 1H), 7.53 (dd, <i>J</i> = 1.0, 4.5 Hz, 1H), 2.95 (s, 3H).</div></div><div id="sec4_1_118" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> 7-Bromo-8-methyl-<i>N</i>-(pyrazin-2-yl)quinolin-4-amine (<b>37</b>)</h4><div class="NLM_p last">Prepared via general procedure G. The title compound was obtained as a brown solid (132 mg, 93%). LCMS [M + H]<sup>+</sup> 315.0 <i>m</i>/<i>z</i> (Br<sup>79</sup>), 317.0 <i>m</i>/<i>z</i> (Br<sup>81</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.83 (d, <i>J</i> = 5.0 Hz, 1H), 8.52 (s, 1H), 8.30–8.29 (m, 1H), 8.21 (d, <i>J</i> = 3.0 Hz, 1H), 8.01 (d, <i>J</i> = 5.0 Hz, 1H), 7.73–7.68 (m, 2H), 2.95 (s, 3H).</div></div><div id="sec4_1_119" class="NLM_sec NLM_sec_level_3"><div id="ac_i166" class="anchor-spacer"></div><h4 class="article-section__title" id="_i166"> 7-(2-(4-Methylpiperazin-1-yl)pyrimidin-5-yl)quinolin-4(1<i>H</i>)-one (<b>38</b>)</h4><div class="NLM_p last">Prepared via general procedure C. A precipitate was isolated by vacuum filtration and washed with water to afford the title compound as a tan solid, (411 mg, 85%). LCMS [M + H]<sup>+</sup> 322.2 <i>m</i>/<i>z</i>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.77 (s, 1H), 8.08–8.15 (m, 1H), 7.87–7.92 (m, 1H), 7.68–7.72 (m, 1H), 7.57–7.63 (m, 1H), 6.31 (s, 2H), 5.99–6.05 (m, 1H), 3.76–3.85 (m, 4H), 2.34–2.42 (m, 4H), 2.22 (s, 3H).</div></div><div id="sec4_1_120" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> 4-Chloro-7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)quinoline (<b>39</b>)</h4><div class="NLM_p last">7-(2-(4-Methylpiperazin-1-yl)pyrimidin-5-yl)quinolin-4(1<i>H</i>)-one (<b>38</b>) (103 mg, 0.32 mmol) was suspended in neat phosphorus oxychloride (excess, 1.0 mL). The reaction mixture was refluxed overnight. Phosphorus oxychloride was then removed by vacuum distillation. The resulting residue was put in an ice bath, diluted with dichloromethane, and quenched using a saturated aqueous sodium bicarbonate solution. The aqueous layer was extracted three times with dichloromethane. The combined organic layers were washed with water and a saturated sodium chloride solution before being dried with sodium sulfate. The volatiles were removed in vacuo to obtain the title compound as a light tan solid (77.2 mg, 71%). LCMS [M + H]<sup>+</sup> 340.1 <i>m</i>/<i>z</i> (Cl<sup>35</sup>), 342.2 <i>m</i>/<i>z</i> (Cl<sup>37</sup>); <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ ppm 8.80 (d, <i>J</i> = 4.9 Hz, 1H), 8.73 (s, 2H), 8.31 (d, <i>J</i> = 8.8 Hz, 1H), 8.23 (d, <i>J</i> = 1.5 Hz, 1H), 7.78–7.83 (m, 1H), 7.48 (d, <i>J</i> = 4.9 Hz, 1H), 3.91–3.98 (m, 4H), 2.51 (t, <i>J</i> = 4.9 Hz, 4H), 2.37 (s, 3H).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i168"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01365" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20412" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20412" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01365" class="ext-link">10.1021/acs.jmedchem.8b01365</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic schemes and characterization data for compounds not presented directly in the manuscript (and not previously published); Log <i>D</i>, p<i>K</i><sub>a</sub>, and rat hepatocyte Cl<sub>int</sub> data for all compounds disclosed in the manuscript; calculated p<i>K</i><sub>a</sub> values for compounds <b>1</b> and <b>10e</b>; comparison of Log <i>P</i> and <i>T. brucei</i> pEC<sub>50</sub>; crystal structure of compound <b>19a</b>; curves obtained from the CEC<sub>50</sub> assay; PK parameters and plasma concentration–time profile for compound <b>22a</b>; human kinase profile of compounds <b>1</b> and <b>22a</b>; Ames test results for <b>22a</b>; HitProfilingScreen panel results of <b>22a</b>; and molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Compound ID numbers and their associated SMILES strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf">jm8b01365_si_001.pdf (1.36 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_002.csv">jm8b01365_si_002.csv (3.13 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01365" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kojo Mensa-Wilmot</span> - <span class="hlFld-Affiliation affiliation">Department
of Cellular Biology, Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia 30602, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f19c949f829086989db1849690df949584"><span class="__cf_email__" data-cfemail="076a62697466706e6b4772606629626372">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lori Ferrins</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8992-0919" title="Orcid link">http://orcid.org/0000-0001-8992-0919</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#44286a222136362d2a37042a2b36302c2125373021362a6a212031"><span class="__cf_email__" data-cfemail="afc381c9caddddc6c1dcefc1c0dddbc7cacedcdbcaddc181cacbda">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kelly
A. Bachovchin</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amrita Sharma</span> - <span class="hlFld-Affiliation affiliation">Department
of Cellular Biology, Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia 30602, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seema Bag</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dana M. Klug</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine M. Schneider</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baljinder Singh</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2828-5768" title="Orcid link">http://orcid.org/0000-0003-2828-5768</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hitesh B. Jalani</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2442-9798" title="Orcid link">http://orcid.org/0000-0002-2442-9798</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa J. Buskes</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naimee Mehta</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Tanghe</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Anti-Infectives Screening
Core, New York University School of Medicine, 430 East 29th Street, New York, New York 10016, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremiah D. Momper</span> - <span class="hlFld-Affiliation affiliation">Skaggs
School of Pharmacy and Pharmaceutical Sciences, University of California, San
Diego, La Jolla, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard J. Sciotti</span> - <span class="hlFld-Affiliation affiliation">Experimental
Therapeutics, Walter Reed Army Institute
for Research, 2460 Linden Lane, Silver Spring, Maryland 20910, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana Rodriguez</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Anti-Infectives Screening
Core, New York University School of Medicine, 430 East 29th Street, New York, New York 10016, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael P. Pollastri</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Chemical Biology, Northeastern
University, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9943-7197" title="Orcid link">http://orcid.org/0000-0001-9943-7197</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>K.A.B. and A.S. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e9536-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i170">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71178" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71178" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Institutes of Health grants (R01AI082577 (M.P.P.), R56AI099476 (K.M.-W. and M.P.P.), R01AI124046 (M.P.P. and K.M.-W.), R21AI127594 (M.P.P.)). The authors are grateful to AstraZeneca for performing the in vitro ADME experiments presented throughout. They thank Dr. Bo Li at the X-ray Crystallography Center at Boston College for obtaining the crystal structure of compound <b>19a</b>. Finally, they acknowledge Biogen for training K.B. in the art of salt formation and characterization.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">DND<i>i</i></td><td class="NLM_def"><p class="first last">Drugs for Neglected Diseases <i>initiative</i></p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">human African trypanosomiasis</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term"><i>T.b. brucei</i></td><td class="NLM_def"><p class="first last"><i>Trypanosoma brucei brucei</i></p></td></tr><tr><td class="NLM_term">TPP</td><td class="NLM_def"><p class="first last">target-product profile</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i172">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karver, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullenberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3820</span>– <span class="NLM_lpage">3832</span>, <span class="refDoi"> DOI: 10.1021/jm400349k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400349k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFSitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3820-3832&author=G.+Patelauthor=C.+E.+Karverauthor=R.+Beheraauthor=P.+Guyettauthor=C.+Sullenbergerauthor=P.+Edwardsauthor=N.+Roncalauthor=K.+Mensa-Wilmotauthor=M.+P.+Pollastri&title=Kinase+scaffold+repurposing+for+neglected+disease+drug+discovery%3A+discovery+of+an+efficacious%2C+lapatanib-derived+lead+compound+for+trypanosomiasis&doi=10.1021%2Fjm400349k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis</span></div><div class="casAuthors">Patel, Gautam; Karver, Caitlin E.; Behera, Ranjan; Guyett, Paul J.; Sullenberger, Catherine; Edwards, Peter; Roncal, Norma E.; Mensa-Wilmot, Kojo; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3820-3832</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lapatinib analogs such as I (X = O, CH2) were prepd. as trypanocidal agents for use as lead compds. in the development of treatments for human African trypanosomiasis which do not require i.v. administration.  Lapatinib was previously shown to kill T. brucei with low micromolar EC50 values; analogs replacing the methylfurylquinazoline moiety with a heteroarylsulfonylphenylquinazolinyl moiety were prepd. and tested against both T. brucei and human hepatocarcinoma cells.  4-Anilinoquinazolines, particularly I (X = O) (NEU617), were found to be highly potent and orally bioavailable inhibitors of trypanosome replication.  I (X = O) blocks duplication of the kinetoplast and arrests cytokinesis in T. brucei, which may make it useful as a chem. tool for studying regulation of the trypanosome cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoliwtzx67q77Vg90H21EOLACvtfcHk0liYP9U9BqxhgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFSitLo%253D&md5=dd278f3bc7c671330e40de210392a278</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm400349k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400349k%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DG.%26aulast%3DKarver%26aufirst%3DC.%2BE.%26aulast%3DBehera%26aufirst%3DR.%26aulast%3DGuyett%26aufirst%3DP.%26aulast%3DSullenberger%26aufirst%3DC.%26aulast%3DEdwards%26aufirst%3DP.%26aulast%3DRoncal%26aufirst%3DN.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DKinase%2520scaffold%2520repurposing%2520for%2520neglected%2520disease%2520drug%2520discovery%253A%2520discovery%2520of%2520an%2520efficacious%252C%2520lapatanib-derived%2520lead%2520compound%2520for%2520trypanosomiasis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3820%26epage%3D3832%26doi%3D10.1021%2Fjm400349k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappuis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burri, C.</span></span> <span> </span><span class="NLM_article-title">Human African trypanosomiasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(09)60829-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2FS0140-6736%2809%2960829-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2010&pages=148-159&author=R.+Brunauthor=J.+Blumauthor=F.+Chappuisauthor=C.+Burri&title=Human+African+trypanosomiasis&doi=10.1016%2FS0140-6736%2809%2960829-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2960829-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252960829-1%26sid%3Dliteratum%253Aachs%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DBlum%26aufirst%3DJ.%26aulast%3DChappuis%26aufirst%3DF.%26aulast%3DBurri%26aufirst%3DC.%26atitle%3DHuman%2520African%2520trypanosomiasis%26jtitle%3DLancet%26date%3D2010%26volume%3D375%26spage%3D148%26epage%3D159%26doi%3D10.1016%2FS0140-6736%2809%2960829-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">World
Health Organization</span>.  <i>Sustaining the
Drive to Overcome the Global
Impact of Neglected Tropical Diseases: Second WHO Report on Neglected
Tropical Diseases</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=World%0AHealth+Organization&title=Sustaining+the%0ADrive+to+Overcome+the+Global%0AImpact+of+Neglected+Tropical+Diseases%3A+Second+WHO+Report+on+Neglected%0ATropical+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DSustaining%2520the%250ADrive%2520to%2520Overcome%2520the%2520Global%250AImpact%2520of%2520Neglected%2520Tropical%2520Diseases%253A%2520Second%2520WHO%2520Report%2520on%2520Neglected%250ATropical%2520Diseases%26pub%3DWorld%2520Health%2520Organization%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Büscher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamonneau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priotto, G.</span></span> <span> </span><span class="NLM_article-title">Human African trypanosomiasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2409</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31510-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2FS0140-6736%2817%2931510-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=28673422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=2397-2409&author=P.+B%C3%BCscherauthor=G.+Cecchiauthor=V.+Jamonneauauthor=G.+Priotto&title=Human+African+trypanosomiasis&doi=10.1016%2FS0140-6736%2817%2931510-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human African trypanosomiasis</span></div><div class="casAuthors">Buscher Philippe; Cecchi Giuliano; Jamonneau Vincent; Priotto Gerardo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10110</span>),
    <span class="NLM_cas:pages">2397-2409</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human African trypanosomiasis (sleeping sickness) is a parasitic infection that almost invariably progresses to death unless treated.  Human African trypanosomiasis caused devastating epidemics during the 20th century.  Thanks to sustained and coordinated efforts over the past 15 years, the number of reported cases has fallen to an historically low level.  Fewer than 3000 cases were reported in 2015, and the disease is targeted for elimination by WHO.  Despite these recent successes, the disease is still endemic in parts of sub-Saharan Africa, where it is a considerable burden on rural communities, most notably in central Africa.  Since patients are also reported from non-endemic countries, human African trypanosomiasis should be considered in differential diagnosis for travellers, tourists, migrants, and expatriates who have visited or lived in endemic areas.  In the absence of a vaccine, disease control relies on case detection and treatment, and vector control.  Available drugs are suboptimal, but ongoing clinical trials provide hope for safer and simpler treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsRgd2Wuil24tfW6udTcc2eZ_3g60rHV_e7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCrsw%253D%253D&md5=521e7f5c04b32c04763c6b7a65af6439</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931510-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931510-6%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25BCscher%26aufirst%3DP.%26aulast%3DCecchi%26aufirst%3DG.%26aulast%3DJamonneau%26aufirst%3DV.%26aulast%3DPriotto%26aufirst%3DG.%26atitle%3DHuman%2520African%2520trypanosomiasis%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D2397%26epage%3D2409%26doi%3D10.1016%2FS0140-6736%2817%2931510-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">World
Health Organization</span>. Department of Control
of Neglected Tropical Diseases,
Human African Trypanosomiasis. <a href="http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_EPH_2001.3.pdf" class="extLink">http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_EPH_2001.3.pdf</a> (accessed November 13, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World%0AHealth+Organization.+Department+of+Control%0Aof+Neglected+Tropical+Diseases%2C%0AHuman+African+Trypanosomiasis.+http%3A%2F%2Fwhqlibdoc.who.int%2Fhq%2F2001%2FWHO_CDS_CSR_EPH_2001.3.pdf+%28accessed+November+13%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Fexinidazole: a new drug for African sleeping sickness on the horizon</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2017.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.pt.2017.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=29275007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=178-179&author=M.+P.+Pollastri&title=Fexinidazole%3A+a+new+drug+for+African+sleeping+sickness+on+the+horizon&doi=10.1016%2Fj.pt.2017.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon</span></div><div class="casAuthors">Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">178-179</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Decades after the last new chem. entity was added to the pharmacopeia for human African trypanosomiasis (or sleeping sickness), orally dosed fexinidazole stands poised to replace the current treatment regimen for Trypanosoma brucei gambiense infections, following a pos. Phase 2/3 clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0dzkKzgAQ8LVg90H21EOLACvtfcHk0lhF-lqTME0XVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsLjK&md5=90c0d6e87ec827b9b788152db9aff51e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2017.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2017.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DFexinidazole%253A%2520a%2520new%2520drug%2520for%2520African%2520sleeping%2520sickness%2520on%2520the%2520horizon%26jtitle%3DTrends%2520Parasitol.%26date%3D2018%26volume%3D34%26spage%3D178%26epage%3D179%26doi%3D10.1016%2Fj.pt.2017.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chappuis, F.</span></span> <span> </span><span class="NLM_article-title">Oral fexinidazole for human African trypanosomiasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)30019-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2FS0140-6736%2818%2930019-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=29353603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvis1ygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=100-102&author=F.+Chappuis&title=Oral+fexinidazole+for+human+African+trypanosomiasis&doi=10.1016%2FS0140-6736%2818%2930019-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fexinidazole for human African trypanosomiasis</span></div><div class="casAuthors">Chappuis Francois</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10116</span>),
    <span class="NLM_cas:pages">100-102</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5wOffiRd7v7jnyZkbE8yXfW6udTcc2eZXWRiCM2Nvt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvis1ygsg%253D%253D&md5=2a395501ebe8006584a60266d4dc0579</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2930019-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252930019-9%26sid%3Dliteratum%253Aachs%26aulast%3DChappuis%26aufirst%3DF.%26atitle%3DOral%2520fexinidazole%2520for%2520human%2520African%2520trypanosomiasis%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D100%26epage%3D102%26doi%3D10.1016%2FS0140-6736%2818%2930019-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarral, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blesson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordt, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torreele, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hovsepian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evene, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gualano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felices, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strub-Wourgaft, N.</span></span> <span> </span><span class="NLM_article-title">Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1007/s40262-014-0136-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1007%2Fs40262-014-0136-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=24535888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVCmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=565-580&author=A.+Tarralauthor=S.+Blessonauthor=O.+V.+Mordtauthor=E.+Torreeleauthor=D.+Sassellaauthor=M.+A.+Brayauthor=L.+Hovsepianauthor=E.+Eveneauthor=V.+Gualanoauthor=M.+Felicesauthor=N.+Strub-Wourgaft&title=Determination+of+an+optimal+dosing+regimen+for+fexinidazole%2C+a+novel+oral+drug+for+the+treatment+of+human+African+trypanosomiasis%3A+first-in-human+studies&doi=10.1007%2Fs40262-014-0136-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies</span></div><div class="casAuthors">Tarral, Antoine; Blesson, Severine; Mordt, Olaf Valverde; Torreele, Els; Sassella, Daniela; Bray, Michael A.; Hovsepian, Lionel; Evene, Eric; Gualano, Virginie; Felices, Mathieu; Strub-Wourgaft, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-580</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objectives: Fexinidazole is a 5-nitroimidazole recently included in a clin. efficacy trial as an oral drug for the treatment of human African trypanosomiasis (HAT).  Preclin. studies showed it acts as a pharmacol. active pro-drug with two key active metabolites: sulfoxide and sulfone (the most active metabolite).  The present studies aimed to det. the best dose regimen for the treatment of stage 2 sleeping sickness patients, which could eventually also treat stage 1 patients.  Methods: Fexinidazole was assessed in 154 healthy adult male subjects of sub-Saharan African origin.  Three initial first-in-human studies and two addnl. studies assessed a single ascending dose and multiple ascending doses (both under fasted conditions), tablet vs. suspension formulation and food effect (fasted vs. high-fat meal and field-adapted food), and multiple ascending doses with a loading dose regimen under fed conditions.  Results: Fexinidazole was well-tolerated in a single dose from 100 to 3,600 mg, with quick absorption of the parent drug and rapid metab. into sulfoxide [time to max. concn. (tmax) 2-5 h] and sulfone (tmax 18-24 h).  The tablet formulation was approx. 25 % less bioavailable than the suspension, and food intake increased drug absorption and plasma concns. of fexinidazole and its two metabolites by approx. 200 %.  Fourteen-day multiple ascending dosing administered up to 3,600 mg/day in fasted conditions showed that fexinidazole was generally well-tolerated (mild to moderate, spontaneously reversible drug-related adverse events).  Following the high-fat food effect finding, another study was conducted to evaluate the impact of a low-fat regimen closer to that of the target population, showing that the type of meal does not influence fexinidazole absorption.  The last study showed that a loading dose of 1,800 mg/day for 4 days followed by a 1,200 mg/day regimen for 6 days with a normal meal provided the desired exposure of fexinidazole and its metabolites, particularly sulfone, with good tolerability.  Based on preclin. evidence from a chronic infection mouse model, systemic drug concns. obtained are expected to be clin. effective in stage 2 HAT.  Conclusions: These studies show that fexinidazole can be safely assessed in patients as a potential oral cure for both stages of HAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpszDba_Qa2j7Vg90H21EOLACvtfcHk0lhB4sHN_NUuxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVCmuro%253D&md5=29ec56e974111a2737fc3bfff67d9511</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs40262-014-0136-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-014-0136-3%26sid%3Dliteratum%253Aachs%26aulast%3DTarral%26aufirst%3DA.%26aulast%3DBlesson%26aufirst%3DS.%26aulast%3DMordt%26aufirst%3DO.%2BV.%26aulast%3DTorreele%26aufirst%3DE.%26aulast%3DSassella%26aufirst%3DD.%26aulast%3DBray%26aufirst%3DM.%2BA.%26aulast%3DHovsepian%26aufirst%3DL.%26aulast%3DEvene%26aufirst%3DE.%26aulast%3DGualano%26aufirst%3DV.%26aulast%3DFelices%26aufirst%3DM.%26aulast%3DStrub-Wourgaft%26aufirst%3DN.%26atitle%3DDetermination%2520of%2520an%2520optimal%2520dosing%2520regimen%2520for%2520fexinidazole%252C%2520a%2520novel%2520oral%2520drug%2520for%2520the%2520treatment%2520of%2520human%2520African%2520trypanosomiasis%253A%2520first-in-human%2520studies%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2014%26volume%3D53%26spage%3D565%26epage%3D580%26doi%3D10.1007%2Fs40262-014-0136-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wring, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sligar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowling, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewerts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaukel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarlett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scandale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Don, R.</span></span> <span> </span><span class="NLM_article-title">SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1151</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0001151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1371%2Fjournal.pntd.0001151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=21738803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlOgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&author=R.+T.+Jacobsauthor=B.+Nareauthor=S.+A.+Wringauthor=M.+D.+Orrauthor=D.+Chenauthor=J.+M.+Sligarauthor=M.+X.+Jenksauthor=R.+A.+Noeauthor=T.+S.+Bowlingauthor=L.+T.+Mercerauthor=C.+Rewertsauthor=E.+Gaukelauthor=J.+Owensauthor=R.+Parhamauthor=R.+Randolphauthor=B.+Beaudetauthor=C.+J.+Bacchiauthor=N.+Yarlettauthor=J.+J.+Plattnerauthor=Y.+Freundauthor=C.+Dingauthor=T.+Akamaauthor=Y.+K.+Zhangauthor=R.+Brunauthor=M.+Kaiserauthor=I.+Scandaleauthor=R.+Don&title=SCYX-7158%2C+an+orally-active+benzoxaborole+for+the+treatment+of+stage+2+human+African+trypanosomiasis&doi=10.1371%2Fjournal.pntd.0001151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 Human African trypanosomiasis</span></div><div class="casAuthors">Jacobs, Robert T.; Nare, Bakela; Wring, Stephen A.; Orr, Matthew D.; Chen, Daitao; Sligar, Jessica M.; Jenks, Matthew X.; Noe, Robert A.; Bowling, Tana S.; Mercer, Luke T.; Rewerts, Cindy; Gaukel, Eric; Owens, Jennifer; Parham, Robin; Randolph, Ryan; Beaudet, Beth; Bacchi, Cyrus J.; Yarlett, Nigel; Plattner, Jacob J.; Freund, Yvonne; Ding, Charles; Akama, Tsutomu; Zhang, Y.-K.; Brun, Reto; Kaiser, Marcel; Scandale, Ivan; Don, Robert</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1151</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting hundreds of thousands of individuals.  An urgent need exists for the discovery and development of new, safe, and effective drugs to treat HAT, as existing therapies suffer from poor safety profiles, difficult treatment regimens, limited effectiveness, and a high cost of goods.  We have discovered and optimized a novel class of small-mol. boron-contg. compds., benzoxaboroles, to identify SCYX-7158 as an effective, safe and orally active treatment for HAT.  Methodol./Principal Findings: A drug discovery project employing integrated biol. screening, medicinal chem. and pharmacokinetic characterization identified SCYX-7158 as an optimized analog, as it is active in vitro against relevant strains of Trypanosoma brucei, including T. b. rhodesiense and T. b. gambiense, is efficacious in both stage 1 and stage 2 murine HAT models and has physicochem. and in vitro absorption, distribution, metab., elimination and toxicol. (ADMET) properties consistent with the compd. being orally available, metabolically stable and CNS permeable.  In a murine stage 2 study, SCYX-7158 is effective orally at doses as low as 12.5 mg/kg (QD × 7 days).  In vivo pharmacokinetic characterization of SCYX-7158 demonstrates that the compd. is highly bioavailable in rodents and non-human primates, has low i.v. plasma clearance and has a 24-h elimination half-life and a vol. of distribution that indicate good tissue distribution.  Most importantly, in rodents brain exposure of SCYX-7158 is high, with Cmax>10 μg/mL and AUC0-24 hr>100 μg*h/mL following a 25 mg/kg oral dose.  Furthermore, SCYX-7158 readily distributes into cerebrospinal fluid to achieve therapeutically relevant concns. in this compartment.  Conclusions/Significance: The biol. and pharmacokinetic properties of SCYX-7158 suggest that this compd. will be efficacious and safe to treat stage 2 HAT.  SCYX-7158 has been selected to enter preclin. studies, with expected progression to phase 1 clin. trials in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdyaAga5lprVg90H21EOLACvtfcHk0lhB4sHN_NUuxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlOgsLY%253D&md5=a54f2d57149e6714c7f6acf5f5280a7d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0001151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0001151%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DR.%2BT.%26aulast%3DNare%26aufirst%3DB.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DOrr%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DSligar%26aufirst%3DJ.%2BM.%26aulast%3DJenks%26aufirst%3DM.%2BX.%26aulast%3DNoe%26aufirst%3DR.%2BA.%26aulast%3DBowling%26aufirst%3DT.%2BS.%26aulast%3DMercer%26aufirst%3DL.%2BT.%26aulast%3DRewerts%26aufirst%3DC.%26aulast%3DGaukel%26aufirst%3DE.%26aulast%3DOwens%26aufirst%3DJ.%26aulast%3DParham%26aufirst%3DR.%26aulast%3DRandolph%26aufirst%3DR.%26aulast%3DBeaudet%26aufirst%3DB.%26aulast%3DBacchi%26aufirst%3DC.%2BJ.%26aulast%3DYarlett%26aufirst%3DN.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DScandale%26aufirst%3DI.%26aulast%3DDon%26aufirst%3DR.%26atitle%3DSCYX-7158%252C%2520an%2520orally-active%2520benzoxaborole%2520for%2520the%2520treatment%2520of%2520stage%25202%2520human%2520African%2520trypanosomiasis%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2011%26volume%3D5%26doi%3D10.1371%2Fjournal.pntd.0001151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kola, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, J.</span></span> <span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1038/nrd1470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fnrd1470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=15286737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-716&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F&doi=10.1038%2Fnrd1470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Can the pharmaceutical industry reduce attrition rates?</span></div><div class="casAuthors">Kola, Ismail; Landis, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry faces considerable challenges, both politically and fiscally.  Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny.  In the United States, drug costs are also the subject of intense political discourse.  This article deals with the fiscal pressures that face the industry from the perspective of R&D.  What impinges on productivity How can we improve current reduced R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAlrpFPFmiLVg90H21EOLACvtfcHk0lilSSDQuNpv3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D&md5=f9025c13a1506f607aaf68415570ed01</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd1470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1470%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D716%26doi%3D10.1038%2Fnrd1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+analysis+of+the+attrition+of+drug+candidates+from+four+major+pharmaceutical+companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lilSSDQuNpv3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520analysis%2520of%2520the%2520attrition%2520of%2520drug%2520candidates%2520from%2520four%2520major%2520pharmaceutical%2520companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craighead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Economides, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, J.</span></span> <span> </span><span class="NLM_article-title">Clinical development success rates for investigational drugs</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nbt.2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fnbt.2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=24406927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=40-51&author=M.+Hayauthor=D.+W.+Thomasauthor=J.+L.+Craigheadauthor=C.+Economidesauthor=J.+Rosenthal&title=Clinical+development+success+rates+for+investigational+drugs&doi=10.1038%2Fnbt.2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development success rates for investigational drugs</span></div><div class="casAuthors">Hay, Michael; Thomas, David W.; Craighead, John L.; Economides, Celia; Rosenthal, Jesse</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The most comprehensive survey of clin. success rates across the drug industry to date shows productivity may be even lower than previous ests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdqyRgsoFYDbVg90H21EOLACvtfcHk0lhzwP_cc8lvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D&md5=87a63ec8d8bb213b3d42519395725038</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2786%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DD.%2BW.%26aulast%3DCraighead%26aufirst%3DJ.%2BL.%26aulast%3DEconomides%26aufirst%3DC.%26aulast%3DRosenthal%26aufirst%3DJ.%26atitle%3DClinical%2520development%2520success%2520rates%2520for%2520investigational%2520drugs%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D40%26epage%3D51%26doi%3D10.1038%2Fnbt.2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delespaux, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span> <span> </span><span class="NLM_article-title">Drugs and drug resistance in African trypanosomiasis</span>. <i>Drug Resistance Updates</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2007.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.drup.2007.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=17409013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslahsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=30-50&author=V.+Delespauxauthor=H.+P.+de+Koning&title=Drugs+and+drug+resistance+in+African+trypanosomiasis&doi=10.1016%2Fj.drup.2007.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and drug resistance in African trypanosomiasis</span></div><div class="casAuthors">Delespaux, Vincent; de Koning, Harry P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">30-50</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite the many decades of use of most of the current trypanocides, we know little of their mode of action.  This may in part be because most of these will act on multiple targets once inside the cell, and they derive their selective action on the parasite from selective accumulation by the pathogen.  Loss of this capacity for drug uptake by the trypanosome would thus be a major cause for drug resistance.  We here discuss the use of current drugs against human and veterinary African trypanosomiasis, the prevalence, causes and mechanisms of drug resistance and new developments in trypanosomiasis therapy such as the introduction of nifurtimox and DB289.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBJZuQC1wb0LVg90H21EOLACvtfcHk0lhzwP_cc8lvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslahsb0%253D&md5=04f98358869b5f02ce4297315268b48f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2007.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2007.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DDelespaux%26aufirst%3DV.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26atitle%3DDrugs%2520and%2520drug%2520resistance%2520in%2520African%2520trypanosomiasis%26jtitle%3DDrug%2520Resistance%2520Updates%26date%3D2007%26volume%3D10%26spage%3D30%26epage%3D50%26doi%3D10.1016%2Fj.drup.2007.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nwaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A.</span></span> <span> </span><span class="NLM_article-title">Innovative lead discovery strategies for tropical diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1038/nrd2144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fnrd2144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=17080030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFGjsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=941-955&author=S.+Nwakaauthor=A.+Hudson&title=Innovative+lead+discovery+strategies+for+tropical+diseases&doi=10.1038%2Fnrd2144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Innovative lead discovery strategies for tropical diseases</span></div><div class="casAuthors">Nwaka, Solomon; Hudson, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">941-955</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lead discovery is currently a key bottleneck in the pipeline for much-needed novel drugs for tropical diseases such as malaria, tuberculosis, African sleeping sickness, leishmaniasis and Chagas disease.  Here, the authors discuss the different approaches to lead discovery for tropical diseases and emphasize a coordination strategy that involves highly integrated partnerships and networks between scientists in academic institutions and industry in both wealthy industrialized countries and disease-endemic countries.  This strategy offers the promise of reducing the inherently high attrition rate of the early stages of discovery research, thereby increasing the chances of success and enhancing cost-effectiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe-gH0kYj7dLVg90H21EOLACvtfcHk0lhzwP_cc8lvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFGjsrzE&md5=93279e133e4133077883d48b1d6d50c8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd2144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2144%26sid%3Dliteratum%253Aachs%26aulast%3DNwaka%26aufirst%3DS.%26aulast%3DHudson%26aufirst%3DA.%26atitle%3DInnovative%2520lead%2520discovery%2520strategies%2520for%2520tropical%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D941%26epage%3D955%26doi%3D10.1038%2Fnrd2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1017/S0031182013001017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1017%2FS0031182013001017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2013&pages=28-36&author=I.+H.+Gilbert&title=Target-based+drug+discovery+for+human+African+trypanosomiasis%3A+selection+of+molecular+target+and+chemical+matter&doi=10.1017%2FS0031182013001017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1017%2FS0031182013001017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182013001017%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DTarget-based%2520drug%2520discovery%2520for%2520human%2520African%2520trypanosomiasis%253A%2520selection%2520of%2520molecular%2520target%2520and%2520chemical%2520matter%26jtitle%3DParasitology%26date%3D2013%26volume%3D141%26spage%3D28%26epage%3D36%26doi%3D10.1017%2FS0031182013001017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klug, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Repurposing strategies for tropical disease drug discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2569</span>– <span class="NLM_lpage">2576</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.bmcl.2016.03.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=27080183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2569-2576&author=D.+M.+Klugauthor=M.+H.+Gelbauthor=M.+P.+Pollastri&title=Repurposing+strategies+for+tropical+disease+drug+discovery&doi=10.1016%2Fj.bmcl.2016.03.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing strategies for tropical disease drug discovery</span></div><div class="casAuthors">Klug, Dana M.; Gelb, Michael H.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2569-2576</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neglected tropical diseases (NTDs) and other diseases of the developing world, such as malaria, attract research investments that are disproportionately low compared to their impact on human health worldwide.  Therefore, pragmatic methods for launching new drug discovery programs have emerged that repurpose existing chem. matter as new drugs or new starting points for optimization.  In this Digest we describe applications of different repurposing approaches for NTDs, and provide a means by which these approaches may be differentiated from each other.  These include drug repurposing, target repurposing, target class repurposing, and lead repurposing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7WuWi-qOAgbVg90H21EOLACvtfcHk0ljQg38DuL7EeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGqt7c%253D&md5=e47072a70623e0e3f771880e31578b26</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.103%26sid%3Dliteratum%253Aachs%26aulast%3DKlug%26aufirst%3DD.%2BM.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DRepurposing%2520strategies%2520for%2520tropical%2520disease%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2569%26epage%3D2576%26doi%3D10.1016%2Fj.bmcl.2016.03.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillingwater, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Anilinoquinoline based inhibitors of trypanosomatid proliferation</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0006834</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0006834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1371%2Fjournal.pntd.0006834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=30475800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWkurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&author=L.+Ferrinsauthor=A.+Sharmaauthor=S.+M.+Thomasauthor=N.+Mehtaauthor=J.+Erathauthor=S.+Tangheauthor=S.+E.+Leedauthor=A.+Rodriguezauthor=K.+Mensa-Wilmotauthor=R.+J.+Sciottiauthor=K.+Gillingwaterauthor=M.+P.+Pollastri&title=Anilinoquinoline+based+inhibitors+of+trypanosomatid+proliferation&doi=10.1371%2Fjournal.pntd.0006834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anilinoquinoline based inhibitors of trypanosomatid proliferation</span></div><div class="casAuthors">Ferrins, Lori; Sharma, Amrita; Thomas, Sarah M.; Mehta, Naimee; Erath, Jessey; Tanghe, Scott; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Gillingwater, Kirsten; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0006834</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">We recently reported the medicinal chem. re-optimization of a series of compds. derived from the human tyrosine kinase inhibitor, lapatinib, for activity against Plasmodium falciparum.  From this same library of compds., we now report potent compds. against Trypanosoma brucei brucei (which causes human African trypanosomiasis), T. cruzi (the pathogen that causes Chagas disease), and Leishmania spp. (which cause leishmaniasis).  In addn., sub-micromolar compds. were identified that inhibit proliferation of the parasites that cause African animal trypanosomiasis, T. congolense and T. vivax.  We have found that this set of compds. display acceptable physicochem. properties and represent progress towards identification of lead compds. to combat several neglected tropical diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1RApwgv5k17Vg90H21EOLACvtfcHk0ljQg38DuL7EeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWkurvF&md5=103b62755c529a9dd829a214e1689b61</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0006834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0006834%26sid%3Dliteratum%253Aachs%26aulast%3DFerrins%26aufirst%3DL.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DS.%2BM.%26aulast%3DMehta%26aufirst%3DN.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DTanghe%26aufirst%3DS.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DGillingwater%26aufirst%3DK.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DAnilinoquinoline%2520based%2520inhibitors%2520of%2520trypanosomatid%2520proliferation%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2018%26volume%3D12%26doi%3D10.1371%2Fjournal.pntd.0006834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devine, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Antiparasitic lead discovery: toward optimization of a chemotype with activity against multiple protozoan parasites</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=350-354&author=W.+Devineauthor=S.+M.+Thomasauthor=J.+Erathauthor=K.+A.+Bachovchinauthor=P.+J.+Leeauthor=S.+E.+Leedauthor=A.+Rodriguezauthor=R.+J.+Sciottiauthor=K.+Mensa-Wilmotauthor=M.+P.+Pollastri&title=Antiparasitic+lead+discovery%3A+toward+optimization+of+a+chemotype+with+activity+against+multiple+protozoan+parasites&doi=10.1021%2Facsmedchemlett.7b00011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites</span></div><div class="casAuthors">Devine, William; Thomas, Sarah M.; Erath, Jessey; Bachovchin, Kelly A.; Lee, Patricia J.; Leed, Susan E.; Rodriguez, Ana; Sciotti, Richard J.; Mensa-Wilmot, Kojo; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">350-354</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis present a significant burden across the developing world.  Existing therapeutics for these protozoal neglected tropical diseases suffer from severe side effects and toxicity.  Previously, NEU-1045 was identified as a promising lead with cross-pathogen activity, though it possessed poor physicochem. properties.  The authors have designed a library of analogs with improved calcd. physicochem. properties built on the quinoline scaffold of 3 incorporating small, polar aminoheterocycles in place of the 4-(3-fluorobenzyloxy)aniline substituent.  The authors report the biol. activity of these inhibitors against Trypanosoma brucei (HAT), T. cruzi (Chagas disease), and Leishmania major (cutaneous leishmaniasis), and describe the identification of N-(5-chloropyrimidin-2-yl)-6-(4-(morpholinosulfonyl)phenyl)quinolin-4-amine (13t) as a promising inhibitor of L. major proliferation and 6-(4-(morpholinosulfonyl)phenyl)-N-(pyrimidin-4-yl)quinolin-4-amine (13j), a potent inhibitor of T. brucei proliferation with improved drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAlrVVjYVs3bVg90H21EOLACvtfcHk0lgrpMLraMbR5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWitbo%253D&md5=64426fb9e05ae3e2f28e0beae1b816e7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00011%26sid%3Dliteratum%253Aachs%26aulast%3DDevine%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DS.%2BM.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DBachovchin%26aufirst%3DK.%2BA.%26aulast%3DLee%26aufirst%3DP.%2BJ.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DAntiparasitic%2520lead%2520discovery%253A%2520toward%2520optimization%2520of%2520a%2520chemotype%2520with%2520activity%2520against%2520multiple%2520protozoan%2520parasites%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D350%26epage%3D354%26doi%3D10.1021%2Facsmedchemlett.7b00011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devine, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodring, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncal, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Protozoan parasite growth inhibitors discovered by cross-screening yield potent scaffolds for lead discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5522</span>– <span class="NLM_lpage">5537</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVagu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5522-5537&author=W.+Devineauthor=J.+L.+Woodringauthor=U.+Swaminathanauthor=E.+Amataauthor=G.+Patelauthor=J.+Erathauthor=N.+E.+Roncalauthor=P.+J.+Leeauthor=S.+E.+Leedauthor=A.+Rodriguezauthor=K.+Mensa-Wilmotauthor=R.+J.+Sciottiauthor=M.+P.+Pollastri&title=Protozoan+parasite+growth+inhibitors+discovered+by+cross-screening+yield+potent+scaffolds+for+lead+discovery&doi=10.1021%2Facs.jmedchem.5b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Protozoan parasite growth inhibitors discovered by cross-screening yield potent scaffolds for lead discovery</span></div><div class="casAuthors">Devine, William; Woodring, Jennifer L.; Swaminathan, Uma; Amata, Emanuele; Patel, Gautam; Erath, Jessey; Roncal, Norma E.; Lee, Patricia J.; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5522-5537</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estd. combined burden of over 87 million disability-adjusted life years.  New drugs are needed for each of these diseases.  Building on the previous identification of NEU-617 as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), the authors have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria).  Based on hits identified in this screening campaign, the authors describe the prepn. of several replacements for the quinazoline scaffold and report these inhibitors' biol. activities against these parasites.  In doing this, the authors have identified several potent proliferation inhibitors for each pathogen, such as NEU-924, I, for T. cruzi and NEU-1017, II, for L. major and P. falciparum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodbrXR55ZLJ7Vg90H21EOLACvtfcHk0lgrpMLraMbR5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVagu7bN&md5=76fef909165981d8e542d28a5ee59c12</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00515%26sid%3Dliteratum%253Aachs%26aulast%3DDevine%26aufirst%3DW.%26aulast%3DWoodring%26aufirst%3DJ.%2BL.%26aulast%3DSwaminathan%26aufirst%3DU.%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DG.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DRoncal%26aufirst%3DN.%2BE.%26aulast%3DLee%26aufirst%3DP.%2BJ.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DProtozoan%2520parasite%2520growth%2520inhibitors%2520discovered%2520by%2520cross-screening%2520yield%2520potent%2520scaffolds%2520for%2520lead%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5522%26epage%3D5537%26doi%3D10.1021%2Facs.jmedchem.5b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of physicochemical properties for 4-anilinoquinoline inhibitors of <i>Plasmodium falciparum</i> proliferation</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.7b00212</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.7b00212" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFGkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=577-591&author=N.+Mehtaauthor=L.+Ferrinsauthor=S.+E.+Leedauthor=R.+J.+Sciottiauthor=M.+P.+Pollastri&title=Optimization+of+physicochemical+properties+for+4-anilinoquinoline+inhibitors+of+Plasmodium+falciparum+proliferation&doi=10.1021%2Facsinfecdis.7b00212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation</span></div><div class="casAuthors">Mehta, Naimee; Ferrins, Lori; Leed, Susan E.; Sciotti, Richard J.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">577-591</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors recently reported the medicinal chem. reoptimization of a known human tyrosine kinase inhibitor, lapatinib, against a variety of parasites responsible for numerous tropical diseases, including human African trypanosomiasis (Trypanosoma brucei), Chagas disease (T. cruzi), Leishmaniasis (Leishmania spp.), and malaria (Plasmodium falciparum).  Herein, the authors report the authors' continuing efforts to optimize this series against P. falciparum.  Through the design of a library of compds. focused on reducing the lipophilicity and mol. wt., followed by an SAR exploration, the authors have identified NEU-1953 (40).  This compd. is a potent inhibitor of P. falciparum with an improved ADME profile over the previously reported compd., NEU-961.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoirOtgWSwlRLVg90H21EOLACvtfcHk0lgWsDj9WYtdpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFGkuw%253D%253D&md5=e0f6363ef9bccd8e489d4954f21c0335</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.7b00212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.7b00212%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DN.%26aulast%3DFerrins%26aufirst%3DL.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DOptimization%2520of%2520physicochemical%2520properties%2520for%25204-anilinoquinoline%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520proliferation%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2018%26volume%3D4%26spage%3D577%26epage%3D591%26doi%3D10.1021%2Facsinfecdis.7b00212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodring, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallerstein, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.ejmech.2017.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=29049963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Oqu7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2017&pages=446-459&author=J.+L.+Woodringauthor=K.+A.+Bachovchinauthor=K.+G.+Bradyauthor=M.+F.+Gallersteinauthor=J.+Erathauthor=S.+Tangheauthor=S.+E.+Leedauthor=A.+Rodriguezauthor=K.+Mensa-Wilmotauthor=R.+J.+Sciottiauthor=M.+P.+Pollastri&title=Optimization+of+physicochemical+properties+for+4-anilinoquinazoline+inhibitors+of+trypanosome+proliferation&doi=10.1016%2Fj.ejmech.2017.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation</span></div><div class="casAuthors">Woodring, Jennifer L.; Bachovchin, Kelly A.; Brady, Kimberly G.; Gallerstein, Mitchell F.; Erath, Jessey; Tanghe, Scott; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">446-459</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Human African trypanosomiasis (HAT) is a deadly disease in need of new chemotherapeutics that can cross into the central nervous system.  The authors previously reported the discovery of (NEU-617), a small mol. with activity against T. brucei bloodstream proliferation.  Further optimization of NEU-617 to improve the physicochem. properties (LogP, LLE, [1], and MPO score) [2] have led us to twelve sub-micromolar compds., most importantly the headgroup variants I and II, and the linker variant III.  Although these 3 compds. had reduced potency compared to NEU-617, they all had improved LogP, LLE and MPO scores.  Cross-screening these analogs against other protozoan parasites uncovered IV with potent activity towards T. brucei, T. cruzi and L. major, while four others compds. showed activity towards P. falciparum D6.  This reinforces the effectiveness of lead repurposing for the discovery of new protozoan disease therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJSNa6HL-xIrVg90H21EOLACvtfcHk0lgWsDj9WYtdpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Oqu7nE&md5=8eff33fa28775b57db396156849c2bbe</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DWoodring%26aufirst%3DJ.%2BL.%26aulast%3DBachovchin%26aufirst%3DK.%2BA.%26aulast%3DBrady%26aufirst%3DK.%2BG.%26aulast%3DGallerstein%26aufirst%3DM.%2BF.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DTanghe%26aufirst%3DS.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DOptimization%2520of%2520physicochemical%2520properties%2520for%25204-anilinoquinazoline%2520inhibitors%2520of%2520trypanosome%2520proliferation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D141%26spage%3D446%26epage%3D459%26doi%3D10.1016%2Fj.ejmech.2017.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, A. K.</span></span> <span> </span><span class="NLM_article-title">Salt selection in drug development</span>. <i>Pharm. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">128</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlKksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=128&author=L.+Kumarauthor=A.+Aminauthor=A.+K.+Bansal&title=Salt+selection+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Salt selection in drug development</span></div><div class="casAuthors">Kumar, Lokesh; Amin, Aeshna; Bansal, Arvind K.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Technology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">128, 130, 132, 134, 136, 140, 142, 144, 146</span>CODEN:
                <span class="NLM_cas:coden">PTHEC9</span>;
        ISSN:<span class="NLM_cas:issn">1543-2521</span>.
    
            (<span class="NLM_cas:orgname">Advanstar Communications, Inc.</span>)
        </div><div class="casAbstract">A review.  A drug's salt form has a major effect on its quality, safety, and performance.  The selection of an appropriate salt form for a potential drug candidate is an opportunity to modulate its characteristics to improve bioavailability, stability, manufacturability, and patient compliance.  Salt selection, however, can be a very difficult task because each salt imparts unique properties to the parent compd.  The authors provide an overview of the pharmaceutical considerations inherent in selecting the salt form of a medicinal compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzsKOC2pDg7Vg90H21EOLACvtfcHk0lgHpsygtjPf5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlKksLo%253D&md5=a7760d38cc0ae4782cab04aa41f0e58a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DL.%26aulast%3DAmin%26aufirst%3DA.%26aulast%3DBansal%26aufirst%3DA.%2BK.%26atitle%3DSalt%2520selection%2520in%2520drug%2520development%26jtitle%3DPharm.%2520Technol.%26date%3D2008%26volume%3D32%26spage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serajuddin, A. T. M.</span></span> <span> </span><span class="NLM_article-title">Salt formation to improve drug solubility</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2007.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.addr.2007.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=17619064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFGksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=603-616&author=A.+T.+M.+Serajuddin&title=Salt+formation+to+improve+drug+solubility&doi=10.1016%2Fj.addr.2007.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Salt formation to improve drug solubility</span></div><div class="casAuthors">Serajuddin, Abu T. M.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">603-616</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Salt formation is the most common and effective method of increasing soly. and dissoln. rates of acidic and basic drugs.  In this article, physicochem. principles of salt soly. are presented, with special ref. to the influence of pH-soly. profiles of acidic and basic drugs on salt formation and dissoln.  Non-ideality of salt soly. due to self-assocn. in soln. is also discussed.  Whether certain acidic or basic drugs would form salts and, if salts are formed, how easily they would dissoc. back into their free acid or base forms depend on interrelationships of several factors, such as S0 (intrinsic soly.), pH, pKa, Ksp (soly. product) and pHmax (pH of max. soly.).  The interrelationships of these factors are elaborated and their influence on salt screening and the selection of optimal salt forms for development are discussed.  Factors influencing salt dissoln. under various pH conditions, and esp. in reactive media and in presence of excess common ions, are discussed, with practical ref. to the development of solid dosage forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZdRvmSUWvN7Vg90H21EOLACvtfcHk0lgHpsygtjPf5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFGksrc%253D&md5=6e77d1385622af6973a6d763746ad0db</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DSerajuddin%26aufirst%3DA.%2BT.%2BM.%26atitle%3DSalt%2520formation%2520to%2520improve%2520drug%2520solubility%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D603%26epage%3D616%26doi%3D10.1016%2Fj.addr.2007.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgHpsygtjPf5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0ljz1mo5fl_kUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.%0AJ.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0ljz1mo5fl_kUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability+%E2%80%93+are+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0ljz1mo5fl_kUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%2520%25E2%2580%2593%2520are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaksma, E. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, O.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency as a guide in fragment hit selection and optimization</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e157</span>– <span class="NLM_lpage">e162</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2010.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.ddtec.2010.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVegsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=e157-e162&author=S.+Schultesauthor=C.+de+Graafauthor=E.+E.+J.+Haaksmaauthor=I.+J.+P.+de+Eschauthor=R.+Leursauthor=O.+Kr%C3%A4mer&title=Ligand+efficiency+as+a+guide+in+fragment+hit+selection+and+optimization&doi=10.1016%2Fj.ddtec.2010.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency as a guide in fragment hit selection and optimization</span></div><div class="casAuthors">Schultes, Sabine; de Graaf, Chris; Haaksma, Eric E. J.; de Esch, Iwan J. P.; Leurs, Rob; Kraemer, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">E157-E162</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fragment-based screening (FBS) has become an established approach for hit identification.  Starting points identified by FBS, are small fragments that require substantial modification to become leads.  As fragments are different from classical hits a process tailored for fragment evolution is required.  Scores for ligand efficiency have been proposed as guides for this process.  Here we review how these have been applied to guide the selection and optimization of fragment hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbfhwn68rv4bVg90H21EOLACvtfcHk0lhpxR8ebWARzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVegsL0%253D&md5=a57c85869d5c829159be31449fd04796</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2010.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2010.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DSchultes%26aufirst%3DS.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DHaaksma%26aufirst%3DE.%2BE.%2BJ.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DO.%26atitle%3DLigand%2520efficiency%2520as%2520a%2520guide%2520in%2520fragment%2520hit%2520selection%2520and%2520optimization%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2010%26volume%3D7%26spage%3De157%26epage%3De162%26doi%3D10.1016%2Fj.ddtec.2010.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency as an important metric in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+efficiency+as+an+important+metric+in+drug+design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lhpxR8ebWARzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520efficiency%2520as%2520an%2520important%2520metric%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petereit, A. C.</span></span> <span> </span><span class="NLM_article-title">Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2012.07.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.ejps.2012.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=22885099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2rs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=589-595&author=C.+Saalauthor=A.+C.+Petereit&title=Optimizing+solubility%3A+kinetic+versus+thermodynamic+solubility+temptations+and+risks&doi=10.1016%2Fj.ejps.2012.07.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing solubility: Kinetic versus thermodynamic solubility temptations and risks</span></div><div class="casAuthors">Saal, Christoph; Petereit, Anna Christine</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">589-595</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The aim of this study was to assess the usefulness of kinetic and thermodn. soly. data in guiding medicinal chem. during lead optimization.  The soly. of 465 research compds. was measured using a kinetic and a thermodn. soly. assay.  In the thermodn. assay, polarized-light microscopy was used to investigate whether the result referred to the cryst. or to the amorphous compd.  From the comparison of kinetic and thermodn. soly. data it was noted that kinetic soly. measurements frequently yielded results which show considerably higher soly. compared to thermodn. soly.  This observation is ascribed to the fact that a kinetic soly. assay typically delivers results which refer to the amorphous compd.  In contrast, results from thermodn. soly. detns. more frequently refer to a cryst. phase.  Accordingly, thermodn. soly. data - esp. when used together with an assessment of the solid state form - are deemed to be more useful in guiding soly. optimization for research compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooxKTQHBpynbVg90H21EOLACvtfcHk0lhXgyYPatOyFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2rs7bJ&md5=ace8b962c04c3a62f028ec3e66522922</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2012.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2012.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DSaal%26aufirst%3DC.%26aulast%3DPetereit%26aufirst%3DA.%2BC.%26atitle%3DOptimizing%2520solubility%253A%2520kinetic%2520versus%2520thermodynamic%2520solubility%2520temptations%2520and%2520risks%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D47%26spage%3D589%26epage%3D595%26doi%3D10.1016%2Fj.ejps.2012.07.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span> <span> </span><span class="NLM_article-title">Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.bmc.2016.04.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2897-2906&author=H.+Kawadaauthor=H.+Ebiikeauthor=M.+Tsukazakiauthor=S.+Yamamotoauthor=K.+Koyamaauthor=M.+Nakamuraauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=K.+Ogawaauthor=N.+Shimmaauthor=T.+Tsukudaauthor=J.+Ohwada&title=Optimization+of+the+phenylurea+moiety+in+a+phosphoinositide+3-kinase+%28PI3K%29+inhibitor+to+improve+water+solubility+and+the+PK+profile+by+introducing+a+solubilizing+group+and+ortho+substituents&doi=10.1016%2Fj.bmc.2016.04.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.060%26sid%3Dliteratum%253Aachs%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DShimma%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOhwada%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520the%2520phenylurea%2520moiety%2520in%2520a%2520phosphoinositide%25203-kinase%2520%2528PI3K%2529%2520inhibitor%2520to%2520improve%2520water%2520solubility%2520and%2520the%2520PK%2520profile%2520by%2520introducing%2520a%2520solubilizing%2520group%2520and%2520ortho%2520substituents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D2897%26epage%3D2906%26doi%3D10.1016%2Fj.bmc.2016.04.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Lowering lipophilicity by adding carbon: one-carbon bridges of morpholines and piperazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8934</span>– <span class="NLM_lpage">8943</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KhtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8934-8943&author=S.+L.+Degorceauthor=M.+S.+Bodnarchukauthor=I.+A.+Cummingauthor=J.+S.+Scott&title=Lowering+lipophilicity+by+adding+carbon%3A+one-carbon+bridges+of+morpholines+and+piperazines&doi=10.1021%2Facs.jmedchem.8b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines</span></div><div class="casAuthors">Degorce, Sebastien L.; Bodnarchuk, Michael S.; Cumming, Iain A.; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8934-8943</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this article, we report our investigation of a phenomenon by which bridging morpholines across the ring with one-carbon tethers leads to a counterintuitive redn. in lipophilicity.  This effect was also found to occur in piperazines and piperidines and lowered the measured log D7.4 of the bridged mols. by as much as -0.8 relative to their unbridged counterparts.  As lowering lipophilicity without introducing addnl. heteroatoms can be desirable, we believe this potentially provides a useful tactic to improve the drug-like properties of mols. contg. morpholine-, piperazine-, and piperidine-like motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhZJB3SYRKD7Vg90H21EOLACvtfcHk0lhXgyYPatOyFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KhtbzK&md5=27f30b8220ea767d6ef1e492f3fa1aba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01148%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBodnarchuk%26aufirst%3DM.%2BS.%26aulast%3DCumming%26aufirst%3DI.%2BA.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DLowering%2520lipophilicity%2520by%2520adding%2520carbon%253A%2520one-carbon%2520bridges%2520of%2520morpholines%2520and%2520piperazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8934%26epage%3D8943%26doi%3D10.1021%2Facs.jmedchem.8b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ressurreição, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitoe, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albuquerque, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Góis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronze, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanscheid, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudêncio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span> <span> </span><span class="NLM_article-title">Structural optimization of quinolon-4(1H)-imines as dual-stage antimalarials: toward increased potency and metabolic stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7679</span>– <span class="NLM_lpage">7690</span>, <span class="refDoi"> DOI: 10.1021/jm4011466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7679-7690&author=A.+S.+Ressurrei%C3%A7%C3%A3oauthor=D.+Gon%C3%A7alvesauthor=A.+R.+Sitoeauthor=I.+S.+Albuquerqueauthor=J.+Gutauthor=A.+G%C3%B3isauthor=L.+M.+Gon%C3%A7alvesauthor=M.+R.+Bronzeauthor=T.+Hanscheidauthor=G.+A.+Biaginiauthor=P.+J.+Rosenthalauthor=M.+Prud%C3%AAncioauthor=P.+O%E2%80%99Neillauthor=M.+M.+Motaauthor=F.+Lopesauthor=R.+Moreira&title=Structural+optimization+of+quinolon-4%281H%29-imines+as+dual-stage+antimalarials%3A+toward+increased+potency+and+metabolic+stability&doi=10.1021%2Fjm4011466"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm4011466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011466%26sid%3Dliteratum%253Aachs%26aulast%3DRessurrei%25C3%25A7%25C3%25A3o%26aufirst%3DA.%2BS.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DD.%26aulast%3DSitoe%26aufirst%3DA.%2BR.%26aulast%3DAlbuquerque%26aufirst%3DI.%2BS.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DG%25C3%25B3is%26aufirst%3DA.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DL.%2BM.%26aulast%3DBronze%26aufirst%3DM.%2BR.%26aulast%3DHanscheid%26aufirst%3DT.%26aulast%3DBiagini%26aufirst%3DG.%2BA.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DPrud%25C3%25AAncio%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%26aulast%3DMota%26aufirst%3DM.%2BM.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DMoreira%26aufirst%3DR.%26atitle%3DStructural%2520optimization%2520of%2520quinolon-4%25281H%2529-imines%2520as%2520dual-stage%2520antimalarials%253A%2520toward%2520increased%2520potency%2520and%2520metabolic%2520stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7679%26epage%3D7690%26doi%3D10.1021%2Fjm4011466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eissenstat, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentland, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingbeil, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danz, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. A.</span></span> <span> </span><span class="NLM_article-title">Potent mammalian topoisomerase II inhibitors: 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-substituted-quinolines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1016/0960-894X(95)00043-S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2F0960-894X%2895%2900043-S" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=399-404&author=G.-H.+Kuoauthor=M.+A.+Eissenstatauthor=M.+P.+Wentlandauthor=R.+G.+Robinsonauthor=K.+M.+Klingbeilauthor=D.+W.+Danzauthor=S.+A.+Coughlin&title=Potent+mammalian+topoisomerase+II+inhibitors%3A+1-cyclopropyl-6%2C8-difluoro-1%2C4-dihydro-7-%282%2C6-dimethyl-4-pyridinyl%29-4-substituted-quinolines&doi=10.1016%2F0960-894X%2895%2900043-S"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900043-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900043-S%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DG.-H.%26aulast%3DEissenstat%26aufirst%3DM.%2BA.%26aulast%3DWentland%26aufirst%3DM.%2BP.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DKlingbeil%26aufirst%3DK.%2BM.%26aulast%3DDanz%26aufirst%3DD.%2BW.%26aulast%3DCoughlin%26aufirst%3DS.%2BA.%26atitle%3DPotent%2520mammalian%2520topoisomerase%2520II%2520inhibitors%253A%25201-cyclopropyl-6%252C8-difluoro-1%252C4-dihydro-7-%25282%252C6-dimethyl-4-pyridinyl%2529-4-substituted-quinolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D399%26epage%3D404%26doi%3D10.1016%2F0960-894X%2895%2900043-S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltynek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baizman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiles, J. W.</span></span> <span> </span><span class="NLM_article-title">WIN 17317-3: novel nonpeptide antagonist of voltage-activated K + channels in human T lymphocytes</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">104</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1995&pages=98-104&author=R.+J.+Hillauthor=A.+M.+Grantauthor=W.+Volbergauthor=L.+Rappauthor=C.+Faltynekauthor=D.+Millerauthor=K.+Paganiauthor=E.+Baizmanauthor=S.+Wangauthor=J.+W.+Guiles&title=WIN+17317-3%3A+novel+nonpeptide+antagonist+of+voltage-activated+K+%2B+channels+in+human+T+lymphocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGrant%26aufirst%3DA.%2BM.%26aulast%3DVolberg%26aufirst%3DW.%26aulast%3DRapp%26aufirst%3DL.%26aulast%3DFaltynek%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DPagani%26aufirst%3DK.%26aulast%3DBaizman%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGuiles%26aufirst%3DJ.%2BW.%26atitle%3DWIN%252017317-3%253A%2520novel%2520nonpeptide%2520antagonist%2520of%2520voltage-activated%2520K%2520%252B%2520channels%2520in%2520human%2520T%2520lymphocytes%26jtitle%3DMol.%2520Pharmacol.%26date%3D1995%26volume%3D48%26spage%3D98%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Cruz, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressurreição, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitoe, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronze, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudêncio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span> <span> </span><span class="NLM_article-title">Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4811</span>– <span class="NLM_lpage">4815</span>, <span class="refDoi"> DOI: 10.1021/jm400246e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400246e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotV2nsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4811-4815&author=T.+Rodriguesauthor=F.+P.+da+Cruzauthor=M.%0AJ.+Lafuente-Monasterioauthor=D.+Gon%C3%A7alvesauthor=A.+S.+Ressurrei%C3%A7%C3%A3oauthor=A.+R.+Sitoeauthor=M.+R.+Bronzeauthor=J.+Gutauthor=G.+Schneiderauthor=M.+M.+Motaauthor=P.+J.+Rosenthalauthor=M.+Prud%C3%AAncioauthor=F.-J.+Gamoauthor=F.+Lopesauthor=R.+Moreira&title=Quinolin-4%281H%29-imines+are+potent+antiplasmodial+drugs+targeting+the+liver+stage+of+malaria&doi=10.1021%2Fjm400246e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolin-4(1H)-imines are Potent Antiplasmodial Drugs Targeting the Liver Stage of Malaria</span></div><div class="casAuthors">Rodrigues, Tiago; da Cruz, Filipa P.; Lafuente-Monasterio, Maria J.; Goncalves, Daniel; Ressurreicao, Ana S.; Sitoe, Ana R.; Bronze, Maria R.; Gut, Jiri; Schneider, Gisbert; Mota, Maria M.; Rosenthal, Philip J.; Prudencio, Miguel; Gamo, Francisco-Javier; Lopes, Francisca; Moreira, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4811-4815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors present a novel series of quinolin-4(1H)-imines as dual-stage antiplasmodials, several-fold more active than primaquine in vitro against Plasmodium berghei liver stage.  Among those, compds. (E)-N-(7-Chloro-1-ethylquinolin-4(1H)-ylidene)-4-(4-chlorophenoxy)aniline trifluoromethanesulfonate and (E)-N-(7-Chloro-1-ethylquinolin-4(1H)-ylidene)-4-(3-(trifluoromethoxy)phenoxy)aniline trifluoromethanesulfonate presented low nanomolar IC50 values.  The compds. are metabolically stable and modulate several drug targets.  These results emphasize the value of quinolin-4(1H)-imines as a new chemotype and their suitable properties for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVq1Th5oXaC7Vg90H21EOLACvtfcHk0liluR1OqC7lkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotV2nsbo%253D&md5=adbe8b82b3b986d04c7e96ac936f7aa8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm400246e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400246e%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3Dda%2BCruz%26aufirst%3DF.%2BP.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DD.%26aulast%3DRessurrei%25C3%25A7%25C3%25A3o%26aufirst%3DA.%2BS.%26aulast%3DSitoe%26aufirst%3DA.%2BR.%26aulast%3DBronze%26aufirst%3DM.%2BR.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DMota%26aufirst%3DM.%2BM.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DPrud%25C3%25AAncio%26aufirst%3DM.%26aulast%3DGamo%26aufirst%3DF.-J.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DMoreira%26aufirst%3DR.%26atitle%3DQuinolin-4%25281H%2529-imines%2520are%2520potent%2520antiplasmodial%2520drugs%2520targeting%2520the%2520liver%2520stage%2520of%2520malaria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4811%26epage%3D4815%26doi%3D10.1021%2Fjm400246e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nwaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, R.</span></span> <span> </span><span class="NLM_article-title">Advancing drug innovation for neglected diseases-criteria for lead progression</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e440</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0000440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1371%2Fjournal.pntd.0000440" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&author=S.+Nwakaauthor=B.+Ramirezauthor=R.+Brunauthor=L.+Maesauthor=F.+Douglasauthor=R.+Ridley&title=Advancing+drug+innovation+for+neglected+diseases-criteria+for+lead+progression&doi=10.1371%2Fjournal.pntd.0000440"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0000440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0000440%26sid%3Dliteratum%253Aachs%26aulast%3DNwaka%26aufirst%3DS.%26aulast%3DRamirez%26aufirst%3DB.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DDouglas%26aufirst%3DF.%26aulast%3DRidley%26aufirst%3DR.%26atitle%3DAdvancing%2520drug%2520innovation%2520for%2520neglected%2520diseases-criteria%2520for%2520lead%2520progression%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2009%26volume%3D3%26doi%3D10.1371%2Fjournal.pntd.0000440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purmal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of a carbazole-derived lead drug for human African trypanosomiasis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">32083</span> <span class="refDoi"> DOI: 10.1038/srep32083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fsrep32083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=27561392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVChtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=S.+M.+Thomasauthor=A.+Purmalauthor=M.+Pollastriauthor=K.+Mensa-Wilmot&title=Discovery+of+a+carbazole-derived+lead+drug+for+human+African+trypanosomiasis&doi=10.1038%2Fsrep32083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis</span></div><div class="casAuthors">Thomas, Sarah M.; Purmal, Andrei; Pollastri, Michael; Mensa-Wilmot, Kojo</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32083</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protozoan parasite Trypanosoma brucei causes the fatal illness human African trypanosomiasis (HAT).  Std. of care medications currently used to treat HAT have severe limitations, and there is a need to find new chem. entities that are active against infections of T. brucei.  Following a "drug repurposing" approach, we tested anti-trypanosomal effects of carbazole-derived compds. called "Curaxins".  In vitro screening of 26 compds. revealed 22 with nanomolar potency against axenically cultured bloodstream trypanosomes.  In a murine model of HAT, oral administration of compd. 1 cured the disease.  These studies established 1 as a lead for development of drugs against HAT.  Pharmacol. time-course studies revealed the primary effect of 1 to be concurrent inhibition of mitosis coupled with aberrant licensing of S-phase entry.  Consequently, polyploid trypanosomes contg. 8C equiv. of DNA per nucleus and three or four kinetoplasts were produced.  These effects of 1 on the trypanosome are reminiscent of "mitotic slippage" or endoreplication obsd. in some other eukaryotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Btu_sKSCprVg90H21EOLACvtfcHk0liluR1OqC7lkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVChtL3N&md5=9ae56c361c9e52312184b78e1fa68e31</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fsrep32083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep32083%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BM.%26aulast%3DPurmal%26aufirst%3DA.%26aulast%3DPollastri%26aufirst%3DM.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520a%2520carbazole-derived%2520lead%2520drug%2520for%2520human%2520African%2520trypanosomiasis%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fsrep32083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirumi, K.</span></span> <span> </span><span class="NLM_article-title">Continuous cultivation of <i>Trypanosoma brucei</i> blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers</span>. <i>J. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.2307/3282883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.2307%2F3282883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=2614608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A280%3ADyaK3c7jtlaksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1989&pages=985-989&author=H.+Hirumiauthor=K.+Hirumi&title=Continuous+cultivation+of+Trypanosoma+brucei+blood+stream+forms+in+a+medium+containing+a+low+concentration+of+serum+protein+without+feeder+cell+layers&doi=10.2307%2F3282883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers</span></div><div class="casAuthors">Hirumi H; Hirumi K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of parasitology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">985-9</span>
        ISSN:<span class="NLM_cas:issn">0022-3395</span>.
    </div><div class="casAbstract">Blood stream forms (BSF) of Trypanosoma brucei brucei GUT at 3.1 were propagated in vitro in the absence of feeder layer cells at 37 C, using a modified Iscove's medium (HMI-18).  The medium was supplemented with 0.05 mM bathocuproine sulfonate, 1.5 mM L-cysteine, 1 mM hypoxanthine, 0.2 mM 2-mercaptoethanol, 1 mM sodium pyruvate. 0.16 mM thymidine, and 20% (v/v) Serum Plus (SP) (Hazleton Biologics, Lenexa, Kansas).  The latter contained a low level of serum proteins (13 micrograms/ml).  Each primary culture was initiated by placing 3.5-4 x 10(6) BSFs isolated from infected mice in a flask containing 5 ml of the medium (HMI-9) supplemented with 10% fetal bovine serum (FBS) and 10% SP.  The cultures were maintained by replacing the medium every 24 hr for 5-7 days.  During this period, many BSFs died.  However, from day 4 onward, long slender BSFs increased in number.  On days 5-7, trypanosome suspensions were pooled and cell debris was removed by means of diethylaminoethyl cellulose (DE52) column chromatography.  Blood stream forms then were collected by centrifugation, resuspended in fresh medium at 7-9 x 10(5)/ml, and transferred to new flasks.  Subcultures were maintained by readjusting the BSF density to 7-9 x 10(5)/ml every 24 hr.  Concentrations of FBS were reduced gradually at 5-7-day intervals by alternating the amounts of FBS and SP in HMI-9 with 5% FBS and 15% SP, with 2% FBS and 18% SP, and finally with 20% SP (HMI-18).  By this method, 2-3 x 10(6) VSFs/ml were obtained consistently every 24 hr. for more than 80 days.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-hsI_lV2EcpPlX7E30qdzfW6udTcc2ebVo-AqiHW3_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c7jtlaksw%253D%253D&md5=a5ec1c8efb4c6572ef8ff09ad88edeb0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2307%2F3282883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3282883%26sid%3Dliteratum%253Aachs%26aulast%3DHirumi%26aufirst%3DH.%26aulast%3DHirumi%26aufirst%3DK.%26atitle%3DContinuous%2520cultivation%2520of%2520Trypanosoma%2520brucei%2520blood%2520stream%2520forms%2520in%2520a%2520medium%2520containing%2520a%2520low%2520concentration%2520of%2520serum%2520protein%2520without%2520feeder%2520cell%2520layers%26jtitle%3DJ.%2520Parasitol.%26date%3D1989%26volume%3D75%26spage%3D985%26epage%3D989%26doi%3D10.2307%2F3282883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornasiero, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isetta, A. M.</span></span> <span> </span><span class="NLM_article-title">MTT colorimetric assay for testing macrophage cytotoxic activity in vitro</span>. <i>J. Immunol. Methods</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1016/0022-1759(90)90187-Z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2F0022-1759%2890%2990187-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=2391427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADyaK3cXmtV2nsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=1990&pages=165-172&author=M.+Ferrariauthor=M.+C.+Fornasieroauthor=A.+M.+Isetta&title=MTT+colorimetric+assay+for+testing+macrophage+cytotoxic+activity+in+vitro&doi=10.1016%2F0022-1759%2890%2990187-Z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">MTT colorimetric assay for testing macrophage cytotoxic activity in vitro</span></div><div class="casAuthors">Ferrari, Mario; Fornasiero, Maria Chiara; Isetta, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunological Methods</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-72</span>CODEN:
                <span class="NLM_cas:coden">JIMMBG</span>;
        ISSN:<span class="NLM_cas:issn">0022-1759</span>.
    </div><div class="casAbstract">The MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide] cleavage assay, originally described by T. Mosmann (1983) for measuring cell survival/proliferation, was used successfully to quantitate macrophage-mediated cytotoxicity.  Peritoneal macrophages, from control or pyran copolymer MVE2-treated mice and from TU5 and L929 murine cell lines, were used as effectors and targets resp. in a 48 h cytotoxicity test, at 3 effector: target ratios (10:1, 5:1, 2:1).  The amt. of MTT reduced by cells to its blue formazan deriv. during an addnl. 4 h of culture was quantified spectrophotometrically at 570 nm using an ELISA reader.  A linear relationship between the formazan generated and the no. of viable TU5 and L929 cells was demonstrated, together with time-dependent growth characteristics for these cells.  The formazan produced by macrophages was independent of their functional state and did not interfere with the target cell signal.  MVE2-activated macrophages strongly inhibited the survival/growth of target cells in a dose-related way, whereas the cytotoxic activity of control macrophages was very low.  Finally, the MTT method compared favorably with the 3H-TdR uptake method in evaluating macrophage cytotoxicity, and both of them were more sensitive than the 3H-TdR release assay.  The MTT cleavage method is a useful alternative to radioisotopic methods for quantitating macrophage cytotoxicity for actively growing in vitro targets.  Its main advantages are: (a) sensitivity and reproducibility; (b) elimination of the need for radioactive compds.; (c) ease with which it can be performed and quantified; and (d) rapidity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrezxA3w4p2ebVg90H21EOLACvtfcHk0lhgB7ABgInjPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmtV2nsLo%253D&md5=e0b83e032dccb6f10faa9fc8a8ca16ce</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2F0022-1759%2890%2990187-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-1759%252890%252990187-Z%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DM.%26aulast%3DFornasiero%26aufirst%3DM.%2BC.%26aulast%3DIsetta%26aufirst%3DA.%2BM.%26atitle%3DMTT%2520colorimetric%2520assay%2520for%2520testing%2520macrophage%2520cytotoxic%2520activity%2520in%2520vitro%26jtitle%3DJ.%2520Immunol.%2520Methods%26date%3D1990%26volume%3D131%26spage%3D165%26epage%3D172%26doi%3D10.1016%2F0022-1759%2890%2990187-Z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konsoula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.ijpharm.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=18562136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2008&pages=19-25&author=R.+Konsoulaauthor=M.+Jung&title=In+vitro+plasma+stability%2C+permeability+and+solubility+of+mercaptoacetamide+histone+deacetylase+inhibitors&doi=10.1016%2Fj.ijpharm.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span></div><div class="casAuthors">Konsoula, Roula; Jung, Mira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers.  In this study, the in vitro plasma stability, permeability, soly., and lipophilicity (log D) of two mercaptoacetamide-based HDACIs (coded as W2 and S2) were evaluated and compared to Vorinostat (SAHA).  The results demonstrated that the compds. manifested high soly. in HCl (pH 1.2) but lower in PBS (pH 7.4) than SAHA.  Moreover, mercaptoacetamide-based HDACIs exhibited higher lipophilicity values compared to SAHA.  The permeability of these compds. was evaluated using the Caco-2 cell monolayer as a model of the intestinal mucosa.  The Caco-2 studies revealed that the compds. S2 and W2 are highly permeable with apparent permeability coeffs. (Papp) in the apical to basolateral direction of 7.33 × 10-6 and 15.0 × 10-6 cm/s, resp.  The in vitro stability was detd. in human, mouse, porcine and rat plasma.  Data showed that the compd. W2 is more stable in human and rat plasma and the S2 is more stable in all plasma species than SAHA.  Taken together, these results indicate that the mercaptoacetamide-based HDACIs possess favorable soly., lipophilicity, permeability and plasma stability features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ60NiaoIn6bVg90H21EOLACvtfcHk0lhgB7ABgInjPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D&md5=32a5ec87e4d150d373a325b3ee296dc7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DKonsoula%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520plasma%2520stability%252C%2520permeability%2520and%2520solubility%2520of%2520mercaptoacetamide%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D361%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.ijpharm.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revankar, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span> <span> </span><span class="NLM_article-title">Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci00063a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADyaL1MXkslSgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1989&pages=163-172&author=V.+N.+Viswanadhanauthor=A.+K.+Ghoseauthor=G.+R.+Revankarauthor=R.+K.+Robins&title=Atomic+physicochemical+parameters+for+three+dimensional+structure+directed+quantitative+structure-activity+relationships.+4.+Additional+parameters+for+hydrophobic+and+dispersive+interactions+and+their+application+for+an+automated+superposition+of+certain+naturally+occurring+nucleoside+antibiotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships.  4.  Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics</span></div><div class="casAuthors">Viswanadhan, Vellarkad N.; Ghose, Arup K.; Revankar, Ganapathi R.; Robins, Roland K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-72</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    </div><div class="casAbstract">At. values for physicochem. properties are an important guide for correlating the obsd. biol. activity of the ligands to their chem. structure.  The objective of the present work was to (i) report the hydrophobicity and the molar refractivity for P and Se atoms at different structural environments that are ubiquitous in biol. active systems, (ii) refine the at. values of the various elements reported earlier to satisfy the largely extended data set, and (iii) suggest a method for selecting the best superposition of different mols. on a ref. structure using these at. physicochem. properties.  The octanol-water partition coeff. was used to scale the at. hydrophobicity.  The hydrophobicity values of 120 atom types were evaluated from 893 compds.  The obsd. and calcd. octanol-water partition coeff. showed a correlation coeff. of 0.926 and a std. deviation of 0.496.  The at. refractivity values were evaluated from the molar refractivities of 538 compds.; the corresponding correlation coeff. and std. deviation were 0.999 and 0.774, resp.  The at. values were tested by predicting the resp. properties for a large no. of compds.  The superposition methods was applied to certain naturally occurring nucleoside antibiotics.  The algorithm presented showed various important superpositions of ≥2 mols. with min. phys. assistance to avoid any personal bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLCJFGlYIlHrVg90H21EOLACvtfcHk0liQbGYM2lntZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkslSgs7w%253D&md5=b2f20d16b51f3405b5799138904de81a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fci00063a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci00063a006%26sid%3Dliteratum%253Aachs%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DRevankar%26aufirst%3DG.%2BR.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26atitle%3DAtomic%2520physicochemical%2520parameters%2520for%2520three%2520dimensional%2520structure%2520directed%2520quantitative%2520structure-activity%2520relationships.%25204.%2520Additional%2520parameters%2520for%2520hydrophobic%2520and%2520dispersive%2520interactions%2520and%2520their%2520application%2520for%2520an%2520automated%2520superposition%2520of%2520certain%2520naturally%2520occurring%2520nucleoside%2520antibiotics%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D1989%26volume%3D29%26spage%3D163%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Baljinder Singh, Rosario Diaz-Gonzalez, Gloria Ceballos-Perez, Domingo I. Rojas-Barros, Naresh Gunaganti, Kirsten Gillingwater, Maria Santos Martinez-Martinez, Pilar Manzano, Miguel Navarro, <span class="NLM_string-name hlFld-ContribAuthor">Michael P. Pollastri</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Optimization of a Diaminopurine Chemotype: Toward a Lead for Trypanosoma brucei Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9912-9927. <a href="https://doi.org/10.1021/acs.jmedchem.0c01017" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BOptimization%252Bof%252Ba%252BDiaminopurine%252BChemotype%25253A%252BToward%252Ba%252BLead%252Bfor%252BTrypanosoma%252Bbrucei%252BInhibitors%26aulast%3DSingh%26aufirst%3DBaljinder%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18062020%26date%3D13082020%26date%3D30072020%26volume%3D63%26issue%3D17%26spage%3D9912%26epage%3D9927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Baljinder Singh, Jean A. Bernatchez, Laura-Isobel McCall, Claudia M. Calvet, Jasmin Ackermann, Julia M. Souza, Diane Thomas, Everton M. Silva, Kelly A. Bachovchin, Dana M. Klug, Hitesh B. Jalani, Seema Bag, Melissa J. Buskes, Susan E. Leed, Norma E. Roncal, Erica C. Penn, Jessey Erath, Ana Rodriguez, Richard J. Sciotti, Robert F. Campbell, James McKerrow, Jair L. Siqueira-Neto, Lori Ferrins, <span class="NLM_string-name hlFld-ContribAuthor">Michael P. Pollastri</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 249-257. <a href="https://doi.org/10.1021/acsmedchemlett.9b00453" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00453%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DScaffold%252Band%252BParasite%252BHopping%25253A%252BDiscovery%252Bof%252BNew%252BProtozoal%252BProliferation%252BInhibitors%26aulast%3DSingh%26aufirst%3DBaljinder%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D01102019%26date%3D10012020%26date%3D22012020%26date%3D10012020%26volume%3D11%26issue%3D3%26spage%3D249%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Melissa J. Buskes, Monica Clements, Kelly A. Bachovchin, Hitesh B. Jalani, Allison Leonard, Seema Bag, Dana M. Klug, Baljinder Singh, Robert F. Campbell, Richard J. Sciotti, Nelly El-Sakkary, Conor R. Caffrey, Michael P. Pollastri, <span class="NLM_string-name hlFld-ContribAuthor">Lori Ferrins</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–Bioactivity Relationships of Lapatinib Derived Analogs against Schistosoma mansoni. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 258-265. <a href="https://doi.org/10.1021/acsmedchemlett.9b00455" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00455</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00455%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure%2525E2%252580%252593Bioactivity%252BRelationships%252Bof%252BLapatinib%252BDerived%252BAnalogs%252Bagainst%252BSchistosoma%252Bmansoni%26aulast%3DBuskes%26aufirst%3DMelissa%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D01102019%26date%3D10012020%26date%3D22012020%26date%3D10012020%26volume%3D11%26issue%3D3%26spage%3D258%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Westley F. Tear, Seema Bag, Rosario Diaz-Gonzalez, Gloria Ceballos-Pérez, Domingo I. Rojas-Barros, Carlos Cordon-Obras, Guiomar Pérez-Moreno, Raquel García-Hernández, Maria Santos Martinez-Martinez, Luis Miguel Ruiz-Perez, Francisco Gamarro, Dolores Gonzalez Pacanowska, Conor R. Caffrey, Lori Ferrins, Pilar Manzano, Miguel Navarro, <span class="NLM_string-name hlFld-ContribAuthor">Michael P. Pollastri</span>. </span><span class="cited-content_cbyCitation_article-title">Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 756-783. <a href="https://doi.org/10.1021/acs.jmedchem.9b01741" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01741</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01741%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelectivity%252Band%252BPhysicochemical%252BOptimization%252Bof%252BRepurposed%252BPyrazolo%25255B1%25252C5-b%25255Dpyridazines%252Bfor%252Bthe%252BTreatment%252Bof%252BHuman%252BAfrican%252BTrypanosomiasis%26aulast%3DTear%26aufirst%3DWestley%2BF.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D21102019%26date%3D08012020%26date%3D17122019%26volume%3D63%26issue%3D2%26spage%3D756%26epage%3D783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kojo  Mensa-Wilmot</span>. </span><span class="cited-content_cbyCitation_article-title">How Physiologic Targets Can Be Distinguished from Drug-Binding Proteins. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2021,</strong> <em>100 </em>
                                    (1)
                                     , 1-6. <a href="https://doi.org/10.1124/molpharm.120.000186" title="DOI URL">https://doi.org/10.1124/molpharm.120.000186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/molpharm.120.000186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmolpharm.120.000186%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DHow%252BPhysiologic%252BTargets%252BCan%252BBe%252BDistinguished%252Bfrom%252BDrug-Binding%252BProteins%26aulast%3DMensa-Wilmot%26aufirst%3DKojo%26date%3D2021%26date%3D2021%26volume%3D100%26issue%3D1%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana Georgina  Gomes-Alves</span>, <span class="hlFld-ContribAuthor ">Margarida  Duarte</span>, <span class="hlFld-ContribAuthor ">Tânia  Cruz</span>, <span class="hlFld-ContribAuthor ">Helena  Castro</span>, <span class="hlFld-ContribAuthor ">Francisca  Lopes</span>, <span class="hlFld-ContribAuthor ">Rui  Moreira</span>, <span class="hlFld-ContribAuthor ">Ana S.  Ressurreição</span>, <span class="hlFld-ContribAuthor ">Ana M.  Tomás</span>. </span><span class="cited-content_cbyCitation_article-title">Biological Evaluation and Mechanistic Studies of Quinolin-(1
              H
              )-Imines as a New Chemotype against Leishmaniasis. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2021,</strong> <em>65 </em>
                                    (7)
                                     <a href="https://doi.org/10.1128/AAC.01513-20" title="DOI URL">https://doi.org/10.1128/AAC.01513-20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.01513-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.01513-20%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DBiological%252BEvaluation%252Band%252BMechanistic%252BStudies%252Bof%252BQuinolin-%2525281%252BH%252B%252529-Imines%252Bas%252Ba%252BNew%252BChemotype%252Bagainst%252BLeishmaniasis%26aulast%3DGomes-Alves%26aufirst%3DAna%2BGeorgina%26date%3D2021%26volume%3D65%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Conor R.  Caffrey</span>, <span class="hlFld-ContribAuthor ">Dietmar  Steverding</span>, <span class="hlFld-ContribAuthor ">Rafaela S.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Renata B.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Anthony J.  O'Donoghue</span>, <span class="hlFld-ContribAuthor ">Ludovica  Monti</span>, <span class="hlFld-ContribAuthor ">Carlo  Ballatore</span>, <span class="hlFld-ContribAuthor ">Kelly A.  Bachovchin</span>, <span class="hlFld-ContribAuthor ">Lori  Ferrins</span>, <span class="hlFld-ContribAuthor ">Michael P.  Pollastri</span>, <span class="hlFld-ContribAuthor ">Kimberley M.  Zorn</span>, <span class="hlFld-ContribAuthor ">Daniel H.  Foil</span>, <span class="hlFld-ContribAuthor ">Alex M.  Clark</span>, <span class="hlFld-ContribAuthor ">Melina  Mottin</span>, <span class="hlFld-ContribAuthor ">Carolina H.  Andrade</span>, <span class="hlFld-ContribAuthor ">Jair L.  Siqueira‐Neto</span>, <span class="hlFld-ContribAuthor ">Sean  Ekins</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery and Development for Kinetoplastid Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-79. <a href="https://doi.org/10.1002/0471266949.bmc235.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc235.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc235.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc235.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BDiscovery%252Band%252BDevelopment%252Bfor%252BKinetoplastid%252BDiseases%26aulast%3DCaffrey%26aufirst%3DConor%2BR.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D79%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ajay  Kumar</span>, <span class="hlFld-ContribAuthor ">Kamlesh  Kumari</span>, <span class="hlFld-ContribAuthor ">Sangeeta  Singh</span>, <span class="hlFld-ContribAuthor ">Indra  Bahadur</span>, <span class="hlFld-ContribAuthor ">Prashant  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Noscapine anticancer drug designed with ionic liquids to enhance solubility: DFT and ADME approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Liquids</span><span> <strong>2021,</strong> <em>325 </em>, 115159. <a href="https://doi.org/10.1016/j.molliq.2020.115159" title="DOI URL">https://doi.org/10.1016/j.molliq.2020.115159</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molliq.2020.115159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molliq.2020.115159%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Liquids%26atitle%3DNoscapine%252Banticancer%252Bdrug%252Bdesigned%252Bwith%252Bionic%252Bliquids%252Bto%252Benhance%252Bsolubility%25253A%252BDFT%252Band%252BADME%252Bapproach%26aulast%3DKumar%26aufirst%3DAjay%26date%3D2021%26volume%3D325%26spage%3D115159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lídia M.  Lima</span>, <span class="hlFld-ContribAuthor ">Marina A.  Alves</span>, <span class="hlFld-ContribAuthor ">Daniel N.  do Amaral</span>. </span><span class="cited-content_cbyCitation_article-title">Homologation: A Versatile Molecular Modification Strategy to Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (19)
                                     , 1734-1750. <a href="https://doi.org/10.2174/1568026619666190808145235" title="DOI URL">https://doi.org/10.2174/1568026619666190808145235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190808145235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190808145235%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DHomologation%25253A%252BA%252BVersatile%252BMolecular%252BModification%252BStrategy%252Bto%252BDrug%252BDiscovery%26aulast%3DLima%26aufirst%3DL%25C3%25ADdia%2BM.%26date%3D2019%26volume%3D19%26issue%3D19%26spage%3D1734%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Hit-to-lead screening cascade employed in this project, along with the goal values used for the various parameters, as determined when considering the TPP for HAT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Scheme for Addition of Ionizable Groups or Increased sp<sup>3</sup> Carbon Content as New Tail Groups for Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) various substituted amines, Et<sub>3</sub>N, EtOH, ambient temperature, 18 h (32–72%); (b) various substituted amines, DIPEA, <i>tert</i>-butanol, 150 °C, microwave, 30 min (57–97%); (c) B<sub>2</sub>pin<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, dioxane, 145 °C, 1 h (49%-assumed quant.); (d) K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/H<sub>2</sub>O, 130 °C, microwave, 30 min (21–99%).</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pseudo-ring analogues of the previously reported compound <b>7</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route for Various Head Group Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span><i>Reagents and conditions:</i> a) saturated primary amine, DIPEA, <i>n</i>-butanol, 200 °C, microwave, 3 h (22–98%); b) aryl primary amine, NaH, DMF, 60 °C (38–75%); c) B<sub>2</sub>pin<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, dioxane, 145 °C, microwave, 1 h (assumed quantitative); d) Cs<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 3:1 dioxane/H<sub>2</sub>O, 80 °C, 48 h (11–44%); e) K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/H<sub>2</sub>O, 130 °C, microwave, 30 min (7–29%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthetic Route to Quinolinimine Core Analogues, and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, R-I, THF, 0 °C to ambient temperature (27–63%); (b) <b>3m</b>, B<sub>2</sub>pin<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, dioxane, 145 °C, microwave, 1 h; (c) K<sub>2</sub>CO<sub>3</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, 3:1 dioxane/H<sub>2</sub>O, 130 °C, microwave, 30 min (36–53% over two steps); (d) 2-aminopyrazine, NaH, CH<sub>3</sub>I, THF, 0 °C to ambient temperature (49%); (e) <b>11</b>, NaH, DMF, ambient temperature (82%).</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Trypanocidal effect of test compounds. Log-phase <i>T.b. brucei</i> (1 × 10<sup>5</sup>/mL) were incubated with the hit (at 25 × EC<sub>50</sub> concentration) for 6 h and transferred into drug-free HMI-9 medium for 48 h at a starting cell density of 1 × 10<sup>4</sup> cells/mL. Trypanosomes were enumerated with a hemocytometer after 48 h (*indicates Student’s <i>T</i>-test <i>p</i> < 0.01; the error bars indicate standard deviation). The dashed line corresponds to expected density of cells if 50% were killed in the earlier 6 h exposure to a hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plot of 25× <i>T. brucei</i> EC<sub>50</sub> against CEC<sub>50</sub> of hits.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/medium/jm-2018-01365z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of <b>22a</b> on trypanosomes in a mouse model of HAT. Mice (four per group) were each infected with 10<sup>5</sup><i>T.b. brucei</i> (day 0). Compound <b>22a</b> (100 mg/kg) was administered p.o. for 6 days (an additional 50 mg/kg was dosed on day 6). Control mice received vehicle. Different shapes represent individual mice, and the horizontal lines in each group indicate mean parasitemia. Parasitemia was determined with a hemocytometer. UND = undetectable.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-2/acs.jmedchem.8b01365/20190116/images/large/jm-2018-01365z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01365&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i172">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karver, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullenberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3820</span>– <span class="NLM_lpage">3832</span>, <span class="refDoi"> DOI: 10.1021/jm400349k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400349k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFSitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3820-3832&author=G.+Patelauthor=C.+E.+Karverauthor=R.+Beheraauthor=P.+Guyettauthor=C.+Sullenbergerauthor=P.+Edwardsauthor=N.+Roncalauthor=K.+Mensa-Wilmotauthor=M.+P.+Pollastri&title=Kinase+scaffold+repurposing+for+neglected+disease+drug+discovery%3A+discovery+of+an+efficacious%2C+lapatanib-derived+lead+compound+for+trypanosomiasis&doi=10.1021%2Fjm400349k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis</span></div><div class="casAuthors">Patel, Gautam; Karver, Caitlin E.; Behera, Ranjan; Guyett, Paul J.; Sullenberger, Catherine; Edwards, Peter; Roncal, Norma E.; Mensa-Wilmot, Kojo; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3820-3832</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lapatinib analogs such as I (X = O, CH2) were prepd. as trypanocidal agents for use as lead compds. in the development of treatments for human African trypanosomiasis which do not require i.v. administration.  Lapatinib was previously shown to kill T. brucei with low micromolar EC50 values; analogs replacing the methylfurylquinazoline moiety with a heteroarylsulfonylphenylquinazolinyl moiety were prepd. and tested against both T. brucei and human hepatocarcinoma cells.  4-Anilinoquinazolines, particularly I (X = O) (NEU617), were found to be highly potent and orally bioavailable inhibitors of trypanosome replication.  I (X = O) blocks duplication of the kinetoplast and arrests cytokinesis in T. brucei, which may make it useful as a chem. tool for studying regulation of the trypanosome cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoliwtzx67q77Vg90H21EOLACvtfcHk0ljaLkpJZSrlig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFSitLo%253D&md5=dd278f3bc7c671330e40de210392a278</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm400349k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400349k%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DG.%26aulast%3DKarver%26aufirst%3DC.%2BE.%26aulast%3DBehera%26aufirst%3DR.%26aulast%3DGuyett%26aufirst%3DP.%26aulast%3DSullenberger%26aufirst%3DC.%26aulast%3DEdwards%26aufirst%3DP.%26aulast%3DRoncal%26aufirst%3DN.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DKinase%2520scaffold%2520repurposing%2520for%2520neglected%2520disease%2520drug%2520discovery%253A%2520discovery%2520of%2520an%2520efficacious%252C%2520lapatanib-derived%2520lead%2520compound%2520for%2520trypanosomiasis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3820%26epage%3D3832%26doi%3D10.1021%2Fjm400349k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappuis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burri, C.</span></span> <span> </span><span class="NLM_article-title">Human African trypanosomiasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(09)60829-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2FS0140-6736%2809%2960829-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2010&pages=148-159&author=R.+Brunauthor=J.+Blumauthor=F.+Chappuisauthor=C.+Burri&title=Human+African+trypanosomiasis&doi=10.1016%2FS0140-6736%2809%2960829-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2960829-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252960829-1%26sid%3Dliteratum%253Aachs%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DBlum%26aufirst%3DJ.%26aulast%3DChappuis%26aufirst%3DF.%26aulast%3DBurri%26aufirst%3DC.%26atitle%3DHuman%2520African%2520trypanosomiasis%26jtitle%3DLancet%26date%3D2010%26volume%3D375%26spage%3D148%26epage%3D159%26doi%3D10.1016%2FS0140-6736%2809%2960829-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">World
Health Organization</span>.  <i>Sustaining the
Drive to Overcome the Global
Impact of Neglected Tropical Diseases: Second WHO Report on Neglected
Tropical Diseases</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=World%0AHealth+Organization&title=Sustaining+the%0ADrive+to+Overcome+the+Global%0AImpact+of+Neglected+Tropical+Diseases%3A+Second+WHO+Report+on+Neglected%0ATropical+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DSustaining%2520the%250ADrive%2520to%2520Overcome%2520the%2520Global%250AImpact%2520of%2520Neglected%2520Tropical%2520Diseases%253A%2520Second%2520WHO%2520Report%2520on%2520Neglected%250ATropical%2520Diseases%26pub%3DWorld%2520Health%2520Organization%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Büscher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamonneau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priotto, G.</span></span> <span> </span><span class="NLM_article-title">Human African trypanosomiasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2409</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31510-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2FS0140-6736%2817%2931510-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=28673422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=2397-2409&author=P.+B%C3%BCscherauthor=G.+Cecchiauthor=V.+Jamonneauauthor=G.+Priotto&title=Human+African+trypanosomiasis&doi=10.1016%2FS0140-6736%2817%2931510-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human African trypanosomiasis</span></div><div class="casAuthors">Buscher Philippe; Cecchi Giuliano; Jamonneau Vincent; Priotto Gerardo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10110</span>),
    <span class="NLM_cas:pages">2397-2409</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human African trypanosomiasis (sleeping sickness) is a parasitic infection that almost invariably progresses to death unless treated.  Human African trypanosomiasis caused devastating epidemics during the 20th century.  Thanks to sustained and coordinated efforts over the past 15 years, the number of reported cases has fallen to an historically low level.  Fewer than 3000 cases were reported in 2015, and the disease is targeted for elimination by WHO.  Despite these recent successes, the disease is still endemic in parts of sub-Saharan Africa, where it is a considerable burden on rural communities, most notably in central Africa.  Since patients are also reported from non-endemic countries, human African trypanosomiasis should be considered in differential diagnosis for travellers, tourists, migrants, and expatriates who have visited or lived in endemic areas.  In the absence of a vaccine, disease control relies on case detection and treatment, and vector control.  Available drugs are suboptimal, but ongoing clinical trials provide hope for safer and simpler treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsRgd2Wuil24tfW6udTcc2eZB516wUy_Lxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCrsw%253D%253D&md5=521e7f5c04b32c04763c6b7a65af6439</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931510-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931510-6%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25BCscher%26aufirst%3DP.%26aulast%3DCecchi%26aufirst%3DG.%26aulast%3DJamonneau%26aufirst%3DV.%26aulast%3DPriotto%26aufirst%3DG.%26atitle%3DHuman%2520African%2520trypanosomiasis%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D2397%26epage%3D2409%26doi%3D10.1016%2FS0140-6736%2817%2931510-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">World
Health Organization</span>. Department of Control
of Neglected Tropical Diseases,
Human African Trypanosomiasis. <a href="http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_EPH_2001.3.pdf" class="extLink">http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_EPH_2001.3.pdf</a> (accessed November 13, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World%0AHealth+Organization.+Department+of+Control%0Aof+Neglected+Tropical+Diseases%2C%0AHuman+African+Trypanosomiasis.+http%3A%2F%2Fwhqlibdoc.who.int%2Fhq%2F2001%2FWHO_CDS_CSR_EPH_2001.3.pdf+%28accessed+November+13%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Fexinidazole: a new drug for African sleeping sickness on the horizon</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2017.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.pt.2017.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=29275007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=178-179&author=M.+P.+Pollastri&title=Fexinidazole%3A+a+new+drug+for+African+sleeping+sickness+on+the+horizon&doi=10.1016%2Fj.pt.2017.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon</span></div><div class="casAuthors">Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">178-179</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Decades after the last new chem. entity was added to the pharmacopeia for human African trypanosomiasis (or sleeping sickness), orally dosed fexinidazole stands poised to replace the current treatment regimen for Trypanosoma brucei gambiense infections, following a pos. Phase 2/3 clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0dzkKzgAQ8LVg90H21EOLACvtfcHk0ljSbl6ZwePHdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsLjK&md5=90c0d6e87ec827b9b788152db9aff51e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2017.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2017.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DFexinidazole%253A%2520a%2520new%2520drug%2520for%2520African%2520sleeping%2520sickness%2520on%2520the%2520horizon%26jtitle%3DTrends%2520Parasitol.%26date%3D2018%26volume%3D34%26spage%3D178%26epage%3D179%26doi%3D10.1016%2Fj.pt.2017.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chappuis, F.</span></span> <span> </span><span class="NLM_article-title">Oral fexinidazole for human African trypanosomiasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)30019-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2FS0140-6736%2818%2930019-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=29353603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvis1ygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=100-102&author=F.+Chappuis&title=Oral+fexinidazole+for+human+African+trypanosomiasis&doi=10.1016%2FS0140-6736%2818%2930019-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fexinidazole for human African trypanosomiasis</span></div><div class="casAuthors">Chappuis Francois</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10116</span>),
    <span class="NLM_cas:pages">100-102</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5wOffiRd7v7jnyZkbE8yXfW6udTcc2eZB516wUy_Lxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvis1ygsg%253D%253D&md5=2a395501ebe8006584a60266d4dc0579</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2930019-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252930019-9%26sid%3Dliteratum%253Aachs%26aulast%3DChappuis%26aufirst%3DF.%26atitle%3DOral%2520fexinidazole%2520for%2520human%2520African%2520trypanosomiasis%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D100%26epage%3D102%26doi%3D10.1016%2FS0140-6736%2818%2930019-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarral, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blesson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordt, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torreele, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hovsepian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evene, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gualano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felices, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strub-Wourgaft, N.</span></span> <span> </span><span class="NLM_article-title">Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1007/s40262-014-0136-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1007%2Fs40262-014-0136-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=24535888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVCmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=565-580&author=A.+Tarralauthor=S.+Blessonauthor=O.+V.+Mordtauthor=E.+Torreeleauthor=D.+Sassellaauthor=M.+A.+Brayauthor=L.+Hovsepianauthor=E.+Eveneauthor=V.+Gualanoauthor=M.+Felicesauthor=N.+Strub-Wourgaft&title=Determination+of+an+optimal+dosing+regimen+for+fexinidazole%2C+a+novel+oral+drug+for+the+treatment+of+human+African+trypanosomiasis%3A+first-in-human+studies&doi=10.1007%2Fs40262-014-0136-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies</span></div><div class="casAuthors">Tarral, Antoine; Blesson, Severine; Mordt, Olaf Valverde; Torreele, Els; Sassella, Daniela; Bray, Michael A.; Hovsepian, Lionel; Evene, Eric; Gualano, Virginie; Felices, Mathieu; Strub-Wourgaft, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-580</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objectives: Fexinidazole is a 5-nitroimidazole recently included in a clin. efficacy trial as an oral drug for the treatment of human African trypanosomiasis (HAT).  Preclin. studies showed it acts as a pharmacol. active pro-drug with two key active metabolites: sulfoxide and sulfone (the most active metabolite).  The present studies aimed to det. the best dose regimen for the treatment of stage 2 sleeping sickness patients, which could eventually also treat stage 1 patients.  Methods: Fexinidazole was assessed in 154 healthy adult male subjects of sub-Saharan African origin.  Three initial first-in-human studies and two addnl. studies assessed a single ascending dose and multiple ascending doses (both under fasted conditions), tablet vs. suspension formulation and food effect (fasted vs. high-fat meal and field-adapted food), and multiple ascending doses with a loading dose regimen under fed conditions.  Results: Fexinidazole was well-tolerated in a single dose from 100 to 3,600 mg, with quick absorption of the parent drug and rapid metab. into sulfoxide [time to max. concn. (tmax) 2-5 h] and sulfone (tmax 18-24 h).  The tablet formulation was approx. 25 % less bioavailable than the suspension, and food intake increased drug absorption and plasma concns. of fexinidazole and its two metabolites by approx. 200 %.  Fourteen-day multiple ascending dosing administered up to 3,600 mg/day in fasted conditions showed that fexinidazole was generally well-tolerated (mild to moderate, spontaneously reversible drug-related adverse events).  Following the high-fat food effect finding, another study was conducted to evaluate the impact of a low-fat regimen closer to that of the target population, showing that the type of meal does not influence fexinidazole absorption.  The last study showed that a loading dose of 1,800 mg/day for 4 days followed by a 1,200 mg/day regimen for 6 days with a normal meal provided the desired exposure of fexinidazole and its metabolites, particularly sulfone, with good tolerability.  Based on preclin. evidence from a chronic infection mouse model, systemic drug concns. obtained are expected to be clin. effective in stage 2 HAT.  Conclusions: These studies show that fexinidazole can be safely assessed in patients as a potential oral cure for both stages of HAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpszDba_Qa2j7Vg90H21EOLACvtfcHk0lg357VMSQ7X4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVCmuro%253D&md5=29ec56e974111a2737fc3bfff67d9511</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs40262-014-0136-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-014-0136-3%26sid%3Dliteratum%253Aachs%26aulast%3DTarral%26aufirst%3DA.%26aulast%3DBlesson%26aufirst%3DS.%26aulast%3DMordt%26aufirst%3DO.%2BV.%26aulast%3DTorreele%26aufirst%3DE.%26aulast%3DSassella%26aufirst%3DD.%26aulast%3DBray%26aufirst%3DM.%2BA.%26aulast%3DHovsepian%26aufirst%3DL.%26aulast%3DEvene%26aufirst%3DE.%26aulast%3DGualano%26aufirst%3DV.%26aulast%3DFelices%26aufirst%3DM.%26aulast%3DStrub-Wourgaft%26aufirst%3DN.%26atitle%3DDetermination%2520of%2520an%2520optimal%2520dosing%2520regimen%2520for%2520fexinidazole%252C%2520a%2520novel%2520oral%2520drug%2520for%2520the%2520treatment%2520of%2520human%2520African%2520trypanosomiasis%253A%2520first-in-human%2520studies%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2014%26volume%3D53%26spage%3D565%26epage%3D580%26doi%3D10.1007%2Fs40262-014-0136-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wring, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sligar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowling, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewerts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaukel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarlett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scandale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Don, R.</span></span> <span> </span><span class="NLM_article-title">SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1151</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0001151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1371%2Fjournal.pntd.0001151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=21738803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlOgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&author=R.+T.+Jacobsauthor=B.+Nareauthor=S.+A.+Wringauthor=M.+D.+Orrauthor=D.+Chenauthor=J.+M.+Sligarauthor=M.+X.+Jenksauthor=R.+A.+Noeauthor=T.+S.+Bowlingauthor=L.+T.+Mercerauthor=C.+Rewertsauthor=E.+Gaukelauthor=J.+Owensauthor=R.+Parhamauthor=R.+Randolphauthor=B.+Beaudetauthor=C.+J.+Bacchiauthor=N.+Yarlettauthor=J.+J.+Plattnerauthor=Y.+Freundauthor=C.+Dingauthor=T.+Akamaauthor=Y.+K.+Zhangauthor=R.+Brunauthor=M.+Kaiserauthor=I.+Scandaleauthor=R.+Don&title=SCYX-7158%2C+an+orally-active+benzoxaborole+for+the+treatment+of+stage+2+human+African+trypanosomiasis&doi=10.1371%2Fjournal.pntd.0001151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 Human African trypanosomiasis</span></div><div class="casAuthors">Jacobs, Robert T.; Nare, Bakela; Wring, Stephen A.; Orr, Matthew D.; Chen, Daitao; Sligar, Jessica M.; Jenks, Matthew X.; Noe, Robert A.; Bowling, Tana S.; Mercer, Luke T.; Rewerts, Cindy; Gaukel, Eric; Owens, Jennifer; Parham, Robin; Randolph, Ryan; Beaudet, Beth; Bacchi, Cyrus J.; Yarlett, Nigel; Plattner, Jacob J.; Freund, Yvonne; Ding, Charles; Akama, Tsutomu; Zhang, Y.-K.; Brun, Reto; Kaiser, Marcel; Scandale, Ivan; Don, Robert</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1151</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting hundreds of thousands of individuals.  An urgent need exists for the discovery and development of new, safe, and effective drugs to treat HAT, as existing therapies suffer from poor safety profiles, difficult treatment regimens, limited effectiveness, and a high cost of goods.  We have discovered and optimized a novel class of small-mol. boron-contg. compds., benzoxaboroles, to identify SCYX-7158 as an effective, safe and orally active treatment for HAT.  Methodol./Principal Findings: A drug discovery project employing integrated biol. screening, medicinal chem. and pharmacokinetic characterization identified SCYX-7158 as an optimized analog, as it is active in vitro against relevant strains of Trypanosoma brucei, including T. b. rhodesiense and T. b. gambiense, is efficacious in both stage 1 and stage 2 murine HAT models and has physicochem. and in vitro absorption, distribution, metab., elimination and toxicol. (ADMET) properties consistent with the compd. being orally available, metabolically stable and CNS permeable.  In a murine stage 2 study, SCYX-7158 is effective orally at doses as low as 12.5 mg/kg (QD × 7 days).  In vivo pharmacokinetic characterization of SCYX-7158 demonstrates that the compd. is highly bioavailable in rodents and non-human primates, has low i.v. plasma clearance and has a 24-h elimination half-life and a vol. of distribution that indicate good tissue distribution.  Most importantly, in rodents brain exposure of SCYX-7158 is high, with Cmax>10 μg/mL and AUC0-24 hr>100 μg*h/mL following a 25 mg/kg oral dose.  Furthermore, SCYX-7158 readily distributes into cerebrospinal fluid to achieve therapeutically relevant concns. in this compartment.  Conclusions/Significance: The biol. and pharmacokinetic properties of SCYX-7158 suggest that this compd. will be efficacious and safe to treat stage 2 HAT.  SCYX-7158 has been selected to enter preclin. studies, with expected progression to phase 1 clin. trials in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdyaAga5lprVg90H21EOLACvtfcHk0li6h7CFkosbhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlOgsLY%253D&md5=a54f2d57149e6714c7f6acf5f5280a7d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0001151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0001151%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DR.%2BT.%26aulast%3DNare%26aufirst%3DB.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DOrr%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DSligar%26aufirst%3DJ.%2BM.%26aulast%3DJenks%26aufirst%3DM.%2BX.%26aulast%3DNoe%26aufirst%3DR.%2BA.%26aulast%3DBowling%26aufirst%3DT.%2BS.%26aulast%3DMercer%26aufirst%3DL.%2BT.%26aulast%3DRewerts%26aufirst%3DC.%26aulast%3DGaukel%26aufirst%3DE.%26aulast%3DOwens%26aufirst%3DJ.%26aulast%3DParham%26aufirst%3DR.%26aulast%3DRandolph%26aufirst%3DR.%26aulast%3DBeaudet%26aufirst%3DB.%26aulast%3DBacchi%26aufirst%3DC.%2BJ.%26aulast%3DYarlett%26aufirst%3DN.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DScandale%26aufirst%3DI.%26aulast%3DDon%26aufirst%3DR.%26atitle%3DSCYX-7158%252C%2520an%2520orally-active%2520benzoxaborole%2520for%2520the%2520treatment%2520of%2520stage%25202%2520human%2520African%2520trypanosomiasis%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2011%26volume%3D5%26doi%3D10.1371%2Fjournal.pntd.0001151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kola, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, J.</span></span> <span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1038/nrd1470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fnrd1470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=15286737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-716&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F&doi=10.1038%2Fnrd1470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Can the pharmaceutical industry reduce attrition rates?</span></div><div class="casAuthors">Kola, Ismail; Landis, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry faces considerable challenges, both politically and fiscally.  Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny.  In the United States, drug costs are also the subject of intense political discourse.  This article deals with the fiscal pressures that face the industry from the perspective of R&D.  What impinges on productivity How can we improve current reduced R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAlrpFPFmiLVg90H21EOLACvtfcHk0li6h7CFkosbhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D&md5=f9025c13a1506f607aaf68415570ed01</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd1470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1470%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D716%26doi%3D10.1038%2Fnrd1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+analysis+of+the+attrition+of+drug+candidates+from+four+major+pharmaceutical+companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0li6h7CFkosbhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520analysis%2520of%2520the%2520attrition%2520of%2520drug%2520candidates%2520from%2520four%2520major%2520pharmaceutical%2520companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craighead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Economides, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, J.</span></span> <span> </span><span class="NLM_article-title">Clinical development success rates for investigational drugs</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nbt.2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fnbt.2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=24406927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=40-51&author=M.+Hayauthor=D.+W.+Thomasauthor=J.+L.+Craigheadauthor=C.+Economidesauthor=J.+Rosenthal&title=Clinical+development+success+rates+for+investigational+drugs&doi=10.1038%2Fnbt.2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development success rates for investigational drugs</span></div><div class="casAuthors">Hay, Michael; Thomas, David W.; Craighead, John L.; Economides, Celia; Rosenthal, Jesse</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The most comprehensive survey of clin. success rates across the drug industry to date shows productivity may be even lower than previous ests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdqyRgsoFYDbVg90H21EOLACvtfcHk0ljxKLGv9uyetQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D&md5=87a63ec8d8bb213b3d42519395725038</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2786%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DD.%2BW.%26aulast%3DCraighead%26aufirst%3DJ.%2BL.%26aulast%3DEconomides%26aufirst%3DC.%26aulast%3DRosenthal%26aufirst%3DJ.%26atitle%3DClinical%2520development%2520success%2520rates%2520for%2520investigational%2520drugs%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D40%26epage%3D51%26doi%3D10.1038%2Fnbt.2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delespaux, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span> <span> </span><span class="NLM_article-title">Drugs and drug resistance in African trypanosomiasis</span>. <i>Drug Resistance Updates</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2007.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.drup.2007.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=17409013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslahsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=30-50&author=V.+Delespauxauthor=H.+P.+de+Koning&title=Drugs+and+drug+resistance+in+African+trypanosomiasis&doi=10.1016%2Fj.drup.2007.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and drug resistance in African trypanosomiasis</span></div><div class="casAuthors">Delespaux, Vincent; de Koning, Harry P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">30-50</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite the many decades of use of most of the current trypanocides, we know little of their mode of action.  This may in part be because most of these will act on multiple targets once inside the cell, and they derive their selective action on the parasite from selective accumulation by the pathogen.  Loss of this capacity for drug uptake by the trypanosome would thus be a major cause for drug resistance.  We here discuss the use of current drugs against human and veterinary African trypanosomiasis, the prevalence, causes and mechanisms of drug resistance and new developments in trypanosomiasis therapy such as the introduction of nifurtimox and DB289.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBJZuQC1wb0LVg90H21EOLACvtfcHk0ljxKLGv9uyetQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslahsb0%253D&md5=04f98358869b5f02ce4297315268b48f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2007.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2007.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DDelespaux%26aufirst%3DV.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26atitle%3DDrugs%2520and%2520drug%2520resistance%2520in%2520African%2520trypanosomiasis%26jtitle%3DDrug%2520Resistance%2520Updates%26date%3D2007%26volume%3D10%26spage%3D30%26epage%3D50%26doi%3D10.1016%2Fj.drup.2007.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nwaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, A.</span></span> <span> </span><span class="NLM_article-title">Innovative lead discovery strategies for tropical diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1038/nrd2144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fnrd2144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=17080030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFGjsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=941-955&author=S.+Nwakaauthor=A.+Hudson&title=Innovative+lead+discovery+strategies+for+tropical+diseases&doi=10.1038%2Fnrd2144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Innovative lead discovery strategies for tropical diseases</span></div><div class="casAuthors">Nwaka, Solomon; Hudson, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">941-955</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lead discovery is currently a key bottleneck in the pipeline for much-needed novel drugs for tropical diseases such as malaria, tuberculosis, African sleeping sickness, leishmaniasis and Chagas disease.  Here, the authors discuss the different approaches to lead discovery for tropical diseases and emphasize a coordination strategy that involves highly integrated partnerships and networks between scientists in academic institutions and industry in both wealthy industrialized countries and disease-endemic countries.  This strategy offers the promise of reducing the inherently high attrition rate of the early stages of discovery research, thereby increasing the chances of success and enhancing cost-effectiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe-gH0kYj7dLVg90H21EOLACvtfcHk0lhEHqHuV176Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFGjsrzE&md5=93279e133e4133077883d48b1d6d50c8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd2144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2144%26sid%3Dliteratum%253Aachs%26aulast%3DNwaka%26aufirst%3DS.%26aulast%3DHudson%26aufirst%3DA.%26atitle%3DInnovative%2520lead%2520discovery%2520strategies%2520for%2520tropical%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D941%26epage%3D955%26doi%3D10.1038%2Fnrd2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1017/S0031182013001017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1017%2FS0031182013001017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2013&pages=28-36&author=I.+H.+Gilbert&title=Target-based+drug+discovery+for+human+African+trypanosomiasis%3A+selection+of+molecular+target+and+chemical+matter&doi=10.1017%2FS0031182013001017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1017%2FS0031182013001017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182013001017%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DTarget-based%2520drug%2520discovery%2520for%2520human%2520African%2520trypanosomiasis%253A%2520selection%2520of%2520molecular%2520target%2520and%2520chemical%2520matter%26jtitle%3DParasitology%26date%3D2013%26volume%3D141%26spage%3D28%26epage%3D36%26doi%3D10.1017%2FS0031182013001017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klug, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelb, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Repurposing strategies for tropical disease drug discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2569</span>– <span class="NLM_lpage">2576</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.bmcl.2016.03.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=27080183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2569-2576&author=D.+M.+Klugauthor=M.+H.+Gelbauthor=M.+P.+Pollastri&title=Repurposing+strategies+for+tropical+disease+drug+discovery&doi=10.1016%2Fj.bmcl.2016.03.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing strategies for tropical disease drug discovery</span></div><div class="casAuthors">Klug, Dana M.; Gelb, Michael H.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2569-2576</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neglected tropical diseases (NTDs) and other diseases of the developing world, such as malaria, attract research investments that are disproportionately low compared to their impact on human health worldwide.  Therefore, pragmatic methods for launching new drug discovery programs have emerged that repurpose existing chem. matter as new drugs or new starting points for optimization.  In this Digest we describe applications of different repurposing approaches for NTDs, and provide a means by which these approaches may be differentiated from each other.  These include drug repurposing, target repurposing, target class repurposing, and lead repurposing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7WuWi-qOAgbVg90H21EOLACvtfcHk0lhEHqHuV176Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGqt7c%253D&md5=e47072a70623e0e3f771880e31578b26</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.103%26sid%3Dliteratum%253Aachs%26aulast%3DKlug%26aufirst%3DD.%2BM.%26aulast%3DGelb%26aufirst%3DM.%2BH.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DRepurposing%2520strategies%2520for%2520tropical%2520disease%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2569%26epage%3D2576%26doi%3D10.1016%2Fj.bmcl.2016.03.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillingwater, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Anilinoquinoline based inhibitors of trypanosomatid proliferation</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0006834</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0006834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1371%2Fjournal.pntd.0006834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=30475800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWkurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&author=L.+Ferrinsauthor=A.+Sharmaauthor=S.+M.+Thomasauthor=N.+Mehtaauthor=J.+Erathauthor=S.+Tangheauthor=S.+E.+Leedauthor=A.+Rodriguezauthor=K.+Mensa-Wilmotauthor=R.+J.+Sciottiauthor=K.+Gillingwaterauthor=M.+P.+Pollastri&title=Anilinoquinoline+based+inhibitors+of+trypanosomatid+proliferation&doi=10.1371%2Fjournal.pntd.0006834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anilinoquinoline based inhibitors of trypanosomatid proliferation</span></div><div class="casAuthors">Ferrins, Lori; Sharma, Amrita; Thomas, Sarah M.; Mehta, Naimee; Erath, Jessey; Tanghe, Scott; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Gillingwater, Kirsten; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0006834</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">We recently reported the medicinal chem. re-optimization of a series of compds. derived from the human tyrosine kinase inhibitor, lapatinib, for activity against Plasmodium falciparum.  From this same library of compds., we now report potent compds. against Trypanosoma brucei brucei (which causes human African trypanosomiasis), T. cruzi (the pathogen that causes Chagas disease), and Leishmania spp. (which cause leishmaniasis).  In addn., sub-micromolar compds. were identified that inhibit proliferation of the parasites that cause African animal trypanosomiasis, T. congolense and T. vivax.  We have found that this set of compds. display acceptable physicochem. properties and represent progress towards identification of lead compds. to combat several neglected tropical diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1RApwgv5k17Vg90H21EOLACvtfcHk0liT78UDicJlbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWkurvF&md5=103b62755c529a9dd829a214e1689b61</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0006834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0006834%26sid%3Dliteratum%253Aachs%26aulast%3DFerrins%26aufirst%3DL.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DS.%2BM.%26aulast%3DMehta%26aufirst%3DN.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DTanghe%26aufirst%3DS.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DGillingwater%26aufirst%3DK.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DAnilinoquinoline%2520based%2520inhibitors%2520of%2520trypanosomatid%2520proliferation%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2018%26volume%3D12%26doi%3D10.1371%2Fjournal.pntd.0006834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devine, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Antiparasitic lead discovery: toward optimization of a chemotype with activity against multiple protozoan parasites</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=350-354&author=W.+Devineauthor=S.+M.+Thomasauthor=J.+Erathauthor=K.+A.+Bachovchinauthor=P.+J.+Leeauthor=S.+E.+Leedauthor=A.+Rodriguezauthor=R.+J.+Sciottiauthor=K.+Mensa-Wilmotauthor=M.+P.+Pollastri&title=Antiparasitic+lead+discovery%3A+toward+optimization+of+a+chemotype+with+activity+against+multiple+protozoan+parasites&doi=10.1021%2Facsmedchemlett.7b00011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites</span></div><div class="casAuthors">Devine, William; Thomas, Sarah M.; Erath, Jessey; Bachovchin, Kelly A.; Lee, Patricia J.; Leed, Susan E.; Rodriguez, Ana; Sciotti, Richard J.; Mensa-Wilmot, Kojo; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">350-354</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis present a significant burden across the developing world.  Existing therapeutics for these protozoal neglected tropical diseases suffer from severe side effects and toxicity.  Previously, NEU-1045 was identified as a promising lead with cross-pathogen activity, though it possessed poor physicochem. properties.  The authors have designed a library of analogs with improved calcd. physicochem. properties built on the quinoline scaffold of 3 incorporating small, polar aminoheterocycles in place of the 4-(3-fluorobenzyloxy)aniline substituent.  The authors report the biol. activity of these inhibitors against Trypanosoma brucei (HAT), T. cruzi (Chagas disease), and Leishmania major (cutaneous leishmaniasis), and describe the identification of N-(5-chloropyrimidin-2-yl)-6-(4-(morpholinosulfonyl)phenyl)quinolin-4-amine (13t) as a promising inhibitor of L. major proliferation and 6-(4-(morpholinosulfonyl)phenyl)-N-(pyrimidin-4-yl)quinolin-4-amine (13j), a potent inhibitor of T. brucei proliferation with improved drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAlrVVjYVs3bVg90H21EOLACvtfcHk0liT78UDicJlbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWitbo%253D&md5=64426fb9e05ae3e2f28e0beae1b816e7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00011%26sid%3Dliteratum%253Aachs%26aulast%3DDevine%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DS.%2BM.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DBachovchin%26aufirst%3DK.%2BA.%26aulast%3DLee%26aufirst%3DP.%2BJ.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DAntiparasitic%2520lead%2520discovery%253A%2520toward%2520optimization%2520of%2520a%2520chemotype%2520with%2520activity%2520against%2520multiple%2520protozoan%2520parasites%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D350%26epage%3D354%26doi%3D10.1021%2Facsmedchemlett.7b00011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devine, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodring, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncal, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Protozoan parasite growth inhibitors discovered by cross-screening yield potent scaffolds for lead discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5522</span>– <span class="NLM_lpage">5537</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVagu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5522-5537&author=W.+Devineauthor=J.+L.+Woodringauthor=U.+Swaminathanauthor=E.+Amataauthor=G.+Patelauthor=J.+Erathauthor=N.+E.+Roncalauthor=P.+J.+Leeauthor=S.+E.+Leedauthor=A.+Rodriguezauthor=K.+Mensa-Wilmotauthor=R.+J.+Sciottiauthor=M.+P.+Pollastri&title=Protozoan+parasite+growth+inhibitors+discovered+by+cross-screening+yield+potent+scaffolds+for+lead+discovery&doi=10.1021%2Facs.jmedchem.5b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Protozoan parasite growth inhibitors discovered by cross-screening yield potent scaffolds for lead discovery</span></div><div class="casAuthors">Devine, William; Woodring, Jennifer L.; Swaminathan, Uma; Amata, Emanuele; Patel, Gautam; Erath, Jessey; Roncal, Norma E.; Lee, Patricia J.; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5522-5537</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estd. combined burden of over 87 million disability-adjusted life years.  New drugs are needed for each of these diseases.  Building on the previous identification of NEU-617 as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), the authors have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria).  Based on hits identified in this screening campaign, the authors describe the prepn. of several replacements for the quinazoline scaffold and report these inhibitors' biol. activities against these parasites.  In doing this, the authors have identified several potent proliferation inhibitors for each pathogen, such as NEU-924, I, for T. cruzi and NEU-1017, II, for L. major and P. falciparum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodbrXR55ZLJ7Vg90H21EOLACvtfcHk0lgPLUBp2NV6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVagu7bN&md5=76fef909165981d8e542d28a5ee59c12</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00515%26sid%3Dliteratum%253Aachs%26aulast%3DDevine%26aufirst%3DW.%26aulast%3DWoodring%26aufirst%3DJ.%2BL.%26aulast%3DSwaminathan%26aufirst%3DU.%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DG.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DRoncal%26aufirst%3DN.%2BE.%26aulast%3DLee%26aufirst%3DP.%2BJ.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DProtozoan%2520parasite%2520growth%2520inhibitors%2520discovered%2520by%2520cross-screening%2520yield%2520potent%2520scaffolds%2520for%2520lead%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5522%26epage%3D5537%26doi%3D10.1021%2Facs.jmedchem.5b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of physicochemical properties for 4-anilinoquinoline inhibitors of <i>Plasmodium falciparum</i> proliferation</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.7b00212</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.7b00212" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFGkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=577-591&author=N.+Mehtaauthor=L.+Ferrinsauthor=S.+E.+Leedauthor=R.+J.+Sciottiauthor=M.+P.+Pollastri&title=Optimization+of+physicochemical+properties+for+4-anilinoquinoline+inhibitors+of+Plasmodium+falciparum+proliferation&doi=10.1021%2Facsinfecdis.7b00212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation</span></div><div class="casAuthors">Mehta, Naimee; Ferrins, Lori; Leed, Susan E.; Sciotti, Richard J.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">577-591</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors recently reported the medicinal chem. reoptimization of a known human tyrosine kinase inhibitor, lapatinib, against a variety of parasites responsible for numerous tropical diseases, including human African trypanosomiasis (Trypanosoma brucei), Chagas disease (T. cruzi), Leishmaniasis (Leishmania spp.), and malaria (Plasmodium falciparum).  Herein, the authors report the authors' continuing efforts to optimize this series against P. falciparum.  Through the design of a library of compds. focused on reducing the lipophilicity and mol. wt., followed by an SAR exploration, the authors have identified NEU-1953 (40).  This compd. is a potent inhibitor of P. falciparum with an improved ADME profile over the previously reported compd., NEU-961.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoirOtgWSwlRLVg90H21EOLACvtfcHk0lgPLUBp2NV6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFGkuw%253D%253D&md5=e0f6363ef9bccd8e489d4954f21c0335</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.7b00212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.7b00212%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DN.%26aulast%3DFerrins%26aufirst%3DL.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DOptimization%2520of%2520physicochemical%2520properties%2520for%25204-anilinoquinoline%2520inhibitors%2520of%2520Plasmodium%2520falciparum%2520proliferation%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2018%26volume%3D4%26spage%3D577%26epage%3D591%26doi%3D10.1021%2Facsinfecdis.7b00212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodring, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallerstein, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leed, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.ejmech.2017.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=29049963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Oqu7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2017&pages=446-459&author=J.+L.+Woodringauthor=K.+A.+Bachovchinauthor=K.+G.+Bradyauthor=M.+F.+Gallersteinauthor=J.+Erathauthor=S.+Tangheauthor=S.+E.+Leedauthor=A.+Rodriguezauthor=K.+Mensa-Wilmotauthor=R.+J.+Sciottiauthor=M.+P.+Pollastri&title=Optimization+of+physicochemical+properties+for+4-anilinoquinazoline+inhibitors+of+trypanosome+proliferation&doi=10.1016%2Fj.ejmech.2017.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation</span></div><div class="casAuthors">Woodring, Jennifer L.; Bachovchin, Kelly A.; Brady, Kimberly G.; Gallerstein, Mitchell F.; Erath, Jessey; Tanghe, Scott; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Pollastri, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">446-459</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Human African trypanosomiasis (HAT) is a deadly disease in need of new chemotherapeutics that can cross into the central nervous system.  The authors previously reported the discovery of (NEU-617), a small mol. with activity against T. brucei bloodstream proliferation.  Further optimization of NEU-617 to improve the physicochem. properties (LogP, LLE, [1], and MPO score) [2] have led us to twelve sub-micromolar compds., most importantly the headgroup variants I and II, and the linker variant III.  Although these 3 compds. had reduced potency compared to NEU-617, they all had improved LogP, LLE and MPO scores.  Cross-screening these analogs against other protozoan parasites uncovered IV with potent activity towards T. brucei, T. cruzi and L. major, while four others compds. showed activity towards P. falciparum D6.  This reinforces the effectiveness of lead repurposing for the discovery of new protozoan disease therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJSNa6HL-xIrVg90H21EOLACvtfcHk0lgPLUBp2NV6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Oqu7nE&md5=8eff33fa28775b57db396156849c2bbe</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DWoodring%26aufirst%3DJ.%2BL.%26aulast%3DBachovchin%26aufirst%3DK.%2BA.%26aulast%3DBrady%26aufirst%3DK.%2BG.%26aulast%3DGallerstein%26aufirst%3DM.%2BF.%26aulast%3DErath%26aufirst%3DJ.%26aulast%3DTanghe%26aufirst%3DS.%26aulast%3DLeed%26aufirst%3DS.%2BE.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DPollastri%26aufirst%3DM.%2BP.%26atitle%3DOptimization%2520of%2520physicochemical%2520properties%2520for%25204-anilinoquinazoline%2520inhibitors%2520of%2520trypanosome%2520proliferation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D141%26spage%3D446%26epage%3D459%26doi%3D10.1016%2Fj.ejmech.2017.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, A. K.</span></span> <span> </span><span class="NLM_article-title">Salt selection in drug development</span>. <i>Pharm. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">128</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlKksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=128&author=L.+Kumarauthor=A.+Aminauthor=A.+K.+Bansal&title=Salt+selection+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Salt selection in drug development</span></div><div class="casAuthors">Kumar, Lokesh; Amin, Aeshna; Bansal, Arvind K.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Technology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">128, 130, 132, 134, 136, 140, 142, 144, 146</span>CODEN:
                <span class="NLM_cas:coden">PTHEC9</span>;
        ISSN:<span class="NLM_cas:issn">1543-2521</span>.
    
            (<span class="NLM_cas:orgname">Advanstar Communications, Inc.</span>)
        </div><div class="casAbstract">A review.  A drug's salt form has a major effect on its quality, safety, and performance.  The selection of an appropriate salt form for a potential drug candidate is an opportunity to modulate its characteristics to improve bioavailability, stability, manufacturability, and patient compliance.  Salt selection, however, can be a very difficult task because each salt imparts unique properties to the parent compd.  The authors provide an overview of the pharmaceutical considerations inherent in selecting the salt form of a medicinal compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRzsKOC2pDg7Vg90H21EOLACvtfcHk0lgQor3teKknMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlKksLo%253D&md5=a7760d38cc0ae4782cab04aa41f0e58a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DL.%26aulast%3DAmin%26aufirst%3DA.%26aulast%3DBansal%26aufirst%3DA.%2BK.%26atitle%3DSalt%2520selection%2520in%2520drug%2520development%26jtitle%3DPharm.%2520Technol.%26date%3D2008%26volume%3D32%26spage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serajuddin, A. T. M.</span></span> <span> </span><span class="NLM_article-title">Salt formation to improve drug solubility</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2007.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.addr.2007.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=17619064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFGksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=603-616&author=A.+T.+M.+Serajuddin&title=Salt+formation+to+improve+drug+solubility&doi=10.1016%2Fj.addr.2007.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Salt formation to improve drug solubility</span></div><div class="casAuthors">Serajuddin, Abu T. M.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">603-616</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Salt formation is the most common and effective method of increasing soly. and dissoln. rates of acidic and basic drugs.  In this article, physicochem. principles of salt soly. are presented, with special ref. to the influence of pH-soly. profiles of acidic and basic drugs on salt formation and dissoln.  Non-ideality of salt soly. due to self-assocn. in soln. is also discussed.  Whether certain acidic or basic drugs would form salts and, if salts are formed, how easily they would dissoc. back into their free acid or base forms depend on interrelationships of several factors, such as S0 (intrinsic soly.), pH, pKa, Ksp (soly. product) and pHmax (pH of max. soly.).  The interrelationships of these factors are elaborated and their influence on salt screening and the selection of optimal salt forms for development are discussed.  Factors influencing salt dissoln. under various pH conditions, and esp. in reactive media and in presence of excess common ions, are discussed, with practical ref. to the development of solid dosage forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZdRvmSUWvN7Vg90H21EOLACvtfcHk0lgQor3teKknMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFGksrc%253D&md5=6e77d1385622af6973a6d763746ad0db</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DSerajuddin%26aufirst%3DA.%2BT.%2BM.%26atitle%3DSalt%2520formation%2520to%2520improve%2520drug%2520solubility%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D603%26epage%3D616%26doi%3D10.1016%2Fj.addr.2007.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhzfH85X6RIYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0lhzfH85X6RIYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.%0AJ.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lhzfH85X6RIYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability+%E2%80%93+are+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0lhdS5rFm8PX6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%2520%25E2%2580%2593%2520are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaksma, E. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, O.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency as a guide in fragment hit selection and optimization</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e157</span>– <span class="NLM_lpage">e162</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2010.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.ddtec.2010.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVegsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=e157-e162&author=S.+Schultesauthor=C.+de+Graafauthor=E.+E.+J.+Haaksmaauthor=I.+J.+P.+de+Eschauthor=R.+Leursauthor=O.+Kr%C3%A4mer&title=Ligand+efficiency+as+a+guide+in+fragment+hit+selection+and+optimization&doi=10.1016%2Fj.ddtec.2010.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency as a guide in fragment hit selection and optimization</span></div><div class="casAuthors">Schultes, Sabine; de Graaf, Chris; Haaksma, Eric E. J.; de Esch, Iwan J. P.; Leurs, Rob; Kraemer, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">E157-E162</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Fragment-based screening (FBS) has become an established approach for hit identification.  Starting points identified by FBS, are small fragments that require substantial modification to become leads.  As fragments are different from classical hits a process tailored for fragment evolution is required.  Scores for ligand efficiency have been proposed as guides for this process.  Here we review how these have been applied to guide the selection and optimization of fragment hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbfhwn68rv4bVg90H21EOLACvtfcHk0lhdS5rFm8PX6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVegsL0%253D&md5=a57c85869d5c829159be31449fd04796</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2010.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2010.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DSchultes%26aufirst%3DS.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DHaaksma%26aufirst%3DE.%2BE.%2BJ.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DO.%26atitle%3DLigand%2520efficiency%2520as%2520a%2520guide%2520in%2520fragment%2520hit%2520selection%2520and%2520optimization%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2010%26volume%3D7%26spage%3De157%26epage%3De162%26doi%3D10.1016%2Fj.ddtec.2010.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency as an important metric in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+efficiency+as+an+important+metric+in+drug+design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lgRjOMSaA1K3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520efficiency%2520as%2520an%2520important%2520metric%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petereit, A. C.</span></span> <span> </span><span class="NLM_article-title">Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2012.07.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.ejps.2012.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=22885099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2rs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=589-595&author=C.+Saalauthor=A.+C.+Petereit&title=Optimizing+solubility%3A+kinetic+versus+thermodynamic+solubility+temptations+and+risks&doi=10.1016%2Fj.ejps.2012.07.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing solubility: Kinetic versus thermodynamic solubility temptations and risks</span></div><div class="casAuthors">Saal, Christoph; Petereit, Anna Christine</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">589-595</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The aim of this study was to assess the usefulness of kinetic and thermodn. soly. data in guiding medicinal chem. during lead optimization.  The soly. of 465 research compds. was measured using a kinetic and a thermodn. soly. assay.  In the thermodn. assay, polarized-light microscopy was used to investigate whether the result referred to the cryst. or to the amorphous compd.  From the comparison of kinetic and thermodn. soly. data it was noted that kinetic soly. measurements frequently yielded results which show considerably higher soly. compared to thermodn. soly.  This observation is ascribed to the fact that a kinetic soly. assay typically delivers results which refer to the amorphous compd.  In contrast, results from thermodn. soly. detns. more frequently refer to a cryst. phase.  Accordingly, thermodn. soly. data - esp. when used together with an assessment of the solid state form - are deemed to be more useful in guiding soly. optimization for research compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooxKTQHBpynbVg90H21EOLACvtfcHk0lgRjOMSaA1K3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2rs7bJ&md5=ace8b962c04c3a62f028ec3e66522922</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2012.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2012.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DSaal%26aufirst%3DC.%26aulast%3DPetereit%26aufirst%3DA.%2BC.%26atitle%3DOptimizing%2520solubility%253A%2520kinetic%2520versus%2520thermodynamic%2520solubility%2520temptations%2520and%2520risks%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D47%26spage%3D589%26epage%3D595%26doi%3D10.1016%2Fj.ejps.2012.07.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebiike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span> <span> </span><span class="NLM_article-title">Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.bmc.2016.04.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2897-2906&author=H.+Kawadaauthor=H.+Ebiikeauthor=M.+Tsukazakiauthor=S.+Yamamotoauthor=K.+Koyamaauthor=M.+Nakamuraauthor=K.+Morikamiauthor=K.+Yoshinariauthor=M.+Yoshidaauthor=K.+Ogawaauthor=N.+Shimmaauthor=T.+Tsukudaauthor=J.+Ohwada&title=Optimization+of+the+phenylurea+moiety+in+a+phosphoinositide+3-kinase+%28PI3K%29+inhibitor+to+improve+water+solubility+and+the+PK+profile+by+introducing+a+solubilizing+group+and+ortho+substituents&doi=10.1016%2Fj.bmc.2016.04.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.060%26sid%3Dliteratum%253Aachs%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DEbiike%26aufirst%3DH.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DMorikami%26aufirst%3DK.%26aulast%3DYoshinari%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DShimma%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOhwada%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520the%2520phenylurea%2520moiety%2520in%2520a%2520phosphoinositide%25203-kinase%2520%2528PI3K%2529%2520inhibitor%2520to%2520improve%2520water%2520solubility%2520and%2520the%2520PK%2520profile%2520by%2520introducing%2520a%2520solubilizing%2520group%2520and%2520ortho%2520substituents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D2897%26epage%3D2906%26doi%3D10.1016%2Fj.bmc.2016.04.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Lowering lipophilicity by adding carbon: one-carbon bridges of morpholines and piperazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8934</span>– <span class="NLM_lpage">8943</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KhtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8934-8943&author=S.+L.+Degorceauthor=M.+S.+Bodnarchukauthor=I.+A.+Cummingauthor=J.+S.+Scott&title=Lowering+lipophilicity+by+adding+carbon%3A+one-carbon+bridges+of+morpholines+and+piperazines&doi=10.1021%2Facs.jmedchem.8b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines</span></div><div class="casAuthors">Degorce, Sebastien L.; Bodnarchuk, Michael S.; Cumming, Iain A.; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8934-8943</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this article, we report our investigation of a phenomenon by which bridging morpholines across the ring with one-carbon tethers leads to a counterintuitive redn. in lipophilicity.  This effect was also found to occur in piperazines and piperidines and lowered the measured log D7.4 of the bridged mols. by as much as -0.8 relative to their unbridged counterparts.  As lowering lipophilicity without introducing addnl. heteroatoms can be desirable, we believe this potentially provides a useful tactic to improve the drug-like properties of mols. contg. morpholine-, piperazine-, and piperidine-like motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhZJB3SYRKD7Vg90H21EOLACvtfcHk0ljhKhFPp-rNag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KhtbzK&md5=27f30b8220ea767d6ef1e492f3fa1aba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01148%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBodnarchuk%26aufirst%3DM.%2BS.%26aulast%3DCumming%26aufirst%3DI.%2BA.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DLowering%2520lipophilicity%2520by%2520adding%2520carbon%253A%2520one-carbon%2520bridges%2520of%2520morpholines%2520and%2520piperazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8934%26epage%3D8943%26doi%3D10.1021%2Facs.jmedchem.8b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ressurreição, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitoe, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albuquerque, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Góis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronze, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanscheid, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudêncio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span> <span> </span><span class="NLM_article-title">Structural optimization of quinolon-4(1H)-imines as dual-stage antimalarials: toward increased potency and metabolic stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7679</span>– <span class="NLM_lpage">7690</span>, <span class="refDoi"> DOI: 10.1021/jm4011466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7679-7690&author=A.+S.+Ressurrei%C3%A7%C3%A3oauthor=D.+Gon%C3%A7alvesauthor=A.+R.+Sitoeauthor=I.+S.+Albuquerqueauthor=J.+Gutauthor=A.+G%C3%B3isauthor=L.+M.+Gon%C3%A7alvesauthor=M.+R.+Bronzeauthor=T.+Hanscheidauthor=G.+A.+Biaginiauthor=P.+J.+Rosenthalauthor=M.+Prud%C3%AAncioauthor=P.+O%E2%80%99Neillauthor=M.+M.+Motaauthor=F.+Lopesauthor=R.+Moreira&title=Structural+optimization+of+quinolon-4%281H%29-imines+as+dual-stage+antimalarials%3A+toward+increased+potency+and+metabolic+stability&doi=10.1021%2Fjm4011466"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm4011466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011466%26sid%3Dliteratum%253Aachs%26aulast%3DRessurrei%25C3%25A7%25C3%25A3o%26aufirst%3DA.%2BS.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DD.%26aulast%3DSitoe%26aufirst%3DA.%2BR.%26aulast%3DAlbuquerque%26aufirst%3DI.%2BS.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DG%25C3%25B3is%26aufirst%3DA.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DL.%2BM.%26aulast%3DBronze%26aufirst%3DM.%2BR.%26aulast%3DHanscheid%26aufirst%3DT.%26aulast%3DBiagini%26aufirst%3DG.%2BA.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DPrud%25C3%25AAncio%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%26aulast%3DMota%26aufirst%3DM.%2BM.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DMoreira%26aufirst%3DR.%26atitle%3DStructural%2520optimization%2520of%2520quinolon-4%25281H%2529-imines%2520as%2520dual-stage%2520antimalarials%253A%2520toward%2520increased%2520potency%2520and%2520metabolic%2520stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7679%26epage%3D7690%26doi%3D10.1021%2Fjm4011466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eissenstat, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentland, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klingbeil, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danz, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. A.</span></span> <span> </span><span class="NLM_article-title">Potent mammalian topoisomerase II inhibitors: 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-substituted-quinolines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1016/0960-894X(95)00043-S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2F0960-894X%2895%2900043-S" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=399-404&author=G.-H.+Kuoauthor=M.+A.+Eissenstatauthor=M.+P.+Wentlandauthor=R.+G.+Robinsonauthor=K.+M.+Klingbeilauthor=D.+W.+Danzauthor=S.+A.+Coughlin&title=Potent+mammalian+topoisomerase+II+inhibitors%3A+1-cyclopropyl-6%2C8-difluoro-1%2C4-dihydro-7-%282%2C6-dimethyl-4-pyridinyl%29-4-substituted-quinolines&doi=10.1016%2F0960-894X%2895%2900043-S"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900043-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900043-S%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DG.-H.%26aulast%3DEissenstat%26aufirst%3DM.%2BA.%26aulast%3DWentland%26aufirst%3DM.%2BP.%26aulast%3DRobinson%26aufirst%3DR.%2BG.%26aulast%3DKlingbeil%26aufirst%3DK.%2BM.%26aulast%3DDanz%26aufirst%3DD.%2BW.%26aulast%3DCoughlin%26aufirst%3DS.%2BA.%26atitle%3DPotent%2520mammalian%2520topoisomerase%2520II%2520inhibitors%253A%25201-cyclopropyl-6%252C8-difluoro-1%252C4-dihydro-7-%25282%252C6-dimethyl-4-pyridinyl%2529-4-substituted-quinolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D399%26epage%3D404%26doi%3D10.1016%2F0960-894X%2895%2900043-S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltynek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baizman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiles, J. W.</span></span> <span> </span><span class="NLM_article-title">WIN 17317-3: novel nonpeptide antagonist of voltage-activated K + channels in human T lymphocytes</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">104</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1995&pages=98-104&author=R.+J.+Hillauthor=A.+M.+Grantauthor=W.+Volbergauthor=L.+Rappauthor=C.+Faltynekauthor=D.+Millerauthor=K.+Paganiauthor=E.+Baizmanauthor=S.+Wangauthor=J.+W.+Guiles&title=WIN+17317-3%3A+novel+nonpeptide+antagonist+of+voltage-activated+K+%2B+channels+in+human+T+lymphocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGrant%26aufirst%3DA.%2BM.%26aulast%3DVolberg%26aufirst%3DW.%26aulast%3DRapp%26aufirst%3DL.%26aulast%3DFaltynek%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DPagani%26aufirst%3DK.%26aulast%3DBaizman%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGuiles%26aufirst%3DJ.%2BW.%26atitle%3DWIN%252017317-3%253A%2520novel%2520nonpeptide%2520antagonist%2520of%2520voltage-activated%2520K%2520%252B%2520channels%2520in%2520human%2520T%2520lymphocytes%26jtitle%3DMol.%2520Pharmacol.%26date%3D1995%26volume%3D48%26spage%3D98%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Cruz, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente-Monasterio, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressurreição, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitoe, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronze, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudêncio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span> <span> </span><span class="NLM_article-title">Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4811</span>– <span class="NLM_lpage">4815</span>, <span class="refDoi"> DOI: 10.1021/jm400246e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400246e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotV2nsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4811-4815&author=T.+Rodriguesauthor=F.+P.+da+Cruzauthor=M.%0AJ.+Lafuente-Monasterioauthor=D.+Gon%C3%A7alvesauthor=A.+S.+Ressurrei%C3%A7%C3%A3oauthor=A.+R.+Sitoeauthor=M.+R.+Bronzeauthor=J.+Gutauthor=G.+Schneiderauthor=M.+M.+Motaauthor=P.+J.+Rosenthalauthor=M.+Prud%C3%AAncioauthor=F.-J.+Gamoauthor=F.+Lopesauthor=R.+Moreira&title=Quinolin-4%281H%29-imines+are+potent+antiplasmodial+drugs+targeting+the+liver+stage+of+malaria&doi=10.1021%2Fjm400246e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolin-4(1H)-imines are Potent Antiplasmodial Drugs Targeting the Liver Stage of Malaria</span></div><div class="casAuthors">Rodrigues, Tiago; da Cruz, Filipa P.; Lafuente-Monasterio, Maria J.; Goncalves, Daniel; Ressurreicao, Ana S.; Sitoe, Ana R.; Bronze, Maria R.; Gut, Jiri; Schneider, Gisbert; Mota, Maria M.; Rosenthal, Philip J.; Prudencio, Miguel; Gamo, Francisco-Javier; Lopes, Francisca; Moreira, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4811-4815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors present a novel series of quinolin-4(1H)-imines as dual-stage antiplasmodials, several-fold more active than primaquine in vitro against Plasmodium berghei liver stage.  Among those, compds. (E)-N-(7-Chloro-1-ethylquinolin-4(1H)-ylidene)-4-(4-chlorophenoxy)aniline trifluoromethanesulfonate and (E)-N-(7-Chloro-1-ethylquinolin-4(1H)-ylidene)-4-(3-(trifluoromethoxy)phenoxy)aniline trifluoromethanesulfonate presented low nanomolar IC50 values.  The compds. are metabolically stable and modulate several drug targets.  These results emphasize the value of quinolin-4(1H)-imines as a new chemotype and their suitable properties for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVq1Th5oXaC7Vg90H21EOLACvtfcHk0lhhELt4nX6Vdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotV2nsbo%253D&md5=adbe8b82b3b986d04c7e96ac936f7aa8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm400246e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400246e%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3Dda%2BCruz%26aufirst%3DF.%2BP.%26aulast%3DLafuente-Monasterio%26aufirst%3DM.%2BJ.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DD.%26aulast%3DRessurrei%25C3%25A7%25C3%25A3o%26aufirst%3DA.%2BS.%26aulast%3DSitoe%26aufirst%3DA.%2BR.%26aulast%3DBronze%26aufirst%3DM.%2BR.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DMota%26aufirst%3DM.%2BM.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DPrud%25C3%25AAncio%26aufirst%3DM.%26aulast%3DGamo%26aufirst%3DF.-J.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DMoreira%26aufirst%3DR.%26atitle%3DQuinolin-4%25281H%2529-imines%2520are%2520potent%2520antiplasmodial%2520drugs%2520targeting%2520the%2520liver%2520stage%2520of%2520malaria%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4811%26epage%3D4815%26doi%3D10.1021%2Fjm400246e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nwaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, R.</span></span> <span> </span><span class="NLM_article-title">Advancing drug innovation for neglected diseases-criteria for lead progression</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e440</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0000440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1371%2Fjournal.pntd.0000440" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&author=S.+Nwakaauthor=B.+Ramirezauthor=R.+Brunauthor=L.+Maesauthor=F.+Douglasauthor=R.+Ridley&title=Advancing+drug+innovation+for+neglected+diseases-criteria+for+lead+progression&doi=10.1371%2Fjournal.pntd.0000440"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0000440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0000440%26sid%3Dliteratum%253Aachs%26aulast%3DNwaka%26aufirst%3DS.%26aulast%3DRamirez%26aufirst%3DB.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DDouglas%26aufirst%3DF.%26aulast%3DRidley%26aufirst%3DR.%26atitle%3DAdvancing%2520drug%2520innovation%2520for%2520neglected%2520diseases-criteria%2520for%2520lead%2520progression%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2009%26volume%3D3%26doi%3D10.1371%2Fjournal.pntd.0000440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purmal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensa-Wilmot, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of a carbazole-derived lead drug for human African trypanosomiasis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">32083</span> <span class="refDoi"> DOI: 10.1038/srep32083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1038%2Fsrep32083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=27561392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVChtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=S.+M.+Thomasauthor=A.+Purmalauthor=M.+Pollastriauthor=K.+Mensa-Wilmot&title=Discovery+of+a+carbazole-derived+lead+drug+for+human+African+trypanosomiasis&doi=10.1038%2Fsrep32083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis</span></div><div class="casAuthors">Thomas, Sarah M.; Purmal, Andrei; Pollastri, Michael; Mensa-Wilmot, Kojo</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32083</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protozoan parasite Trypanosoma brucei causes the fatal illness human African trypanosomiasis (HAT).  Std. of care medications currently used to treat HAT have severe limitations, and there is a need to find new chem. entities that are active against infections of T. brucei.  Following a "drug repurposing" approach, we tested anti-trypanosomal effects of carbazole-derived compds. called "Curaxins".  In vitro screening of 26 compds. revealed 22 with nanomolar potency against axenically cultured bloodstream trypanosomes.  In a murine model of HAT, oral administration of compd. 1 cured the disease.  These studies established 1 as a lead for development of drugs against HAT.  Pharmacol. time-course studies revealed the primary effect of 1 to be concurrent inhibition of mitosis coupled with aberrant licensing of S-phase entry.  Consequently, polyploid trypanosomes contg. 8C equiv. of DNA per nucleus and three or four kinetoplasts were produced.  These effects of 1 on the trypanosome are reminiscent of "mitotic slippage" or endoreplication obsd. in some other eukaryotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1Btu_sKSCprVg90H21EOLACvtfcHk0ljwz88DdW8EbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVChtL3N&md5=9ae56c361c9e52312184b78e1fa68e31</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fsrep32083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep32083%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BM.%26aulast%3DPurmal%26aufirst%3DA.%26aulast%3DPollastri%26aufirst%3DM.%26aulast%3DMensa-Wilmot%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520a%2520carbazole-derived%2520lead%2520drug%2520for%2520human%2520African%2520trypanosomiasis%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fsrep32083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirumi, K.</span></span> <span> </span><span class="NLM_article-title">Continuous cultivation of <i>Trypanosoma brucei</i> blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers</span>. <i>J. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.2307/3282883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.2307%2F3282883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=2614608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A280%3ADyaK3c7jtlaksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1989&pages=985-989&author=H.+Hirumiauthor=K.+Hirumi&title=Continuous+cultivation+of+Trypanosoma+brucei+blood+stream+forms+in+a+medium+containing+a+low+concentration+of+serum+protein+without+feeder+cell+layers&doi=10.2307%2F3282883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers</span></div><div class="casAuthors">Hirumi H; Hirumi K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of parasitology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">985-9</span>
        ISSN:<span class="NLM_cas:issn">0022-3395</span>.
    </div><div class="casAbstract">Blood stream forms (BSF) of Trypanosoma brucei brucei GUT at 3.1 were propagated in vitro in the absence of feeder layer cells at 37 C, using a modified Iscove's medium (HMI-18).  The medium was supplemented with 0.05 mM bathocuproine sulfonate, 1.5 mM L-cysteine, 1 mM hypoxanthine, 0.2 mM 2-mercaptoethanol, 1 mM sodium pyruvate. 0.16 mM thymidine, and 20% (v/v) Serum Plus (SP) (Hazleton Biologics, Lenexa, Kansas).  The latter contained a low level of serum proteins (13 micrograms/ml).  Each primary culture was initiated by placing 3.5-4 x 10(6) BSFs isolated from infected mice in a flask containing 5 ml of the medium (HMI-9) supplemented with 10% fetal bovine serum (FBS) and 10% SP.  The cultures were maintained by replacing the medium every 24 hr for 5-7 days.  During this period, many BSFs died.  However, from day 4 onward, long slender BSFs increased in number.  On days 5-7, trypanosome suspensions were pooled and cell debris was removed by means of diethylaminoethyl cellulose (DE52) column chromatography.  Blood stream forms then were collected by centrifugation, resuspended in fresh medium at 7-9 x 10(5)/ml, and transferred to new flasks.  Subcultures were maintained by readjusting the BSF density to 7-9 x 10(5)/ml every 24 hr.  Concentrations of FBS were reduced gradually at 5-7-day intervals by alternating the amounts of FBS and SP in HMI-9 with 5% FBS and 15% SP, with 2% FBS and 18% SP, and finally with 20% SP (HMI-18).  By this method, 2-3 x 10(6) VSFs/ml were obtained consistently every 24 hr. for more than 80 days.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-hsI_lV2EcpPlX7E30qdzfW6udTcc2eadSucR_PBL77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c7jtlaksw%253D%253D&md5=a5ec1c8efb4c6572ef8ff09ad88edeb0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2307%2F3282883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3282883%26sid%3Dliteratum%253Aachs%26aulast%3DHirumi%26aufirst%3DH.%26aulast%3DHirumi%26aufirst%3DK.%26atitle%3DContinuous%2520cultivation%2520of%2520Trypanosoma%2520brucei%2520blood%2520stream%2520forms%2520in%2520a%2520medium%2520containing%2520a%2520low%2520concentration%2520of%2520serum%2520protein%2520without%2520feeder%2520cell%2520layers%26jtitle%3DJ.%2520Parasitol.%26date%3D1989%26volume%3D75%26spage%3D985%26epage%3D989%26doi%3D10.2307%2F3282883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornasiero, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isetta, A. M.</span></span> <span> </span><span class="NLM_article-title">MTT colorimetric assay for testing macrophage cytotoxic activity in vitro</span>. <i>J. Immunol. Methods</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1016/0022-1759(90)90187-Z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2F0022-1759%2890%2990187-Z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=2391427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADyaK3cXmtV2nsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=1990&pages=165-172&author=M.+Ferrariauthor=M.+C.+Fornasieroauthor=A.+M.+Isetta&title=MTT+colorimetric+assay+for+testing+macrophage+cytotoxic+activity+in+vitro&doi=10.1016%2F0022-1759%2890%2990187-Z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">MTT colorimetric assay for testing macrophage cytotoxic activity in vitro</span></div><div class="casAuthors">Ferrari, Mario; Fornasiero, Maria Chiara; Isetta, Anna Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunological Methods</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-72</span>CODEN:
                <span class="NLM_cas:coden">JIMMBG</span>;
        ISSN:<span class="NLM_cas:issn">0022-1759</span>.
    </div><div class="casAbstract">The MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide] cleavage assay, originally described by T. Mosmann (1983) for measuring cell survival/proliferation, was used successfully to quantitate macrophage-mediated cytotoxicity.  Peritoneal macrophages, from control or pyran copolymer MVE2-treated mice and from TU5 and L929 murine cell lines, were used as effectors and targets resp. in a 48 h cytotoxicity test, at 3 effector: target ratios (10:1, 5:1, 2:1).  The amt. of MTT reduced by cells to its blue formazan deriv. during an addnl. 4 h of culture was quantified spectrophotometrically at 570 nm using an ELISA reader.  A linear relationship between the formazan generated and the no. of viable TU5 and L929 cells was demonstrated, together with time-dependent growth characteristics for these cells.  The formazan produced by macrophages was independent of their functional state and did not interfere with the target cell signal.  MVE2-activated macrophages strongly inhibited the survival/growth of target cells in a dose-related way, whereas the cytotoxic activity of control macrophages was very low.  Finally, the MTT method compared favorably with the 3H-TdR uptake method in evaluating macrophage cytotoxicity, and both of them were more sensitive than the 3H-TdR release assay.  The MTT cleavage method is a useful alternative to radioisotopic methods for quantitating macrophage cytotoxicity for actively growing in vitro targets.  Its main advantages are: (a) sensitivity and reproducibility; (b) elimination of the need for radioactive compds.; (c) ease with which it can be performed and quantified; and (d) rapidity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrezxA3w4p2ebVg90H21EOLACvtfcHk0ljwz88DdW8EbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmtV2nsLo%253D&md5=e0b83e032dccb6f10faa9fc8a8ca16ce</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2F0022-1759%2890%2990187-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-1759%252890%252990187-Z%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DM.%26aulast%3DFornasiero%26aufirst%3DM.%2BC.%26aulast%3DIsetta%26aufirst%3DA.%2BM.%26atitle%3DMTT%2520colorimetric%2520assay%2520for%2520testing%2520macrophage%2520cytotoxic%2520activity%2520in%2520vitro%26jtitle%3DJ.%2520Immunol.%2520Methods%26date%3D1990%26volume%3D131%26spage%3D165%26epage%3D172%26doi%3D10.1016%2F0022-1759%2890%2990187-Z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konsoula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=10.1016%2Fj.ijpharm.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=18562136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2008&pages=19-25&author=R.+Konsoulaauthor=M.+Jung&title=In+vitro+plasma+stability%2C+permeability+and+solubility+of+mercaptoacetamide+histone+deacetylase+inhibitors&doi=10.1016%2Fj.ijpharm.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span></div><div class="casAuthors">Konsoula, Roula; Jung, Mira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers.  In this study, the in vitro plasma stability, permeability, soly., and lipophilicity (log D) of two mercaptoacetamide-based HDACIs (coded as W2 and S2) were evaluated and compared to Vorinostat (SAHA).  The results demonstrated that the compds. manifested high soly. in HCl (pH 1.2) but lower in PBS (pH 7.4) than SAHA.  Moreover, mercaptoacetamide-based HDACIs exhibited higher lipophilicity values compared to SAHA.  The permeability of these compds. was evaluated using the Caco-2 cell monolayer as a model of the intestinal mucosa.  The Caco-2 studies revealed that the compds. S2 and W2 are highly permeable with apparent permeability coeffs. (Papp) in the apical to basolateral direction of 7.33 × 10-6 and 15.0 × 10-6 cm/s, resp.  The in vitro stability was detd. in human, mouse, porcine and rat plasma.  Data showed that the compd. W2 is more stable in human and rat plasma and the S2 is more stable in all plasma species than SAHA.  Taken together, these results indicate that the mercaptoacetamide-based HDACIs possess favorable soly., lipophilicity, permeability and plasma stability features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ60NiaoIn6bVg90H21EOLACvtfcHk0lgDXNyBCY8PnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D&md5=32a5ec87e4d150d373a325b3ee296dc7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DKonsoula%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520plasma%2520stability%252C%2520permeability%2520and%2520solubility%2520of%2520mercaptoacetamide%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D361%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.ijpharm.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revankar, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span> <span> </span><span class="NLM_article-title">Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci00063a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;key=1%3ACAS%3A528%3ADyaL1MXkslSgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1989&pages=163-172&author=V.+N.+Viswanadhanauthor=A.+K.+Ghoseauthor=G.+R.+Revankarauthor=R.+K.+Robins&title=Atomic+physicochemical+parameters+for+three+dimensional+structure+directed+quantitative+structure-activity+relationships.+4.+Additional+parameters+for+hydrophobic+and+dispersive+interactions+and+their+application+for+an+automated+superposition+of+certain+naturally+occurring+nucleoside+antibiotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships.  4.  Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics</span></div><div class="casAuthors">Viswanadhan, Vellarkad N.; Ghose, Arup K.; Revankar, Ganapathi R.; Robins, Roland K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-72</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    </div><div class="casAbstract">At. values for physicochem. properties are an important guide for correlating the obsd. biol. activity of the ligands to their chem. structure.  The objective of the present work was to (i) report the hydrophobicity and the molar refractivity for P and Se atoms at different structural environments that are ubiquitous in biol. active systems, (ii) refine the at. values of the various elements reported earlier to satisfy the largely extended data set, and (iii) suggest a method for selecting the best superposition of different mols. on a ref. structure using these at. physicochem. properties.  The octanol-water partition coeff. was used to scale the at. hydrophobicity.  The hydrophobicity values of 120 atom types were evaluated from 893 compds.  The obsd. and calcd. octanol-water partition coeff. showed a correlation coeff. of 0.926 and a std. deviation of 0.496.  The at. refractivity values were evaluated from the molar refractivities of 538 compds.; the corresponding correlation coeff. and std. deviation were 0.999 and 0.774, resp.  The at. values were tested by predicting the resp. properties for a large no. of compds.  The superposition methods was applied to certain naturally occurring nucleoside antibiotics.  The algorithm presented showed various important superpositions of ≥2 mols. with min. phys. assistance to avoid any personal bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLCJFGlYIlHrVg90H21EOLACvtfcHk0lgDXNyBCY8PnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkslSgs7w%253D&md5=b2f20d16b51f3405b5799138904de81a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fci00063a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci00063a006%26sid%3Dliteratum%253Aachs%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DRevankar%26aufirst%3DG.%2BR.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26atitle%3DAtomic%2520physicochemical%2520parameters%2520for%2520three%2520dimensional%2520structure%2520directed%2520quantitative%2520structure-activity%2520relationships.%25204.%2520Additional%2520parameters%2520for%2520hydrophobic%2520and%2520dispersive%2520interactions%2520and%2520their%2520application%2520for%2520an%2520automated%2520superposition%2520of%2520certain%2520naturally%2520occurring%2520nucleoside%2520antibiotics%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D1989%26volume%3D29%26spage%3D163%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i168"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01365">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83263"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01365">10.1021/acs.jmedchem.8b01365</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic schemes and characterization data for compounds not presented directly in the manuscript (and not previously published); Log <i>D</i>, p<i>K</i><sub>a</sub>, and rat hepatocyte Cl<sub>int</sub> data for all compounds disclosed in the manuscript; calculated p<i>K</i><sub>a</sub> values for compounds <b>1</b> and <b>10e</b>; comparison of Log <i>P</i> and <i>T. brucei</i> pEC<sub>50</sub>; crystal structure of compound <b>19a</b>; curves obtained from the CEC<sub>50</sub> assay; PK parameters and plasma concentration–time profile for compound <b>22a</b>; human kinase profile of compounds <b>1</b> and <b>22a</b>; Ames test results for <b>22a</b>; HitProfilingScreen panel results of <b>22a</b>; and molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Compound ID numbers and their associated SMILES strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_001.pdf">jm8b01365_si_001.pdf (1.36 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01365/suppl_file/jm8b01365_si_002.csv">jm8b01365_si_002.csv (3.13 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01365&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-2%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01365" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01365" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992546a8a73d82","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
